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Dravet syndrome is a rare, severe form of pediatric epilepsy, accompanied by cognitive, 
behavioral and motor disturbances. Haploinsufficiency of the Scn1a gene, encoding the 
function of sodium channels on GABAergic neurons, has been detected in over 80 % of 
patients. Thus, it is considered the main cause of hyperexcitability. Albeit few drugs have 
received orphan drug status over the past years, pharmacoresistance remains the biggest 
challenge in the treatment of Dravet syndrome. Therefore, novel therapeutic strategies are 
urgently needed.  
Characterization of a novel, conditional, Scn1a-A1783V knock-in mouse model confirmed an 
increased seizure susceptibility, behavioral and motor alterations and thus demonstrated 
excellent face validity for the further investigation of Dravet syndrome.  
The untargeted proteomic screening displayed more pronounced changes following the onset 
of spontaneous seizures, dominated by the down-regulation of proteins involved in synaptic 
and glutamatergic signaling in the hippocampus of Dravet mice. The proteomic data was 
complemented by metabolome data that detected lower levels of glutamate and GABA in the 
hippocampus, suggesting a disturbed glutamate/GABA-glutamine cycle and an increased 
GABA:glutamate ratio. This can later be supported by GABAergic drugs.  
A comparison of proteomic data to published data from animal models of acquired epilepsies 
revealed common molecular alterations between genetic and acquired epilepsies comprising 
proteins linked with synaptic plasticity, astrogliosis and angiogenesis.  
Metabolomic screening of hippocampal tissue in Dravet mice showed pronounced alterations 
in energy metabolism and an impact of Dravet genotype on concentrations of several glycolysis 
and tricarboxylic acid (TCA) cycle intermediates. These changes in energy metabolism may 




therapeutic potential of a ketogenic diet, which aims to shift energy metabolism towards a more 
fat-based energy supply. This diet improved the motor deficits observed in Dravet mice. 
Overall, the proteome and metabolome analysis in a mouse model of Dravet syndrome 
demonstrated complex molecular alterations in the hippocampus. Whether these alterations 
may contribute to hyperexcitability or, instead, represent a compensatory mechanism, will have 
to be confirmed by further investigations. The proteomic data indicated more complex 
pathophysiological mechanisms during the course of the disease, which should be considered 
in the management of Dravet syndrome. However, future studies investigating the functional 
relevance of the aforementioned molecular changes may confirm our data and provide valuable 






1. Epilepsy: history and definition  
The mention of epilepsy and epileptic seizures dates back to the year 2000 B.C. and the 
Assyrian empire, where epilepsy and seizures were believed to be a manifestation of evil spirits. 
Over the centuries, these beliefs remained through other civilizations up until the ancient Greeks 
who called it a sacred disease. Hippocrates was the first to describe it as the medical condition 
known today, believing its cause originates in the brain. He named it the great disease, which 
would later become the globally accepted term for generalized seizures (grand-mal) 
(Magiorkinis et al., 2010).  
According to The International League Against Epilepsy (ILAE), an epileptic seizure is defined 
as “a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous 
neuronal activity in the brain.” (Fisher et al., 2005). Over the years, the exact definition of 
epilepsy has changed. Today, ILAE’s practical clinical definition describes epilepsy as a brain 
disease including one of three conditions: (1) at least two unprovoked seizures occurring  within 
a 24-hour interval; (2) one unprovoked seizure and high risk for recurrent seizures occurring 





2. Dravet Syndrome 
2.1. Epidemiology 
Dravet syndrome is a rare, severe, lifelong form of epileptic encephalopathy that begins within 
the first year of life (Dravet, 2011). It is defined as a syndrome, due to its specific clinical picture 
and accompanying electroencephalogram (EEG) abnormalities (Scheffer et al., 2016). 
Previously known as Severe Myoclonic Epilepsy of Infancy (SMEI), Dravet syndrome was first 
described by doctor Charlotte Dravet in 1978 (Dravet, 2011), after whom it was later named. 
Besides frequent and/or prolonged seizures, the syndrome comprises of intellectual and motor 
disabilities, behavioral and developmental delays, poor immune responses etc. The worldwide 
Dravet syndrome prevalence is one in 40,000 individuals. Thus, the syndrome is listed as a rare 
disease (https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=33069&lng=EN, 
ORPHA: 33069).   
2.2. Scn1a mutation 
Until 2001, it was not known that Dravet syndrome is caused by a genetic deficiency of the 
Scn1a gene in the majority of patients. The Scn1a gene encodes the NaV1.1 sodium channel α 
subunit (Claes et al., 2001) that is widely expressed throughout the brain. It is localized to the 
cell body, dendrites and the initial axonal segments of fast-spiking parvalbumin-positive 
neurons (Ogiwara et al., 2007) and somatostatin-positive neurons (Tai et al., 2014). The channel 
is comprised of four homologous domains (I–IV), each consisting of six transmembrane 
segments (S1–S6) (Escayg and Goldin, 2010). Although numerous mutations in the Scn1a gene 
have been identified, most causing Dravet syndrome were found in the transmembrane region 
(Lossin, 2009). The current state of knowledge is that the mutation causes deficits in action 
potential firing of GABA inhibitory interneurons thus leading to abnormal excitability and 





Over the years, increasing proportions of patients with Dravet syndrome tested positive for the 
SCN1A mutation, reaching a prevalence of over 80% (Rosander and Hallbook, 2015). 
Interestingly, mutations in the same gene can also provoke Generalized Epilepsy with Febrile 
Seizures Plus (GEFS+), usually linked to a missense SCN1A mutation and a milder clinical 
picture (Catterall et al., 2010; Meisler and Kearney, 2005). Furthermore, mutations causing the 
abnormal ion selectivity (segments S5, S6 and S5-S6 linker of NaV1.1 channel) are more 
frequent in Dravet syndrome (Kanai et al., 2004). In Dravet patients, mutations in SCN1A 
mostly result in loss of function (Escayg and Goldin, 2010). While all SCN1A mutations are 
dominantly inherited (Escayg and Goldin, 2010), the majority of mutations in Dravet patients 
occur de novo (Poryo et al., 2017), frequently originating from the paternal chromosomes 
(Heron et al., 2010; Sun et al., 2010). Nonetheless, a large proportion of patients have a family 
history of epilepsy or febrile seizures, with or without SCN1A mutations (Dravet, 2011). 
Interestingly, truncating mutations found in 40-50 % of patients are associated with earlier 
seizure onset and a more severe phenotype (Zuberi et al., 2011). Slightly less abundant were 
missense (40%) and splice site mutations (0-10%). Interestingly, all inherited SCN1A mutations 
were missense (Connolly, 2016).  
2.3. Disease phases 
The first disease phase is known as the “febrile stage” (Dravet, 2011). The initial seizure in 
Dravet patients occurs within the first year of life, mostly between 5 and 8 months of age. The 
seizures, most commonly thermally provoked by a hot bath, fever or vaccination, are clonic, 
unilateral or generalized and frequently prolonged (Dravet, 2011). Vaccination is reported as 
the trigger for the first seizure in more than 50 % of children (Tro-Baumann et al., 2011; von 
Spiczak et al., 2011). Although this link was thought to be due to a provoked fever, a shift 
towards a pro-inflammatory profile in Dravet patients has been demonstrated in vitro (Auvin et 




seizure is not associated with vaccination (McIntosh et al., 2010). Prior to the first convulsive 
seizure, focal myoclonic jerking has been reported in some patients (Dravet, 2011).  
Following the first seizure, repeated febrile or afebrile seizures usually occur once per month 
up until the end of the first year and frequently do not respond well to benzodiazepines 
(Gataullina and Dulac, 2017). Whilst diagnosis may point towards febrile seizures, the 
temperature of Dravet patients is not sufficiently high and seizures are clonic, unilateral, more 
frequent, prolonged and start at an earlier age (Dravet, 2011). The EEG remains normal for 
several years with prominent theta activity starting from the second year of life (Bureau and 
Dalla Bernardina, 2011). 
Following the first year of life until the age of ten, the “worsening” or “catastrophic stage” takes 
place (Dravet, 2011). This phase is characterized by the onset of different types of seizures that 
are the hallmark of Dravet syndrome. Patients start experiencing myoclonic, atypical absence 
seizures, with or without loss of consciousness, and focal seizures sometimes with secondary 
generalization. Convulsions are still present and can progress into status epilepticus (SE). Tonic 
seizures are rarely present (Dravet, 2011; Gataullina and Dulac, 2017). During this stage, EEG 
abnormalities can be detected that can help diagnosis (Dravet, 2011). Hyperthermia remains a 
seizure trigger but other common epilepsy triggers also appear such as photosensitivity, noise, 
altered emotions etc (Dravet, 2011; Gataullina and Dulac, 2017). 
After the sixth year of life, the “stabilization stage” begins characterized by reduced seizure 
frequency and duration (Dravet, 2011). Convulsive seizures frequently occur during sleep, 
absence and myoclonic seizures may disappear and focal seizures occur with a reduced density. 
Nevertheless, in several cases epileptic phenotype worsens even after the age of five (Dravet, 




structural abnormalities. However, within the second decade a global volume reduction of white 
and gray matter has been detected in several brain structures (Gataullina and Dulac, 2017).  
2.4. Dravet syndrome phenotype  
In Dravet syndrome, it is thought that seizures themselves contribute to brain impairment and 
the development of cognitive, motor and behavioral alterations (Berg, 2011). Accordingly, 
cognitive and behavioral impairments are associated with seizure frequency (Brunklaus and 
Zuberi, 2014). However, nowadays this claim is rather challenged in epileptic encephalopathies 
where both seizure frequency and phenotype disturbances can be triggered by a particularly 
aggressive epileptogenic process (Avanzini et al., 2013). Preclinical studies have also pointed 
towards NaV1.1 dysfunction in different brain regions affecting the complete phenotype in 
Dravet syndrome (Brunklaus and Zuberi, 2014). For instance, defects in the action potential 
firing of cerebellar GABAergic Purkinje cells are known to cause ataxia (Kalume et al., 2007).  
In patients older than 5 years, whereafter seizures generally decline (Dravet, 2011), at least one 
bad phenotype outcome has been reported, with learning deficits being the most common, then 
speech and motor impairments, autism, attention deficit hyperactivity syndrome and other 
behavioral difficulties (Lagae et al., 2018). 
2.4.1. Intellectual disability 
Cognitive deterioration is a hallmark of Dravet syndrome. Children develop normally in the 
first few months of life, showing the first deficits in the second or third year (Cassé-Perrot et 
al., 2001). However, pre-cognitive abilities such as vision, are affected even before the first 
seizure (Chieffo et al., 2011). Children show slower language development, with a stronger 
effect on speech production than on comprehension (Acha et al., 2015; Chieffo et al., 2016). 
Between 2 and 6 years of age, children develop dysarthria and poor articulation (Chieffo et al., 




different clinical symptoms. Teenagers with Dravet syndrome and milder retardation mostly 
show visuo-motor disabilities with preserved verbal skills, while moderately and severely 
retarded patients show pronounced cognitive decline (Olivieri et al., 2016). Some patients 
experience attention deficit hyperactivity disorder with hyperkinesia to the detriment of their 
learning abilities. Additionally, over 30 % of patients with Dravet syndrome exhibit autistic 
behaviors, with a higher prevalence of social reserve observed in male patients (Gataullina and 
Dulac, 2017; Villas et al., 2017). 
Children who experience the early appearance of myoclonus, absence seizures and worse 
seizure control, show a poorer cognitive profile (Catarino et al., 2011; Ragona et al., 2011). As 
a consequence of the total seizure accumulation and poor pharmacoresponse, cognitive decline 
increases with age (Acha et al., 2015; Catarino et al., 2011). In line with this, speech alterations 
positively correlate with higher seizure frequency (Lagae et al., 2018). 
2.4.2. Motor dysfunction 
Motor disabilities are frequently observed in Dravet patients. The symptoms seem to deteriorate 
with age. The first clinical sign of motor disabilities is the delayed onset of independent sitting 
and walking by 3 and 8 months on average, respectively (Gitiaux et al., 2016; Verheyen et al., 
2019). Up to the age of six, gait is frequently described as normal or with possible hypermobility 
and ataxia (Gitiaux et al., 2016; Rodda et al., 2012). Most patients develop a crouched gait 
following 6 years of age which worsens during adolescence (Gitiaux et al., 2016; Rilstone et 
al., 2012; Rodda et al., 2012; Wyers et al., 2019). This is characterized by hip and passive knee 
flexion extension, lateral tibial torsion and feet planoabductovalgus (Gitiaux et al., 2016). 
Additionally, ataxia and spasticity progress with age (Gataullina and Dulac, 2017; Rodda et al., 
2012) while parkinsonian gait, antecollis and extrapyramidal signs are frequently observed in 




vary, ranging from mild motor impairments to immobility and the need for a wheelchair (Rodda 
et al., 2012). 
Though frequent seizures can worsen gait and ataxia, there is a strong connection between gait 
disturbances and SCN1A mutations in patients with Dravet syndrome. Namely, NaV1.1 channels 
located on nodes of Ranvier and the initial axonal segment are crucial for the electrical outputs 
of neurons. Their dysfunction could explain motor deficits, gait disturbance and crouching in 
Dravet syndrome (Duflocq et al., 2008). Additionally, the impact of these channels’ dysfunction 
on the basal ganglia is linked to parkinsonian features. Severe SCN1A deficiency is linked to an 
earlier onset of symptoms in children (Aljaafari et al., 2017). Importantly, these patients showed 
a good response to levodopa treatment (Fasano et al., 2014). Lastly, data from animal models 
imply the role of impaired GABAergic firing of Purkinje cells as a mechanism of ataxia 
(Kalume et al., 2007; Ogiwara et al., 2007; Yu et al., 2006). 
2.4.3. Sleep disturbances 
Sleep disturbances are frequently reported by caregivers of patients with Dravet syndrome 
(Gataullina and Dulac, 2017; Villas et al., 2017). They are considered a risk factor for nocturnal 
seizures, which occur more frequently after the age of 10 (Dravet and Oguni, 2013). Patients 
usually experience difficulties with initiating and maintaining sleep, sleep-wake transitions and 
sleep breathing (Licheni et al., 2018; Schoonjans et al., 2019). Excessive somnolence and 
daytime sleepiness are consequences of these disturbances. Melatonin has shown some 
beneficial effect on sleep initiation and maintenance, contributing to a better quality of life 
(Myers et al., 2018).     
While data from humans do not provide information about circadian rhythm, preclinical models 
indicate that it may be impaired in Dravet syndrome. Patients show a fragmented rhythm of 




2019). Interestingly, NaV1.1 channels are located in the suprachiasmatic nucleus, whose 
dysfunction could explain the slow EEG background rhythm and sleep impairments starting 
from the second year of life (Gataullina and Dulac, 2017). Moreover, in a mouse model of 
Dravet syndrome, an imbalance between excitatory and inhibitory neurons in the thalamic 
ventrobasal and reticular nucleus could further delay the onset and maintenance of sleep 
(Kalume et al., 2015b). 
2.4.4. Other symptoms of Dravet syndrome 
Caregivers frequently report problems with thermoregulation, overheating and insufficient 
sweating in patients with Dravet syndrome, altogether increasing the risk of thermally provoked 
seizures. Furthermore, Dravet patients frequently suffer from slowed growth, digestion issues 
and constipation (Skluzacek et al., 2011). Osteopenia and increased fracture risk are mentioned 
as major concerns in drug-resistant epilepsy (Connolly, 2016). Additionally, a poor immune 
response with frequent respiratory and urinary tract infections is another concern in Dravet 
patients (Skluzacek et al., 2011). Cardiovascular irregularities are also observed in some 
patients (Skluzacek et al., 2011). 
2.5. Sudden unexpected death in epilepsy 
Dravet syndrome has a high rate of premature death ranging from 3.1 to 20.8 % (Connolly, 
2016). Children from 3 to 7 years of age seem to have the highest death incidence (Sakauchi et 
al., 2011). Sudden unexpected death in epilepsy (SUDEP) is known as the leading cause of 
death, explaining over 50 % of mortalities in patients with Dravet syndrome (Sakauchi et al., 
2011; Skluzacek et al., 2011). SUDEP is defined as sudden, unexpected death in patients 
suffering from epilepsy when no other disease, drowning or injury can be considered causative. 
It may occur with or without confirmed seizures, but status epilepticus (SE) does not precede 
the death (Nashef et al., 2012). In Dravet syndrome, the risk of SUDEP is roughly 15 times 




accidents with drowning are the next leading causes of death (Connolly, 2016; Sakauchi et al., 
2011). The exact mechanism of SUDEP is not yet fully understood but current data from 
patients imply a role of peri-ictal respiratory dysfunction leading to central apnea, bradycardia 
and heart arrest (Kim, 2017). Heart rate variability has also been shown to be a biomarker of 
SUDEP in some patients (Myers et al., 2018). Further research in Dravet patients is still 
necessary to establish the exact mechanisms behind SUDEP and validate the findings from 
animal models.  
2.6. Diagnosis 
Today, according to the 2017 consensus of North American neurologists with expertise in 
Dravet syndrome (Wirrell et al., 2017), the diagnosis of the syndrome is purely clinical using 
the following criteria:  
o typical disease onset within the first year of life, on average 5.2 months (Cetica et al., 
2017; Wirrell et al., 2017)  
o children experience recurrent convulsive or hemiconvulsive seizures, which are 
frequently prolonged  
o myoclonic seizures appear by the age of two, followed by obtundation status, focal 
seizures with loss of consciousness and atypical absence seizures 
o patients are susceptible to thermally provoked seizures with fever, vaccination and 
warm baths as the most frequent triggers 
o photosensitivity, eating, and bowel movements are observed as potential seizure triggers 
o children develop normally until disease onset 
o sodium channel agents are contraindicated and may exacerbate seizures 
In older children and adults the clinical picture consists of: 
o persistent seizures with less frequent and obvious SE over time  




o intellectual disability presenting between 18 and 60 months  
o motor impairment: crouch gait, lack of coordination and muscle tonus, impaired 
physical dexterity 
o normal MRI with mild generalized atrophy and/or hippocampal sclerosis 
o EEG potentially showing diffuse background slowing with multifocal and/or 





3. Animal models 
A major step in filling the gaps in knowledge about Dravet syndrome was the development of 
an animal model back in 2006 (Yu et al., 2006). Today, there are several other models accessible 
to a broad scientific community that have improved our understanding of the 
pathophysiological mechanisms underlying the disease, providing a solid foundation for the 
development of novel treatment candidates in Dravet syndrome. 
Following the discovery of SCN1A deficiency in Dravet children, the exact mechanism of 
epileptogenesis was explained using an Scn1a knock-out mouse model (Ogiwara et al., 2007; 
Yu et al., 2006). These studies elucidated why a loss of function mutation in sodium channels 
leads to seizures by showing that the mutation reduces sodium currents and neuronal firing of 
GABAergic hippocampal interneurons, leading to general hyperexcitability and a lower seizure 
threshold (Ogiwara et al., 2007; Yu et al., 2006). 
Whilst Dravet mutations are present from birth, both mice and humans only experience the first 
seizure later in life. The reason behind this phenomenon was clarified in an animal model of 
Dravet syndrome (Cheah et al., 2012). Namely, the expression of NaV1.1 channels is low at 
birth and increases with age. On the contrary, the expression of NaV1.3 sodium channels 
declines with age in mice, reaching the lowest expression levels around 3 weeks of age, 
corresponding to weaning age. Over these 3 weeks, NaV1.1 deficits in Dravet mice are rescued 
by an up-regulation of NaV1.3 channels in hippocampal interneurons. Thus, the natural decrease 
in NaV1.3 expression along with the failure of NaV1.1 channels to replace their function defines 
the starting point for developing Dravet syndrome, characterized by the disinhibition of 
neuronal circuits, seizures, and other comorbidities (Cheah et al., 2013). Importantly, the same 
pattern was noted in humans, showing that the decline of NaV1.3 and the increase of NaV1.1 
expression at the age of 5-6 months corresponds to the approximate age of seizure onset in 




In addition to neuronal hyperexcitation, the NaV1.1 channelopathy was linked to motor deficits 
including ataxia. Experimental proof came from homozygous Scn1a-/- mice, which related to 
the lack of NaV1.1-positive cerebellar Purkinje cells, exhibit impaired firing of Purkinje cells 
and severe ataxia (Ogiwara et al., 2007; Yu et al., 2006). 
Similarly, a selective NaV1.1 deletion and impaired GABAegic neurotransmission in the 
prefrontal cortex was linked to autistic-like behavior and spatial learning and memory deficits 
in Dravet mice. Low-dose clonazepam fully rescued these social and cognitive deficits in 
Dravet mice, thus demonstrating impaired GABAergic neurotransmission as a cause of Scn1a 
haploinsuficiency (Han et al., 2012). Furthermore, another study has shown that the selective 
blockade of NaV1.1 channels in the basal forebrain region leads to learning and memory 
impairment but no spontaneous seizures (Bender et al., 2013). These findings suggest that 
impaired GABAergic neurotransmission may not only lead to seizure protection but also to 
improved behavioral and motor phenotypes in patients. 
Great progress has been made in understanding the mechanism of SUDEP using animal models 
of Dravet syndrome. Video monitoring of Scn1a heterozygous knock-out mice observed 
SUDEP shortly after generalized tonic-clonic seizures (Kalume, 2013). Moreover, the study 
showed that SUDEP is triggered by increased parasympathetic activity following tonic-clonic 
seizures, resulting in ventricle electrical dysfunction and lethal bradycardia (Kalume, 2013).  
On the other hand, a high rate of seizure-related respiratory difficulties including 
hypoventilation and apnea have been reported in most witnessed SUDEP cases, listing it as a 
possible cause of SUDEP. Additionally, patients who suffered from SUDEP reported impaired 
respiratory function throughout earlier seizures (Kalume, 2013; Langan, 2000). A recent study 
in Dravet mice expressing an Scn1a mutation demonstrated disordered breathing comprised of 




brainstem neurons and hyperexcitability of glutamatergic chemosensitive neurons, responsible 
for the CO2/H
+ ventilatory response, were observed in the retrotrapezoid nucleus of Dravet 
mice. This has therefore been proposed as a possible underlying mechanism in SUDEP (Kuo et 
al., 2019).  
Lastly, animal models of Dravet syndrome used in preclinical drug discovery and development 
studies have been instrumental in the licensing of new therapeutics for Dravet syndrome. For 
instance, some preclinical studies in Dravet animal models provided critical evidence for the 
efficacy and tolerability of cannabidiol, stiripentol and fenfluramine (Cao et al., 2012; Kaplan 
et al., 2017; Zhang et al., 2015) facilitating their approval for the treatment of Dravet syndrome 
in subsequent years. Similarly, the efficacy of a ketogenic diet in seizure protection and 
reducing susceptibility to SUDEP was confirmed in mouse models of Dravet syndrome (Dutton 





4. Current therapeutic options in the treatment of Dravet syndrome 
Currently, the treatment of Dravet syndrome remains very challenging. Medication has to be 
tailored to the types of seizures which demonstrate great interpatient variability. During the 
“febrile” stage, the aim of therapy is to prevent prolonged seizures including SE, which 
frequently require medical intervention (Knupp and Wirrell, 2018). During the “worsening” 
phase, patients require better control of nonconvulsive seizures, which can further contribute 
towards cognitive decline (Ragona, 2011; Ragona et al., 2011). During the “stabilization” 
phase, the focus of therapy is to reduce convulsive nocturnal seizures which are a great risk 
factor for SUDEP (Genton et al., 2011; Knupp and Wirrell, 2018). 
Most patients with Dravet syndrome have an SCN1A sodium channel mutation. The use of 
sodium channels agents is therefore strongly contraindicated as they may exacerbate seizures. 
Moreover, truncating mutations in SCN1A gene can serve as biomarkers predicting a bad 
prognosis to sodium channel blockers (Weber et al., 2014). Thus, carbamazepine, 
oxcarbazepine, phenytoin, lamotrigine and rufinamide should be avoided in the treatment of 
Dravet syndrome. Additionally, an irreversible inhibitor of GABA aminotransferase 
(vigabatrin) should be avoided due to its proconvulsant effect in Dravet patients (Knupp and 
Wirrell, 2018). 
4.1. Stiripentol 
In 2007, Stiripentol (Diacomit) was the first drug approved for the treatment of Dravet patients 
(older than 2 years) in the European Union (EU). Approved as an add-on medication in 
combination with clobazam or valproate, stiripentol is indicated for the treatment of generalized 
tonic-clonic seizures (EU/3/01/071). Recently, the Food and Drug Administration (FDA) also 




Stiripentol is a novel drug that is structurally different from other antiepileptic drugs. There are 
several proposed mechanisms of action. Stiripentol enhances GABAergic neurotransmission 
by increasing GABAA receptor activity (Fisher, 2011). Due to its effect on α4- and δ-containing 
GABAA receptors, it does not lose efficacy during prolonged SE as a consequence of receptor 
internalization (Grosenbaugh and Mott, 2013). Additionally, stiripentol inhibits lactate 
dehydrogenase leading to neuronal hyperpolarization (Sada et al., 2015) and blocks calcium- 
and sodium-channel mediated neurotoxicity (Verleye et al., 2016). It must be considered that 
stiripentol interacts with CYP2C19 and CYP3A4, thus affecting the pharmacokinetics of other 
drugs such as clobazam and valproate (Chiron, 2005; Jogamoto et al., 2017). Therefore, it is 
necessary to adjust its dose when used in combination with other antiseizure drugs. 
The first randomized placebo-controlled clinical studies demonstrated stiripentol’s efficacy in 
the treatment of Dravet syndrome, with 67 and 71 % of patients exhibiting a reduction in the 
frequency of convulsive seizures by more than 50 %, compared to 9 and 5 % observed in the 
placebo groups (Chiron, 2007; Chiron et al., 2000). Further studies confirmed its efficacy for 
generalized tonic-clonic and focal seizures (Myers et al., 2018) as well as for the prevention of 
SE (Buck and Goodkin, 2019). It is considered a safe therapeutic, with anorexia and 
somnolence as the most common adverse events (Buck and Goodkin, 2019). 
4.2. Cannabidiol 
Cannabinoids or derivatives of Cannabis sativa have been used for centuries in herbal medicine 
to treat epilepsy. The story of Charlotte Figi, a girl with Dravet syndrome, whose seizures 
almost completely disappeared with cannabidiol-enriched extract attracted a lot of media 
attention (Maa and Figi, 2014). As one of the dominant non-psychoactive components in 
cannabis, cannabidiol has been widely used in children with Dravet syndrome and reported as 
very promising by their parents (Porter and Jacobson, 2013). Preclinical studies confirmed its 




double-blind, placebo-controlled clinical study showed that cannabidiol reduces seizures by ≥ 
50 % in 43 % of Dravet patients, as compared to 27 % observed in the placebo group (Devinsky 
et al., 2018b). Furthermore, seizure frequencies of all but non-convulsive seizures were reduced 
and the treatment was well tolerated. Diarrhea, fatigue, somnolence, decreased appetite and 
elevated liver transaminases were the most common adverse events (Devinsky et al., 2018b).  
The proposed mechanism of action is the modulation of intracellular calcium and adenosine 
uptake by antagonizing GPR55-mediated increased excitotoxicity, desensitizing TRPV1 
channels and inhibiting nucleoside transporters (ENT1) (Nichol et al., 2019). Cannabidiol can 
strongly increase the concentration of clobazam and its active metabolite when applied together 
(Geffrey et al., 2015). Thus, dose optimization should be kept in mind. 
In 2019, cannabidiol (Epidiolex) was the first drug approved by the FDA as a single-use therapy 
for Dravet patients older than 2 years, thus receiving orphan drug designation 
(https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/3466-epidiolex-
cannabidiol; ID: 4282447). A year later, cannabidiol was also approved by the EU as an add-
on therapy (EU/3/14/1339).  
4.3. Fenfluramine 
The most recent drug to receive orphan drug designation for the treatment of Dravet syndrome 
is fenfluramine. The drug was approved for the treatment of patients over 2 years of age by the 
FDA (reference ID: 4631810) and as an add-on therapy by the European Medicines Agency 
(EMA) (EU/3/14/1219). 
Fenfluramine is an amphetamine derivate, previously registered as an appetite suppressor in the 
treatment of obesity. Its frequent combination with the monoamine oxidase inhibitor 
phentermine, raised pulmonary hypertension (Douglas et al., 1981). Later on, severe 




(Connolly et al., 1997; Gardin et al., 2000). Nevertheless, a great improvement was observed 
in seizure control in patients with self-induced epilepsy, among which were patients with Dravet 
syndrome. The drug was further examined in lower doses (Schoonjans et al., 2015). In 
comparison to up to 120 mg/day used for appetite suppression, fenfluramine was tested in doses 
under 1 mg/kg/day, thus minimizing risk for cardiac side effects (Knupp and Wirrell, 2018). 
Additionally, Belgian Dravet patients were continuously treated with fenfluramine (10-20 
mg/day) over 28 years with no signs of cardiac valve disease or pulmonary hypertension, thus 
providing the first valid safety data in Dravet patients (Schoonjans et al., 2017). A recent long-
term open-label study further confirmed this finding (Lai et al., 2020). 
Whilst the exact mechanism of action is still unclear, it is know that fenfluramine hydrochloride 
is a  serotonin 5HT-2 receptor agonist that inhibits serotonin transporters thereby increasing 
extracellular serotonin availability (Knupp and Wirrell, 2018). Recent findings demonstrated 
that fenfluramine also acts as a positive allosteric modulator of sigma-1 receptors (Martin et al., 
2020). 
Two double-blind placebo-controlled randomized clinical trials provided crucial data for 
fenfluramine’s approval. The first study showed a clinically relevant seizure frequency 
reduction (≥ 50 %) in 74.9 % of patients treated with fenfluramine hydrochloride as compared 
to 19.2 % observed in the placebo group (Lagae et al., 2019). Additionally, compared to 
placebo, the monthly convulsive seizure frequency was reduced by 62.3 % and 32.4 % with 0.7 
and 0.2 mg/kg/day fenfluramine hydrochloride, respectively (Lagae et al., 2019). The other 
study confirmed its clinical efficacy by reducing monthly convulsive seizure frequency (≥ 50 
%) in 54 % of patients as compared to 5 % in the placebo group (Nabbout et al., 2020). The 
main adverse effects were decreased appetite and body weight, diarrhea, fatigue, pyrexia, 




4.4. Other antiseizure drugs  
While medicating Dravet patients remains very individualized, several standard antiepileptic 
drugs have shown promising effects. As first-line therapeutics, valproic acid and clobazam are 
commonly used (Wirrell et al., 2017). The efficacy of these drugs individually has not shown 
promising results and so they are frequently combined with second-line therapeutics such as 
stiripentol and topiramate. Bromides, zonisamide, levetiracetam, phenobarbital or clonazepam 
serve as third-line therapeutics (Knupp and Wirrell, 2018; Wirrell et al., 2017). In addition, 
ethosuximid can be used for the treatment of absence seizures (Wirrell et al., 2017).  
Buccal or rectal benzodiazepines are indicated in persistent seizures lasting more than 5 
minutes, while intravenous benzodiazepines are indicated in the case of SE (Gataullina and 
Dulac, 2017). According to ILAE, “Tonic-clonic SE is a condition resulting either from the 
failure of the mechanisms responsible for seizure termination or from the initiation of 
mechanisms which lead to abnormally prolonged seizures (> 5 minutes). It is a condition that 
can have long-term consequences if lasting over 30 minutes.” Importantly, after frequent usage 
tolerance to benzodiazepines can develop due to GABAA receptor internalization (Hu and 
Ticku, 1994). 
4.5. Adjunctive therapy 
Although a variety of drugs are available for Dravet patients, the results of individual drug trials 
are often disappointing. Thus, doctors frequently prescribe adjunctive therapies, among which 
a ketogenic diet is commonly used. Both the traditional and modified ketogenic diets are 
commonly prescribed as second-line treatments (Wirrell et al., 2017). The diet consists of a 
high fat to carbohydrate and fat to protein ratio (3:1 to 4:1 respectively), thereby replacing 





Vagal nerve stimulation is another treatment option. The left cervical vagus nerve is stimulated 
with electrical impulses through a stimulator device consisting of a helical electrode connected 
to a pulse generator. The device emits electrical signals to the brainstem, which further sends 
signals to certain areas in the brain. The treatment has shown encouraging results, reducing 
seizures by more than 50 % in 52.9 % of Dravet patients (Dibué-Adjei et al., 2017). Currently, 
it is considered as a third-line treatment in Dravet patients (Wirrell et al., 2017). The right vagal 
nerve should be avoided except in specific circumstances since its innervation of the sinoatrial 
node could provoke bradycardia, asystole and further cardiac side effects (Giordano et al., 
2017). 
Corpus callosotomy and temporal lobectomy (in cases of temporal sclerosis) have been tested 
in a small number of Dravet patients. However, the success of these procedures was rather 
limited with more than 50 % seizure reduction achieved only in single patients (Dlouhy et al., 
2016; Wirrell et al., 2017). 
4.6. Polytherapy 
Although there are several therapeutic options available, polytherapy seems to be 
predominantly prescribed in Dravet patients of which 40 % use three and 25 % use four different 
antiepileptic drugs (Aras et al., 2015). In Europe, the most frequently prescribed antiseizure 
drugs are valproate, clobazam, topiramate, and stiripentol, used by 86, 55, 44, and 42 % of 
patients with Dravet syndrome, respectively (Brigo et al., 2018). Moreover, a combination of 
stiripentol, clobazam and valproate was the most commonly used combination, prescribed in 
29 % of patients (Brigo et al., 2018).  
The main challenge in Dravet syndrome is the achievement of seizure-freedom. Over time, 
certain algorithms for its treatment have been developed, such as the current one proposed by 




Figure 1. Algorithm for the treatment of Dravet syndrome proposed by the North American 





5. Ketogenic diet  
5.1 Origin and subtypes 
Fasting has been implemented in human medicine to treat epilepsy since at least 500 BC. It was 
also the only therapeutic measure mentioned in the Hippocratic collection (Wheless, 2008). 
Several centuries later, fasting appeared in the bible as a therapy for seizures, believed to be a 
demonic possession. The bible states that Jesus recommended fasting along with praying for 
curing convulsing demon possession (Wheless, 2008). 
In 1921, an important observation was made. Specifically, both starvation and a diet with high-
fat and low-carbohydrate content resulted in increased β-hydroxybutyrate and acetone 
production, today recognized as ketone bodies along with acetoacetate (Peterman, 1924; 
Woodyatt, 1921). In the same year, the ketogenic diet was offered to epileptic patients as a 
substitution for fasting (WILDER, 1921). Even though the diet showed promising effects with 
improvements in both seizure and behavioral outcomes, it was placed aside for decades due to 
the discovery of antiseizure drugs in the late 1930s (Wheless, 2008). In 1997, a captive 
television drama about a two-year-old boy, Charlie, suffering from intractable generalized 
seizures who became seizure-free following the introduction of a ketogenic diet over the next 
5 years, placed the scientific focus back on the ketogenic diet (Wheless, 2008). Numerous 
studies have been executed, leading to the discovery of the emerging role of the diet, not only 
in epilepsy, but also in other diseases (Freeman et al., 2007). Today, a ketogenic diet is the first 
choice in the treatment of glucose transporter deficiency syndrome (Glut1DS) and pyruvate 
dehydrogenase deficiency (PDHD) and second choice in the treatment of Dravet syndrome. In 
addition, it may be one of the early choices in the treatment for epilepsy with myoclonic‐atonic 
seizures, febrile infection-related epilepsy syndrome (FIRES), Angelman syndrome, infantile 




Currently, there are four different types of ketogenic diet. The classical, traditional diet is 
defined by a 3:1 to 4:1 mass ratio of fats to combined carbohydrates and proteins. On average, 
about 90 % of calories are ingested from fats.  The medium chain triglyceride diet is based on 
the consumption of more ketogenic oil, which due to its shorter chains of fatty acids allows 
more carbohydrates in the diet. The low glycemic index diet allows an increased intake of low 
glycemic index carbohydrates, leading to a lower calorie intake from fats (around 60 %). 
Finally, the modified Atkins diet is based on greater food variety, yet carbohydrates are limited 
to only 10-20 g per day (Knupp and Wirrell, 2018). 
Overall, the ketogenic diet is generally well tolerated in patients. Hypoglycemia, 
hyperlipidemia, acidosis, dehydration, lethargy, gastrointestinal symptoms, weight loss and 
kidney stones are the main side effects (Tian et al., 2019). 
5.2. Mechanism of action in epilepsy management 
The exact mechanism underlying the anticonvulsive effects of the ketogenic diet remains a 
mystery. Although several hypotheses have been proposed, it seems like the ketogenic diet 
targets multiple pathophysiological mechanisms that can contribute to neuronal 
hyperexcitability (Rho, 2017).  
For instance, ketone bodies demonstrated a direct anti-seizure effect in several animal models 
(Likhodii et al., 2003; Rho et al., 2002). In addition, ketone bodies can indirectly affect 
neurotransmission by increasing GABA and adenosine levels (Masino et al., 2012; Yudkoff et 
al., 2005), activating ATP-sensitive potassium channels (Rho, 2017), enhancing mitochondrial 
biogenesis and reducing oxidative stress (Bough et al., 2006; Rowley and Patel, 2013).  
Furthermore, the ketogenic diet reduces glycolysis by switching the cell’s metabolism to a more 
fat-based energy supply including fatty acids and ketone bodies (Masino and Rho, 2012). 




Titus and Priestley, 2014). Modulation of the tricarboxylic cycle by refilling its intermediates 
with acetyl-CoA produced from the oxidation of ketone bodies or fatty acids and increasing 
ATP production, represents another possible anti-seizure mechanism of the ketogenic diet (Rho, 
2017). The diet is indicated in patients with pyruvate dehydrogenase deficiency, the enzyme 
that converts pyruvate to acetyl-CoA. This deficiency limits cell bioenergetics, which can be 
compensated for by using ketone bodies for the direct synthesis of acetyl-CoA and enhancement 
of the TCA cycle (Wexler et al., 1997).  
As previously mentioned, the ketogenic diet is also indicated in patients with Glut1 deficiency. 
GLUT-1 transports glucose across the blood-brain barrier and its deficiency causes brain 
hypoglycemia that is associated with infantile seizures, acquired microcephaly, ataxia and 
spasticity. The ketogenic diet provides ketone bodies as an alternative brain fuel. They have the 
ability to enter the brain via the monocarboxylic acid transporter (Koch and Weber, 2019).  
5.3. Ketogenic diet for the treatment of Dravet syndrome 
Evidence for the efficacy of the ketogenic diet in the treatment of Dravet syndrome is constantly 
emerging. Several studies presented promising results by showing a diet response rate with ≥ 
50 % in seizure reduction in 52-77 % of patients. The outcome largely depended on the length 
of treatment. The effect was observed for all seizure types including generalized convulsions, 
hemiconvulsions, myoclonic seizures, atypical absence seizures, and status epilepticus 
(Caraballo, 2011; Dressler et al., 2015; Laux and Blackford, 2013; Nabbout et al., 2011; Tian 
et al., 2019; Yan et al., 2018). In addition, EEG abnormalities showed an improvement, 
especially in patients with better seizure protection (Caraballo, 2011). Furthermore, a 
significant improvement in cognition, language production, hyperactivity, attention and motor 
function was observed (Laux and Blackford, 2013; Nabbout et al., 2011; Tian et al., 2019; Yan 
et al., 2018) altogether implying that a ketogenic diet can greatly improve the quality of life in 




continued the diet because of its positive behavioral and cognitive effects (Nabbout et al., 2011). 
Aditionally, fewer antiseizure drugs were prescribed with the application of the diet (Caraballo, 
2011; Yan et al., 2018). Overall, the diet was well tolerated among patients and the main reason 
for termination was lack of efficacy.  
Adverse events arising during the first 2 weeks of the diet application are usually transient. 
They include hypoglycemia, ketosis, irritability, lethargy, lack of appetite and gastrointestinal 
symptoms (Yan et al., 2018). During diet maintenance, the main side effects comprise 
gastrointestinal symptoms (severe vomiting, constipation and diarrhea) and metabolic disorders 
(transitory anorexia, hyperlipidemia, acidosis) (Caraballo, 2011; Nabbout et al., 2011; Tian et 
al., 2019; Yan et al., 2018). With adjustments of the diet, some of the side effects like kidney 
stones, liver dysfunction and gastrointestinal symptoms were reduced to a tolerable level (Tian 
et al., 2019). The diet also showed advantages over pharmacological treatments including fewer 
neurotoxic adverse events such as lethargy, behavioral and cognitive symptoms (Laux and 
Blackford, 2013). 
Lastly, the ketogenic diet has been compared to other antiseizure drugs in Dravet syndrome. 
Surprisingly, it proved to be equally or more efficacious in seizure reduction than antiseizure 
drugs, including the gold standard combination of clobazam, stiripentol and valproate (Dressler 
et al., 2015). 
As a result, the ketogenic diet is proposed as an alternative treatment strategy in Dravet patients 
who did not reach sufficient improvement in seizures profile with three to four different 
antiseizure drugs (Cross et al., 2019; Wirrell et al., 2017).  The traditional ketogenic diet is 
indicated for children under 2 years of age, the traditional or modified Atkins diet for children 
between 2 and 12 years, and a modified Atkins diet for children over 12 years of age (Wirrell 




5.4. Ketogenic diet for other indications 
Over the last 20 years, the potential of the ketogenic diet in the treatment of other disorders has 
been established. The diet seems to be protective in many neurodegenerative disorders due to 
the improvement of mitochondrial function. For instance, impaired activity of mitochondrial 
complex I in Parkinson’s disease is assumed to be associated with the death of substantia nigra 
dopaminergic neurons and the development of motor symptoms. Ketone bodies are 
hypothesized to replace glucose as an energy source and therefore bypass the dysfunctional 
mitochondrial complex I (Barañano and Hartman, 2008). In Alzheimer’s disease, ketone bodies 
are postulated to overcome amyloid-induced pyruvate dehydrogenase and GLUT deficiency, 
mitochondrial dysfunction, and possibly protect against extracellular amyloid-β deposition 
(Barañano and Hartman, 2008; Paoli et al., 2014). Moreover, the ketogenic diet has been linked 
to the preservation of motor function in amyotrophic lateral sclerosis, possibly by increasing 
mitochondrial ATP production or reducing cell oxidative stress (Barañano and Hartman, 2008). 
Lastly, it has demonstrated protective effects in brain trauma and ischemia, possibly because 
ketones are the preferred energy source in an injured brain (Prins, 2008). 
The ketogenic diet also caused a marked improvement in the treatment of autism-spectrum 
disorders, depression, migraine and narcolepsy. However, the disease-modifying mechanisms 
remain unknown (Barañano and Hartman, 2008).   
The diet has also proved efficacious in the management of some metabolic diseases including 
phosphofructokinase deficiency and McArdle disease, with a specific glycogen phosphorylase 
deficiency, by improving energy deficits and switching to an alternative energy source (ketone 
bodies). In addition, the diet has been successful in the treatment of diabetes mellitus type 2, 
obesity and metabolic syndrome. By restricting carbohydrate ingestion, glycemic control is 
increased therefore reducing variations in insulin concentration and increasing fats beneficial 




Interestingly, the ketogenic diet may also play a role in the treatment of cancer. The underlying 
mechanism may comprise a lower metabolic flexibility of malignant cells, which cannot equally 
adjust to ketones as a novel energy substrate in comparison to normal cells (Seyfried and 
Mukherjee, 2005). In contrast to glucose, ketone bodies cannot produce essential products for 






6. Omics techniques 
6.1. Definition, application, benefits and limitations  
Over the past decades, the investigation of cellular and subcellular processes in different 
pathologies has become available using a range of new techniques, including “Omics” 
techniques. The beginning of the “Omics” era tracks back to 2003, when the entire human 
genome was sequenced as part of the human genome project (HGP). “Omics” comprises 
branches of science based on novel technologies for high-throughput biomolecular analysis, 
which enables simultaneous quantification of up to thousands of molecules at different cellular 
function levels (Vasilopoulou et al., 2016). The main aim of “Omics” is to fully characterize 
and quantify pools of biological molecules, thus gathering knowledge about the complete 
network of genes and gene products in a biological system (Vidal et al., 2011). Therefore, 
instead of regular hypothesis-driven studies, these studies are exploratory and knowledge-based 
systemic investigations. All “Omics” techniques share a name ending with the same suffix -
omics, such as proteomics, genomics, metabolomics etc. 
The central nervous system represents one of the most complex networks in the human body, 
due to various synergistic and complementary interactions between different brain regions. In 
order to fully understand its architecture and function, a systemic investigation with 
comprehensive brain function mapping combined with should be used and the high-throughput 
quantitative approaches of “Omics” studies could provide a valuable contribution 
(Vasilopoulou et al., 2016).  Among these, connectomics are already widely used for mapping 
neuronal connections (Lichtman et al., 2014) whilst proteomics, transcriptomics and 
metabolomics are used for molecular fingerprinting showing proteins, genes and metabolites 
profiles, respectively (Geschwind and Konopka, 2009). Altogether, these data could advance 
our current state of knowledge and identify novel disease biomarkers and diagnostic tools as 




Proteomic profiling is comprised of complete proteome characterization looking at protein 
structure, function, expression, interaction and any kind of modifications (Domon and 
Aebersold, 2006). It provides comprehensive information about gene function and is considered 
the most valuable dataset for biological system characterization. In contrast to transcriptomics, 
which relies on mRNA expression, proteomic profiling measures proteins that are biological 
function effectors, thus capturing not only their expression, but also any proteome modifications 
due to the cellular response to any perturbation at the protein activation level and downstream 
consequences of gene expression regulation (Cox and Mann, 2007).  
Metabolomics is the newest “Omics” discipline. It detects and quantifies free metabolites with 
a low molecular weight. As the metabolite concentration depends on metabolic reactions, the 
profiling provides a metabolic physiology fingerprint and information about in vivo enzymatic 
activity and regulation. In contrast, other screening techniques like transcriptomics or 
proteomics, only capture current gene or protein expression without quantification of the 
ongoing biochemical processes leading to those changes (Hollywood et al., 2006; Kanani et al., 
2008; Patti et al., 2012). Metabolomic screening is particularly relevant for brain research, 
where it combines molecular biology and neurophysiology, thus giving a completely new 
insight into systems biology (Vasilopoulou et al., 2016). 
While this area of research can provide extensive information about early disease diagnosis and 
monitoring, detection of disease biomarkers and novel drug target molecules, the main 
limitations of these technique remain to be the reproducibility and higher costs (Vasilopoulou 
et al., 2016). Therefore, hypothesis-driven techniques are still necessary for confirmatory 
research. 
Another limitation in human “Omics” studies is the difficulty in obtaining biopsies. Only bodily 




Animal models therefore play a crucial role in collecting valuable information about 
neurological diseases. They can be used for the comprehensive screening of brain tissue (Chen 
et al., 2015b; Constantinou et al., 2011; Davidovic et al., 2011; González-Domínguez et al., 
2015; Salek et al., 2010), thus avoiding concerns regarding post-mortem tissue (different causes 
of death, processing and sampling time etc). However, interspecies differences need be 
considered.  
In addition, metabolome, proteome or genome changes may vary depending on how well the 
model recapitulates disease pathology (McGonigle and Ruggeri, 2014; Suvorov and Takser, 
2008). Moreover, depending on the pathology in the model, one or more brain regions of 
interest should be carefully chosen for investigation (Ivanisevic et al., 2014; Salek et al., 2010). 
For accuracy, a critical amount of tissue is required, which is hard to obtain in rodents due to 
their small brain size. Therefore, samples are frequently pooled (Vasilopoulou et al., 2016). The 
examination of brain metabolomics in animal models can lead to the discovery of metabolic 
alterations contributing to brain dysfunction. Therefore, metabolomic data can help to 
understand the molecular basis of various neurological and psychiatric diseases (Vasilopoulou 
et al., 2016).  
“Omics” studies are very practical for broad data screening; however, their main limitation is 
the lack of precision. For instance, while proteomics studies can quantify the abundance of a 
certain protein in a specific brain region, they provide no data on protein distribution either 
within the cell layers or in individual cells and elucidate nothing about protein function. 
Therefore, these studies frequently serve as a research starting point to generate hypotheses. 
Lastly, metabolomics experiments should be thoroughly designed in advance in order to ensure 
that research aims can be accomplished. For example, tissue selection and preparation should 




genetic differences taken into account, and sampling times as well as the necessity for fasting 
should be determined. All aforementioned factors can significantly impact metabolome results 
and lead to unreliable data.  
6.2. “Omics” studies in epilepsy research 
Proteomics data have provided crucial information about physiological and pathophysiological 
brain function and contributed to the identification of disease-associated processes, pathway 
modifications and novel drug candidates (Khurana et al., 2020). Similarly, in epilepsy research, 
the application of molecular techniques could help elucidate molecular alterations underlying 
epileptogenesis and ictogenesis (Bosque et al., 2019). To date, most data comes from animal 
models of acquired structural epilepsy, which have provided evidence for molecular alterations 
associated with neuronal inflammation, synaptic and cellular plasticity, microglial activation, 
angiogenesis, cell stress, blood-brain barrier perturbation, cytoskeleton modification etc 
(Bitsika et al., 2016; Keck et al., 2017; Keck et al., 2018; Li et al., 2010; Liu et al., 2008; Walker 
et al., 2016). Data from the genetic epilepsies have so far been limited to genetic absence 
epilepsy and fragile X syndrome.  These findings pointed towards a change in the regulation of 
proteins involved in energy generation, synaptic transmission, inflammatory processes, 
membrane conductance and ribosomal translation (Danış et al., 2011a; Liao et al., 2008b; Xu 
et al., 2018).  A single transcriptomic study in a mouse model of Dravet syndrome showed 
developmental deficits in neural connectivity (Tsai et al., 2015). As of yet, a broad large-scale 
proteomic data set from Dravet syndrome has not been acquired.  
One of the first metabolomic studies in epileptology demonstrated that glutamate reuptake and 
glutamate-glutamine cycling are affected in patients with epilepsy leading to the accumulation 
of extracellular glutamate, cell toxicity and poor glucose and lactate utilization, thus resulting 




patients with epilepsy identified numerous biomarkers of disease, pharmacological targets, and 
evidence of epilepsy (Donatti et al., 2020).  
Recently, the term “metabolic epilepsies” has been introduced for all epilepsies with a 
metabolic etiology (Scheffer et al., 2016). Importantly, most patients with these disorders also 
possess a genetic defect (Scheffer et al., 2016). Therefore, there is a strong interest in the 
investigation of genetic epilepsies including Dravet syndrome to determine the associated 
metabolic changes and assess if their management could improve patients’ responsiveness to 










7. Future directions in Dravet syndrome treatment – knowledge gap 
The facilitation of orphan drug approval by the Orphan Drug Act in the USA (1983) and in the 
EU (2000) combined with technology advancement, led to greater higher interest and 
investment from pharma companies in the development of treatments for rare diseases, 
including Dravet syndrome (https://pharmaboardroom.com/articles/investments-and-deal-
activity-in-orphan-drug-products/). Over the last decade, progress in the treatment of Dravet 
syndrome has been made, resulting in three drugs gaining approval for its therapeutic 
management. However, we are still far away from the main goal of the treatment, which is 
seizure-freedom. While the available drugs do improve seizure control in some patients, most 
are not seizure-free even with the combination of several antiepileptic drugs. In addition, other 
disease symptoms progress drastically over time, the treatment of which is poorly managed. 
Therefore, the aim of Dravet syndrome treatment may be early disease management which 
should also prove prophylactic for symptoms occurring later in the disease course.  
Most findings regarding the pathophysiological mechanisms underlying the disease are derived 
from animal models of acquired structural epilepsy, while the knowledge about neurobiological 
changes associated with genetic epilepsies including Dravet syndrome, is still very limited. A 
better understanding of these mechanisms and their metabolic consequences may facilitate the 
identification of alternate targets and the development of therapeutic agents tailored to the 
patient’s needs. Therefore, patients could benefit not only from better seizure management, but 
also from an improvement of cognitive, motor and behavioral symptoms. In addition, the 
identification of novel biomarkers may facilitate a more rational selection of drugs or dietary 
approaches. 
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AIMS OF THE THESIS 
The aims of this thesis comprise: 
1. Characterization of a novel mouse model of Dravet syndrome, evaluating its face validity 
and suitability for future pharmacological and biomedical evaluation. 
2. Understanding the molecular and metabolic consequences of Scn1a genetic deficiency 
and the pathophysiological mechanisms developing through the course of the disease. 
3. Identification of possible candidates that could be therapeutically targeted in the 
treatment of Dravet syndrome. 













1. Manuscript I  
This chapter contains a manuscript submitted to the journal Neurobiology of Disease (doi: 
10.1016/j.nbd.2021.105423). The manuscript aimed to provide the first phenotype 
characterization of a mouse model of Dravet syndrome and highlight relevant proteome 





Proteomic signature of the Dravet syndrome in the genetic mouse 
model Scn1a-A1783V.  
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Background: Dravet syndrome is a rare, severe pediatric epileptic encephalopathy associated 
with intellectual and motor disabilities. Proteomic profiling in a mouse model of Dravet 
syndrome can provide information about the molecular consequences of the genetic deficiency 
and about pathophysiological mechanisms developing during the disease course.  
Methods: A knock-in mouse model of Dravet syndrome with Scn1a haploinsufficiency was 
used for whole proteome, seizure and behavioral analysis. Hippocampal tissue was dissected 
from two- (prior to epilepsy manifestation) and four- (following epilepsy manifestation) week-
old male mice and analyzed using LC-MS/MS with label-free quantification. Proteomic data 
sets were subjected to a bioinformatic analysis including pathway enrichment analysis. 
Differential expression of selected proteins was confirmed by immunohistochemical staining.  
Results: Analysis of seizure susceptibility and behavioral patterns confirmed an excellent face 
validity of the novel Dravet mouse model. As expected, proteomic analysis demonstrated more 
pronounced alterations following epilepsy manifestation. In particular, proteins involved in 
neurotransmitter dynamics, receptor and ion channel function, synaptic plasticity, astrogliosis, 
neoangiogenesis, and nitric oxide signaling showed a pronounced regulation in Dravet mice. 
Pathway enrichment analysis identified several significantly regulated pathways at the later 
time point, with pathways linked to synaptic transmission and glutamatergic signaling 
dominating the list. Interestingly, comparison of these data from a genetic epilepsy model to 
published data from acquired epilepsies suggests commonalities in molecular alterations 
comprising protein groups linked with GABAergic, glutamatergic, and dopaminergic 
neurotransmission, voltage-gated ion channels, synaptic plasticity, astrogliosis, angiogenesis, 




Conclusion: In conclusion, the whole proteome analysis in a mouse model of Dravet syndrome 
demonstrated complex molecular alterations in the hippocampus. Some of these alterations may 
have an impact on excitability or may serve a compensatory function, which, however, needs 
to be further confirmed by future investigations. The proteomic data indicate that due to 
molecular consequences of the genetic deficiency the pathophysiological mechanisms may 
become more complex during the course of the disease, and that the management of Dravet 
syndrome may need to consider further molecular and cellular alterations. Along this line, based 
on functional follow-up studies, the data set may provide valuable guidance for future 
development of novel therapeutic approaches.  
Key words: proteome, genetic epilepsy, epileptic encephalopathy, Scn1a, mice.  
 
Abbreviation list: 
MS  Mass spectrometry 
LC-MS/MS Liquid chromatography with tandem mass spectrometry 
Hprt  Hypoxanthine-guanine phosphoribosyltransferase 
VEGF   Vascular endothelial growth factor 
JAK-STAT The Janus kinase/signal transducers and activators of transcription 
PSD  Postsynaptic density 
CaMK  Calcium/calmodulin-dependent protein kinases   
nNOS  Neuronal nitric oxide synthase  
NO  Nitric oxide 







In the vast majority of patients with Dravet syndrome an SCN1A mutation can be identified, 
which results in functional deficiency of the encoded sodium channel subunit Nav1.1 
(Brunklaus and Zuberi, 2014; Dravet and Oguni, 2013). Dravet syndrome is characterized by 
seizures with a poor pharmacoresponse to available antiepileptic drugs (Wallace et al., 2016). 
Moreover, there is a high risk of sudden unexpected death in epilepsy (SUDEP) in Dravet 
patients (Kalume, 2013). Thus, despite the licensing of orphan drugs for Dravet syndrome there 
is still a particular need for novel therapeutic approaches tailored to the disease. While 
knowledge about the genetic cause provides a first basis for rational development of precision 
medicine approaches (Dugger et al., 2018), the elucidation of the molecular consequences of 
the genetic deficiency can further improve our understanding of the pathophysiological 
mechanisms and can provide a broader framework for the identification of novel targets and 
the subsequent development of innovative therapeutic concepts.   
Proteomic large-scale profiling constitutes one of the most promising tools providing 
comprehensive information about epilepsy-associated alterations at a functionally relevant 
molecular level. During recent years, first studies have been completed that identified proteome 
alteration in models of acquired epilepsy (Bitsika et al., 2016; Keck et al., 2017; Keck et al., 
2018; Li et al., 2010; Liu et al., 2008; Walker et al., 2016). Respective data for genetic epilepsies 
are rather limited with a focus on models of genetic absence epilepsy and fragile X syndrome 
(Danış et al., 2011b; Liao et al., 2008a; Xu et al., 2018). To our knowledge, the molecular 
consequences of Scn1a genetic deficiency have so far not been studied by quantitative whole 
proteome analysis. The characterization of the molecular signature of the Dravet syndrome may 
provide important clues to understand disease-associated alterations of neuronal homeostasis.  
Here, we completed a large-scale proteomic profiling study in a novel conditional mouse line 
carrying a human Dravet syndrome SCN1A mutation (Kuo et al., 2019; Ricobaraza et al., 2019). 




seizures in order to obtain information about both, molecular patterns during epileptogenesis 
and following epilepsy manifestation. The list of differentially expressed proteins was 
compared with published data sets from models of acquired epilepsy aiming to identify 
common epileptogenesis- and epilepsy-associated molecular patterns.  
Taken together, our findings improve the understanding of the complex molecular 
consequences of SCN1A genetic deficiency and provide a basis for discovery of novel 
innovative targets for prevention of disease progression and for therapeutic management of 





Material and methods 
Genetic mouse model: breeding and genotyping  
Breeding colonies of the parental lines B6(Cg)-Scn1atm1.1Dsf/J (#026133(Kuo et al., 2019; 
Ricobaraza et al., 2019)) and 129S1/Sv-Hprttm1(CAG-cre)Mnn/J (#004302(Tang et al., 2002)) were 
generated based on breeding pairs purchased from the Jackson Laboratory (Bar Harbor, Maine, 
USA). Conditional knock-in male mice with floxed Scn1a (mutation A1783V in exon 26) were 
crossed with female mice heterozygous for Cre recombinase (X-linked to neuronal promoter 
Hprt gene). The offspring resulted in heterozygous Dravet mice carrying the A1783V mutation 
(wildtype or heterozygous for Cre recombinase) or wildtype mice without the A1783V mutation 
(wildtype or heterozygous for Cre recombinase). Since the presence of Cre did not affect the 
phenotype, animals were divided into a Dravet group and a wildtype control group depending 
on the presence of the A1783V-Scn1a mutation. The mouse line has been chosen for the 
experiments considering that A1783V represents one of the clinically relevant mutations 
affecting the domain IV S6 transmembrane region of the alpha subunit of the type I voltage-
gated sodium channel in patients with Dravet syndrome (Lossin, 2009). 
The genotype of the animals was confirmed by PCR, using 5′-
GCAACTCTTCACATGGTACTTTCA-3′, 5’-GCACCTCTCCTCCTTAGAACA-3’ and 5′-
GGAGAAACACGAGCAGGAAG-3′ primers: wildtype, 164 bp; heterozygous pre Cre, 164, 
198 and 410 bp; and heterozygous post Cre, 164 and 198 bp (Fig. 1A). Presence of Cre 
recombinase in mice was also confirmed by PCR, using 5′-CTGGTGCTTTACGGTATCGC-
3′, 5’-TTCATAGAGACAAGGAATGTGTCC-3’ and 5′-AATCCAGCAGGTCAGCAAAG-3′ 
primers: WT allele, 217 bp; Cre allele, 450 bp. 
Experiments were approved by the responsible government of Upper Bavaria (license number 
55.2-1-54-2532-166-2015 and 55.2-1-54-2532-168-2016). All experiments were conducted in 




Welfare act. All experiments were planned and carried out considering the ARRIVE guidelines 
and the Basel declaration (http://www.basel.declaration.org) including the 3R concept. 
Twenty mice were used for sampling of brain tissue for proteomic analysis with five animals 
per genotype and time point. Sections from four wildtype and four Dravet mice aged 4 weeks 
were used for qualitative immunohistochemical analysis of selected proteins.  
Another group of animals was used for characterization of the phenotype and face validity of 
the line. From 38 heterozygous mutant mice, 23 (11 male; 12 female) survived the phase around 
weaning, which is characterized by a high seizure-associated mortality rate. Data from these 
animals were compared with those from 21 wildtype littermate controls (11 male; 10 female). 
One wildtype and one Dravet female mouse from this group were later used for EEG-telemetry 
recordings.  
In addition, baseline data from 22 heterozygous mutant mice were considered for seizure 
monitoring based on parallel video monitoring and telemetric EEG recordings. These animals 
were also prepared for ECG recordings and were further used for a separate study assessing 
effects of ketogenic diet in Dravet mice (manuscript in preparation). 
 
Housing of animals 
Each litter was housed in individually ventilated cages (Tecniplast, Hohenpeißenberg, 
Germany) from birth until weaning time (3 weeks). Following this phase, mice were grouped 
in 3-5 animals per standard Makrolon type III cage (Ehret, Emmendingen, Germany). Animals 
used for sampling of brain tissue for proteomic analysis were single caged following weaning 
in type II open cage (Ehret, Emmendingen, Germany) in order to confirm presence of seizures. 
Animals used for behavioral assessment were single caged 2 weeks prior to behavioral 
assessment. The order of cages was randomized (randomizer.org). 
Each cage was supplied once weekly with fresh sawdust as a bedding material (Lignocel, 




(Tecniplast, Hohenpeißenberg, Germany; Zoonlab GmbH, Castrop-Rauxel, Germany). 
Standard conditions in the animal facility were set to: lights on from 6 am to 6 pm, temperature 
22 ± 2 ̊ C, and humidity 50 ± 10 %. Animals received food (ssniff® R/M-H, Sniff, Soest, 
Germany) and water ad libitum with Dietgel76A offered as a supplement (Sniff, Soest, 
Germany) between postnatal days P14 and P26.   
 
Brain samples for proteomic analysis 
Brain samples were obtained at two different time points from five mice per genotype and time 
point. Two-week-old mice (early time point, prior to seizure onset) were sacrificed by 
decapitation, whilst the four-week-old mice (later time point) were sacrificed by cervical 
dislocation. Hippocampal tissue from the left hemisphere was dissected and fresh frozen in 
liquid nitrogen (Besamungsstation München-Grub, Poing, Germany) using 1.5 ml Protein 
LoBind Tubes (Eppendorf, Wesseling-Berzdorf, Germany. The experimenter was blinded to 
animals’ genotype and order of animals for dissection was randomized (randomizer.org). Once 
the samples were frozen and stored at -80 °C until analysis. The right brain hemisphere was 
collected and left in 4% PFA solution for 24 hours and then switched to 30 % sucrose solution. 
The brain was cut into 40 µm thick slices, which were later used for immunohistochemistry. 
 
Proteome analysis 
Untargeted proteome analysis was carried out by an experimenter not involved in the in vivo 
experiments, to avoid any expectation-triggered bias. Snap frozen hippocampus samples were 
directly bead milled with a Precellys homogenizer (Peqlab, Lutterworth, U.K.) in extraction 
buffer (10mM Tris-HCl pH 7.6 with 1 % NP40, 10 mM NaCl and Complete protease inhibitors) 
as previously described (Molin et al., 2015). The total protein concentration in sample was 
measured by the Bradford assay. A modified filter-aided sample preparation (FASP) method 




A Q Exactive HF mass spectrometer was used for proteomic screening (ThermoFisher 
Scientific, Dreieich, Germany) with operation in the data independent acquisition (DIA) mode 
(Lepper et al., 2018). Per sample one injection unit of the HRM Calibration Kit (Biognosys, 
Schlieren, Switzerland, #Ki-3003) was used for spiking 1 µg of peptides for indexing of 
retention time. Samples were loaded automatically onto the UPLC system (Ultimate 3000, 
Dionex, Sunnyvale, CA). The system contained a nano trap column (inner ∅ = 300 μm × 5 mm, 
packed with Acclaim PepMap100 C18, 5 μm, 100 Å; LC Packings, Sunnyvale, CA). Following 
5 minutes of elution from the trap column, the peptides were separated by reversed-phase 
chromatography (Acquity UPLC M-Class HSS T3 Column, 1.8 μm, 75 μm × 250 mm; Waters, 
Milford, MA) using a 7−27 % gradient of acetonitrile (flow rate of 250 nL/minute, 90 minutes), 
followed by two short gradients of 27−41 % acetonitrile (15 minutes) and 41−85 % acetonitrile 
(5 minutes). After 5 minutes at 85 % acetonitrile, the gradient was reduced to 3 % acetonitrile 
over 2 minutes and then allowed to equilibrate for 8 minutes. All acetonitrile solutions 
contained 0.1 % formic acid. 
The DIA method comprised alternating mass spectrometry (MS) full scans spanning from 
300−1650 m/z at 120,000 resolution, followed by 37 DIA window scans at 30,000 resolution 
for peptide fragmentation with a variable width ranging from 300−1650 m/z. Normalized 
collision energy was adjusted to 28, with profile type spectra recording.  
The DIA liquid chromatography with tandem MS (LC−MS/MS) raw files were converted 
(HTRMS converter) and analyzed (Spectronaut version 11, Biognosys, Schlieren, Switzerland) 
as described (Lepper et al., 2018). An automatic calibration mode was chosen with precision 
indexed retention time (iRT) alignment enabled for the application of the nonlinear iRT 
calibration strategy. Peptides were identified by comparison with an in-house accumulated 
spectral library, which has been obtained from mouse brain samples measured on the same MS 
set-up with a data-dependent acquisition mode. Peptide identification was filtered for a false 




proteins, applying MS2 area based summed precursor quantities. The data filtering function 
was set to q-value percentile mode applying a 50 % setting, thus enabling a match between 
runs. This setting allows only peptide precursor signals passing the FDR threshold of 1 % in 
over 50 % of all samples to be further considered for identification and quantification, thus 
working towards a reduction of false positive identifications. The sum of abundances of all 
unique peptides per protein was log2 transformed, and obtained values were compared between 
groups with unpaired Student’s t-test and p<0.05 was set as the level of significance. 
 
Pathway enrichment analysis  
Pathway enrichment analysis was completed using a publicly available pathway tool 
(Consensus PathDB over-representation tool, (Kamburov et al., 2009)). A background list was 
used, comprising of all identified proteins. Only pathways with both, a p<0.01 and at least two 
dysregulated proteins, were considered. Only pathways reaching a q<0.01 (=p-value corrected 
for multiple testing using the FDR method) were considered significant and discussed in this 
study. Protein abundances of all proteins assigned to significantly changed pathways were 
visualized in a heat map. Individual fold changes for each animal were calculated by dividing 
their value against the wildtype group’s mean and then log2 transform the value. The resulting 
matrix was visualized using R software version 3.5.1 (Team, 2017) and “gplots” package 
(Warnes et al., 2016). 
 
Immunohistochemical staining of PPP1R1B (DARPP-32) 
In order to further confirm expression alterations of selected proteins, brains from four-week-
old wildtype and Dravet mice (n=4 per group) were used for immunohistochemistry. Free-
floating sections were washed in PBST (Phosphat-buffered saline, 0.1% Tween 20) at room 
temperature and heat-induced epitope retrieval (HIER) was performed at 80 °C for 30 minutes 




Endogenous peroxidase was inhibited (3 % H₂O₂ in TBS for 60 minutes). Slices were rinsed in 
PBST and a blocking step in 6 % goat serum (60 minutes) was performed to prevent non-
specific antibody binding. Sections were then incubated overnight at 4 °C with a monoclonal 
rabbit DARPP32 primary antibody (Abcam, Berlin, Germany, Cat# ab40801, lot# GR3213231-
3) at 1:2500 dilution. The next day, sections were washed in PBST and incubated for 60 minutes 
at room temperature with biotinylated goat anti-rabbit secondary antibody (Vector laboratories, 
Cat# BA-1000, lot# 2F0430) at 1:1000 dilutions. After washing steps in TBST, brain sections 
were incubated at room temperature in VECTASTAIN ABC-Peroxidase Kit (Vector 
Laboratories Cat# PK-4000, RRID: AB_2336818, lot#2337238, dilution 1:100, 60 minutes). 
The slices were washed in PBS and stained using SIGMAFAST™ 3,3′-Diaminobenzidine 
tablets (Sigma-Aldrich, Darmstadt, Germany, Cat# D4418, lot# SLBR2966V) for 1 minute.   
Brain sections were quickly rinsed in distilled H2O, washed in PBS, mounted on microscope 
glasses using PBST, and cover slipped with Entellan® (107960, Merck, Darmstadt, Germany). 
Negative controls were processed in parallel without the primary antibody.  
 
Immunohistochemical staining of HSD11B1  
The staining protocol for HSD11B1 was identical to the one described above (DARPP-32), 
with the following exceptions. Inhibition of endogenous peroxidase was done in 3 % H₂O₂ in 
TBS for 15 minutes.  A blocking step was performed in 1.5 % goat serum for 120 minutes. The 
primary antibody was HSD11B1 (Abcam, Berlin, Germany; Cat# ab39364, lot# GR3247054-




Bright field images were captured at 4x, 10x and 40x magnification with an Olympus BH2 




Göttingen, Germany), and an AMD AthlonTM 64 processor based computer with an image 
capture interface card (Axiocam MR Interface Rev.A; Zeiss, Göttingen, Germany).  
 
Hyperthermia-induced seizures and threshold determination 
Hyperthermia-induced seizures were analyzed in mice at postnatal day 23, 25, and 32. Mice 
were transported to the laboratory 30 minutes prior to seizure induction. Temperature and light 
in the laboratory were adjusted to 22 ± 2 ̊ C and 600 lux. At all experimental days, tests began 
at 12 p.m. with a randomized order of animals (randomizer.org). Observers were blind to 
animals’ genotype as far as possible. At the early time point blinding proved to be difficult 
considering the obvious phenotype (lower body weight). The whole procedure was video 
recorded (Axis communications, Lund, Sweden). Body temperature was measured 
continuously with a RET-4 rectal probe (Physitemp, Clifton, New Jersey, USA), which was 
placed in warm saline solution (B. Braun Vet Care GmbH, Tuttlingern, Germany) before use. 
Subjects were placed in a plexiglass cylinder for 5 minutes to habituate to the environment and 
to record basal body temperature data. Then, the IR lamp connected to the temperature 
controller (Physitemp, Clifton, New Jersey, USA) was turned on to slowly increase the body 
temperature with a ramping of 0.5 ̊ C per 2 minutes (Oakley et al., 2009). Heating was stopped 
immediately when generalized tonic-clonic seizures were observed or when the body 
temperature reached 42 ̊C. Animals were allowed to cool down before returning them to their 
home cage. All equipment was cleaned between subjects with 70 % ethanol (CLN, Langenbach, 
Germany). 
Severity of hyperthermia-induced seizures was assessed based on the Racine scoring system 
with scores: I (mouth and facial movements), II (head nodding), III (forelimb clonus), IV 
(rearing with forelimb clonic convulsions) and score V (generalized clonic convulsions 





Spontaneous seizures  
In order to obtain first information about the onset of spontaneous seizures, their frequency, 
duration and severity score, a continuous video monitoring was started in all animals in the 
second postnatal week and continued following weaning with a total monitoring time of 6 
weeks. Videos have been carefully reviewed by experienced technicians with maximum 8x 
speed and all generalized seizures were documented.  
Two eight-month-old female mice (one wildtype, one Dravet) and 22 twelve-week-old Dravet 
mice (11 males, 11 females) underwent survival surgery for telemetry (ETA-F10 or HD-X02, 
DSI, St. Paul, USA) and EEG electrodes implantation. The order of animals was randomized 
(randomizer.org). Thirty minutes before anesthesia induction, mice received 1 mg/kg 
meloxicam s.c. (Metacam®, Boehringer Ingelheim, Germany). For general anesthesia mice 
received 400 mg/kg chloral hydrate i.p. (Carl Roth, Karlsruhe, Germany) (n=2) or isoflurane 
(Isofluran CP®, Henry Schein Vet, Hamburg, Germany) with a concentration of 4 % and 1.5 
% for anesthesia induction and maintenance, respectively (n=22). The local anesthetic 
bupivacaine (0.5 %; Jenapharm®, Mibe GmbH, Brehna, Germany) was applied subcutaneously 
to surgical areas affected by transmitter implants and placement of leads. For intracranial 
electrode placement, bupivacaine with epinephrine (0.5 % + 0.0005 %; Jenapharm®, Mibe 
GmbH, Brehna, Germany) was applied subcutaneously.  
Firstly, the skin was opened in the dorsocaudal part of the scapula region for placing the 
telemetric transmitter subcutaneously. Mice were then fixed in a stereotactic frame and three 
screws were inserted in the skull. The negative EEG lead was connected to the screw over the 
cerebellum. The positive EEG lead was connected to a bipolar Teflon-isolated stainless-steel 
electrode, which was implanted into the CA1 region of the hippocampus (ap: - 2,00; lat: + 1,3; 
dv: - 1,6). The electrode was fixed with Paladur (Heraeus®, Hanau, Germany). The skin over 
the skull was closed with absorbable sutures, while the initial cut for the transmitter placement 




As stated above 22 animals were prepared for additional ECG analysis in the context of another 
study. Therefore, the negative ECG lead was fixed intramuscularly to the right pectoral muscle, 
whilst the positive ECG lead was fixed left to xyphoid prior to electrode implantation. Skin 
over the ECG connections was closed with absorbable sutures (Smi AG, St. Vith, Belgium). 
Animals were given oxygen until regaining consciousness. On the following day, mice received 
1 mg/kg meloxicam s.c. Mice were allowed to recover for full 2 weeks followed by a two-week 
continuous recording phase. In parallel, animals were video monitored (Axis communications, 
Lund, Sweden) in order to confirm and analyze behavioral seizure activity. Data were acquired 
with Ponemah software (Ponemah R, v. 5.2.0, DSI, St. Paul, USA), and seizure activity was 
detected automatically (NeuroscoreTM v. 3.0, DSI, St. Paul, USA).  
 
Behavioral characterization 
Following hyperthermia-induced seizures, all animals were tested in different behavioral 
paradigms except for one female Dravet mouse and one female wildtype mouse related to an 
age difference to the remaining animals. Thus, 22 Dravet mice (11 males; 11 females) and 20 
wildtype (11 males; 9 females) mice were used for behavioral assessment.  
One male Dravet mouse died following a spontaneous seizure and was therefore not exposed 
to the elevated plus maze and accelerated rotarod test. Data from one male Dravet mouse were 
not considered in the saccharin preference test, due to leakage of one of the water bottles. 
During all behavioral paradigms, animals were single-housed as a presupposition for the social 
interaction test. Social interaction was analyzed at an age of 7 weeks. The order of the 
subsequent tests was as follows: open field test, saccharin preference test, elevated plus maze 
and accelerated rotarod test (Fig. 1B). The testing was completed until an age of 10 weeks. The 
order of animals for each test was randomized (randomizer.org). 
Nest-building activity as well as saccharin preference were assessed in the home cage. All other 




were completed in a test room (temperature 22 ± 2 ̊ C, humidity 55 ± 5 %) under different light 
conditions adjusted to the specific paradigm (stated below). All tests were carried out in 
morning hours (starting from 8 a.m.). All behavioral test runs were documented by 
photographing (nest complexity) or video-recording (all other tests).  
  
 
Fig. 1. A PCR genotyping for distinguishing Dravet mice with Cre activated A1783V mutation 
(post Cre heterozygous) and wildtype mice. B Experimental timeline. 
 
Open field test 
The open field paradigm is a widely used test for assessment of exploratory behavior and 
locomotion in an unfamiliar environment (Carola et al., 2002). Mice were placed in the test 
room for 1 hour to habituate (lighting 15-20 lux). Two round shaped arenas (Ø 61 cm, height 
40 cm) were simultaneously used for the test. Time spend in three different zones (wall, middle 
and center) was analyzed with Ethovision 8.5 software (EthoVision XT, RRID:SCR_000441). 
Each mouse was placed in one arena, 10 cm from the wall, and facing the wall. Locomotion 
was recorded for 30 minutes. Rearing behavior was counted manually. After completing the 
test, mice were returned to their home cage. The arena was cleaned with 0.1 % acetic acid before 
continuing with the next animal. 
 
Saccharin preference test  
The saccharin preference test was used to test anhedonia-associated behavior as one of the 




consecutive test days in the home cage. Animals were provided with two water bottles. Tests 
were done in four consecutive 24 hours long periods. First, both bottles were filled with water 
to determine water intake over 24 hours. Then, the bottle on the left side was filled with a 0.1 
% saccharin solution. During the next day, both bottles were again filled with water. At the last 
day, the right bottle was filled with saccharin solution in order to test for a potential side 
preference bias. Liquid consumption was measured after each period.  
 
Nest-building activity  
During postnatal week five, mice were placed individually in type III open cages. The following 
week animals were as always provided with two new nestlets and nest complexity was assessed 
on a daily basis. Nests were photographed each morning. The images were later scored by an 
investigator unaware of the group allocation. Nest complexity was ranked according to the 
scoring system developed by Jirkof and colleagues (Jirkof et al., 2013): score 0 = nestlet intact, 
possibly carried around the cage; score 1 = nestlet is poorly manipulated with more than 80% 
of the nestlet intact; score 3 = evident nest site with most of shreds in the nest site, less than 
80% nestlet material intact, nest is hollow in bedding and mice begin to build walls; score 4 = 
flat nest, hollow in bedding, walls are higher than mice and encasing the nest less than 50%; 
score 5 = complex, bowl-shaped nest with walls higher than mice and encasing the nest more 
than 50%. 
 
Social interaction test  
The social interaction test was performed to assess autism-associated behavioral patterns and 
affinity towards interaction with another mouse. Mice were kept single in a type III open cage 
for 2 weeks prior to testing. On the first 2 days, animals were transported to the test room 
(lighting 15-20 lux) and placed in an empty type III open cage for 10 minutes to habituate. On 




the same sex, same genotype and approximately same weight were then simultaneously placed 
in an empty cage and left for 10 minutes. Active and passive social interaction were measured 
with a stopwatch by an observer blind to animal genotype and sex. The cage was cleaned with 
0.1 % acetic acid between subjects. Sniffing, grooming or following the partner as well as 
aggressive behavior were considered as active social interaction. Laying or sitting next to each 
other, without any interaction was classified as passive social interaction (Holter et al., 2015). 
 
Elevated plus maze  
The elevated plus maze is generally used to assess anxiety-like behavior in rodents (Ben-Hamo 
et al., 2016). Mice were placed in the test room for 1 hour prior to the experiment. The maze 
comprises two open arms (40 cm long and 10 cm wide) and two closed arms (same dimensions 
with walls 15 cm high). The plus maze was elevated 68 cm above the floor. Light was set to 
approximately 200 lux in open and 60 lux in closed arms. Animals were placed in the center of 
the maze facing the open arm. Five-minute-long trial was recorded with Ethovision XT. Head-
dipping and stretching behavior (exploring open arms with head, while the body stays in closed 
arms or center part of the maze) were recorded manually by observers blinded to animals’ group 
allocation. The maze was cleaned with 0.1 % acetic acid between animals.  
 
Accelerated rotarod test 
The accelerated rotarod test is widely used to evaluate motor performance in mice (Shiotsuki 
et al., 2010). Before experiment onset, mice were placed in the test room for 1 hour to habituate 
(15-20 lux). A rotarod apparatus (Ugo Basile 47600, Varese, Italy) was used to assess animals’ 
motor coordination. The settings were chosen so that the rotation accelerates from 4 to 40 rpm 
over 5 minutes. Each animal was subjected to four consecutive trials with approximately 2 
minutes break for cleaning the rod (0.1 % acetic acid). Testing was carried out at three 




were always tested before females. Passive rotations were counted and time staying on rod as 
well as current speed were noted. 
 
Statistical analysis 
Statistical analysis was performed with R version 3.5.1. GraphPad Prism (Version 5.04 and 
6.01, GraphPad, USA) was used for data visualization, except for heat maps visualized with R 
and Venn diagrams with an online tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). 
Spearman correlation matrix was calculated using R version 3.5.2. The significance level for 
correlation analysis was set at < - 0.5 or > 0.5. Animals with missing data were not considered 
for the respective correlation analysis. 
All data were expressed as mean ± SEM with exception of nest complexity data, for which the 
median is illustrated in the respective graph. All results were first checked for possible batch 
effects. If present, batch effects were considered in the statistical analysis.  
Two-tailed unpaired t-tests were used for comparison between experimental and control group 
where indicated. Two-, three-, four- and five-way ANOVAs were used to test the effects of 
genotype, sex, time, batch and their interaction where appropriate. Comparisons, which 
included multiple measurements, were tested using repeated measures ANOVA. ANOVA tests 
were followed by a Bonferroni post-hoc test. Two-tailed Mann-Whitney non-parametric test 
was used for analyzing nest complexity scores. The significance level was set at p < 0.05 for 
all tests.  
 
Data availability 
A complete list of abbreviations of significantly regulated proteins mentioned in the 






Breeding pattern and outcome 
Twenty-three female mice heterozygous for Cre recombinase (129S1/Sv-Hprttm1(CAG-cre)Mnn/J) 
were bred with 21 conditional knock-in male mice with floxed Scn1a-1783V (B6(Cg)-
Scn1atm1.1Dsf/J) in pairwise and trio matings split in two different batches. Eighteen of them 
delivered litters with a total of 38 heterozygous mutant mice (Dravet mice) and 41 wildtype 
littermates. The sex ratio in the offspring was almost balanced with 38 males (19 Dravet; 19 
WT) and 41 females (18 Dravet; 23 WT). Due to the 40 % mortality rate around the time of 
weaning we lost 15 Dravet mice. The remaining 23 Dravet mice and randomly selected 21 
wildtype mice (randomizer.org) were used for model characterization.  
 
General condition, body weight development, seizure thresholds and spontaneous seizures  
The body weight of Dravet mice proved to be significantly lower at the time point of weaning. 
However, following weaning affected animals showed a good development of body 
conditioning scores finally reaching a body weight comparable to wildtype mice (Fig. 2A).  
In response to hyperthermia induction all Dravet mice exhibited generalized tonic-clonic 
seizures at all three testing days. In contrast, their wildtype littermates did not exhibit motor 
seizure activity despite ramping of the body temperature up to at least 41 °C.  
The number of Dravet mice showing running and bouncing behavior increased with repeated 
hyperthermia induction reaching 18/23 animals on P32. The average threshold temperature for 
seizure induction on P23, P25 and P32 amounted to 39.7 ± 0.9 °C at P23, 39.7 ± 0.6 °C at P25, 
and 39.1 ± 0.5 °C at P32 (mean ± SD, Fig. 2B). Seizure duration increased in a significant 
manner with subsequent stimulations (Fig. 2C). No differences were observed when comparing 




Fig. 2. Body weight, spontaneous and hyperthermia-induced seizures. A Body weight 
development following weaning. Body weight in animals with a Dravet genotype (males n = 
11; females n = 11) proved to be significantly lower in the early phase following weaning 
(females until P25, males until P41) as compared to wildtype mice (males n = 11, females n = 
9) (Unpaired t-test; * p < 0.05 males, # p < 0.05 females, mean ± SEM). B Seizure threshold 
temperature at P23, P25, and P32. The threshold significantly decreased on P32 compared to 
previous testing. C Total duration of hyperthermia-induced seizure activity, calculated as the 
sum of all motor seizure periods occurring immediately following stimulation. The duration 
significantly increased with repeated stimulations.  B-C Data are from 11 male and 12 female 
animals with a Dravet genotype (Two-way RM ANOVA, Bonferroni post hoc; * p < 0.05, mean 
± SEM). D Representative EEG recording of a generalized tonic-clonic seizure (Racine score 
V, followed by running und bouncing) in an adult female mouse. 
 
Video monitoring of experimental animals in their home cages demonstrated that the animals 
develop spontaneous motor seizures starting at P16. The seizures observed included generalized 
tonic-clonic seizures, sometimes associated with running and bouncing indicating seizure 


























































































and lack of responsiveness to external stimuli were observed. Between P20 and P23 several 
Dravet mice died. In several instances video monitoring indicated that death occurred directly 
associated with a generalized seizure in these animals, thus, indicating that animals died from 
probable SUDEP. The mortality rate reached 40 %. The remaining 23 Dravet animals were 
used for behavioral characterization. SUDEP or probable SUDEP seems to be a rare event in 
older animals as only one animal was found dead in the cage at a later time point following the 
fourth postnatal week.  
To further confirm spontaneous seizure activity, first telemetric EEG recordings were 
performed in combination with simultaneous video recordings in an adult female Dravet mouse 
in comparison with a female wildtype mouse. During the one-week recording, a Dravet mouse 
exhibited multiple generalized tonic-clonic seizures often followed by running and bouncing. 
Assessment of the EEG recordings confirmed electrographic seizure activity with high 
amplitude spiking over 500 µV (Fig. 2D). In the wildtype mouse, we did not obtain evidence 
for electrographic seizure events.   
Additional recordings in a group of three-month-old Dravet mice confirmed a high penetrance 
of the epilepsy phenotype with multiple generalized tonic-clonic seizures in 19/22 mice. On 
average, mice experienced seven seizures per week (range: two to 16; data not shown). Seizures 
frequently occurred in clusters with animals often exhibiting seizures at only two subsequent 
days per week (range: one to four, data not shown). The average seizure duration was 50.19 s 
(data not shown).  
 
Phenotype: behavioral alterations  
In the open field paradigm, hyperlocomotion was evident in male and female Dravet mice. 
Throughout the 30 minutes test, the total distance moved and the rearing frequency reached 
significantly higher levels in Dravet mice as compared to wildtype animals (Fig. 3A-B). 




thigmotaxis proved to be increased in Dravet mice with more time spent in the wall zone. Time 
spent in the other zones (middle and center) was not affected by the genotype (Fig. A.1C).  
 
 
Fig. 3. Open field test, saccharin preference and nest-building behavior. A Distance moved 
in open field test over 30 minutes, divided into mean intervals of 5 minutes. The total distance 
moved of Dravet mice significantly exceeded that of wildtype mice. B Rearing frequency. 
Dravet mice exhibited more frequent rearing positions than wildtype mice.  A-B Data are from 
22 animals with a Dravet genotype and 20 wildtype animals (Three-way RM ANOVA, 
Bonferroni post hoc; * p < 0.05, mean ± SEM). C-D Water or saccharin solution consumption 
per 24 hours. Both, Dravet mice and wildtype mice preferred saccharin solution over water, 
independent of a side preference. E Total saccharin solution consumption over both days. 
Dravet mice consumed significantly less saccharin solution as compared to wildtype mice. C-
E Data shown are from 21 animals with a Dravet genotype and 20 wildtype animals (Three-
way ANOVA, Bonferroni post hoc; * p < 0.05, mean ± SEM). F Nest complexity score over 7 
days. As shown in the graph, nests of Dravet mice (n=22) received lower scores as compared 

































































































































































Regardless of the genotype a preference of saccharin solution over water was observed. 
However, the amount of saccharin consumed by wildtype mice exceeded that in mice with the 
Dravet genotype. In line with this finding, the percentage of consumed saccharin solution 
proved to be reduced in Dravet mice (mean ± SD: Dravet mice 64.07 ± 8.64 %; wildtype mice 
70.38 ± 6.41 %) (Fig. 3E). 
Interestingly, when saccharin consumption was compared between the first and the second 
exposure, Dravet mice consumed similar amounts, while an increase in the consumption of 
saccharin solution became evident in wildtype mice (Fig. 3C-D). Findings proved to be 
comparable in male and female mice.  
Assessment of nest-building behavior as a non-essential activity, demonstrated a poorer 
performance in mice with a Dravet genotype (Fig. 3F). 
When analyzing social interaction following a period of social isolation with single-housing, 
all Dravet mice spent more time engaged in active and less time in passive social interaction, 
when compared to wildtype littermates (Fig. A.1A-B).  
In the elevated plus maze Dravet mice spent an increased time in aversive parts, i.e. the open 
arms of the maze (Fig. A.1D). In addition, a higher frequency of head dips, as well as a reduction 
in stretching behavior, was evident in all Dravet mice (Fig. A.1E-F). Sex differences were not 
observed. 
We applied the accelerated rotarod test to address disturbances in motor coordination. During 
the habituation, animals from both groups showed a “learning” curve with an improvement in 
the performance with subsequent trials. Thereby, it was evident that the improved performance 
was related to an increased focus of the animals on the task. When compared to wildtype mice, 
Dravet mice stayed longer on the rod. Also, females performed better than males in both, control 
and experimental group (Fig. A.1G-I).  
The Spearman correlation coefficients between selected parameters were calculated. Open field 




social interaction (active r=0.69, passive r=-0.52), nest complexity score (r=-0.57), time spent 
in aversive parts (r=0.58), and number of head-dips in the elevated plus maze test (r=0.76).  
 
Proteomic profiling 
Proteomic profiling identified over 4000 different proteins in the mouse hippocampus samples. 
Comparison of protein abundance revealed significant alterations in the expression of 205 and 
881 proteins as a consequence of the Scn1a genetic deficiency in two- and four-week-old Dravet 
mice as compared to wildtype littermates, respectively (unpaired t-test, p<0.05, Fig. 4A). While 
the majority of these differentially expressed proteins were up-regulated at the early time point, 
more proteins proved to be down-regulated at the later time point (Fig. 4B). As a down-
regulation of proteins can be a general consequence of neuronal damage and cell loss, we 
checked the expression of the neuronal marker NeuN, which remained at control level at both 
time points (data not shown). Moreover, we confirmed that the heterozygous loss-of-function 
Scn1a mutation did not result in changes in NaV1.1 protein abundance regardless of the time 
point (data not shown). Although one would not necessarily expect changes in protein 
expression as a consequence of a missense mutation, this finding is of relevance for model 
characterization as, both, enhanced degradation of a non-functional protein as well as a 
compensatory up-regulation of expression would have been possible.  
A direct comparison of the datasets from both time points revealed an overlap of 67 
differentially expressed proteins (Fig. 4A). Most of the proteins maintained the direction of 
change. However, some proteins were down-regulated at the earlier time point, but later showed 




Fig. 4. Differentially expressed proteins in Dravet mice. A Overlap in differentially expressed 
proteins of two- and four-week-old Dravet mice illustrated by Venn diagram. B Total number 
of differentially expressed proteins in two- and four-week-old Dravet mice. C Heat map 
illustrating differential protein expression in in two- and four-week-old Dravet mice.  
 
While a more pronounced proteome alteration was evident at the late time point, the functional 
annotation of differentially expressed proteins from both time points revealed some similarities 
in the qualitative pattern of protein regulation with a comparable distribution of regulated 
proteins to different functional groups (Fig. 5A).  
The majority of regulated proteins were classified as nucleic acid binders, enzyme modulators 
and transferases at the earlier time point, and enzyme modulators, hydrolases and transferases 




pronounced protein regulation was evident at the later time point (Fig. 5B). Proteins associated 
with catalytic activity and binding exhibited the strongest regulation at both time points.  
 
Fig.  5. Classification of differently expressed proteins. Functional (A) and molecular (B) 
annotation of differentially expressed proteins in two- and four-week-old Dravet mice.  
 
Differential Protein Expression – early time point 
Proteomic profiling in Dravet mice prior to the occurrence of first spontaneous seizures and 
epilepsy manifestation can provide information about the process of epileptogenesis as a direct 
consequence of Scn1a genetic deficiency. As mentioned above, a pathway enrichment analysis 
was completed to obtain general information about the regulation pattern concerning function 
and neurobiological significance. Pathway enrichment analysis did not identify any 
significantly regulated pathway (q<0.01).  
When considering significantly regulated individual proteins in Dravet mice (unpaired t-test, 
p<0.05), the most prominent down-regulation became evident for Ras-specific guanine 
nucleotide releasing factor 1 (RASGRF1). RASGRF1 is a member of the Ras GTP protein 
family, which plays a role in synaptic plasticity (Brambilla et al., 1997). RASGRF1 is 




has been discussed in the context of epileptogenesis and epilepsy manifestation (Chen et al., 
2018; Tonini et al., 2001; Vlaskamp et al., 2019). 
Taking the more modest regulation of the majority of significantly regulated proteins into 
account, we only want to highlight a selection of the remaining list of significantly regulated 
proteins. These proteins have been chosen considering their putative functional relevance and 
a minimum change of at least 15 % compared to expression rates in wildtype mice (Fig. 6A).  
CAMK2A encodes the alpha subunit of calcium/calmodulin-dependent protein kinase and 
represents a key player in synaptic plasticity (Lisman et al., 2002). Two-week-old mice 
exhibited a reduced expression rate that proved to persist at the four-week time point. 
Additionally, Dravet mice showed an up-regulation of VEGF receptor KDR (VEGFR2), linked 
with tight junction disassembly and blood-brain barrier dysfunction, which in turn can 
contribute to epileptogenesis (Morin-Brureau et al., 2012).  
Cytidine triphosphate synthetase 2 (CTPS2) is a protein mediating CTP synthesis from UTP a 
process that is linked with glutamine deamination to glutamate (Kassel et al., 2010). In two-
week-old Dravet mice, we obtained evidence for an increased expression level of CTPS2.  
 
Differential Protein Expression – later time point 
Proteomic profiling following epilepsy manifestation capturing direct and indirect 
consequences of Scn1a deficiency in Dravet mice revealed 881 regulated proteins (unpaired t-
test, p<0.05) and 42 regulated pathways (q<0.01, Table 1). A heat map, which illustrates the 
level of individual protein change in relation to the mean of the wildtype group is presented in 
Fig. 6B.   
Pathways functionally linked to synaptic transmission dominated the list of significantly 
enriched pathways, in total comprising five pathways associated with general synaptic function 
and its regulation (Neurotransmitter receptors and postsynaptic signal transmission; 




adhesion-like molecules and Neurexins and neuroligins with corresponding q-values 4.14e-05; 
4.14e-05; 2.33e-04; 0.002; 0.006). The list of differentially expressed proteins linked with these 
pathways comprised 68 proteins. Several of these proteins proved to be down-regulated as a 
consequence of the genetic deficiency. These include synaptic adhesion-like molecules such as 
neurexins and neuroligins (Fig. 6B: NLGN2, NLGN3), which mediate trans-synaptic signaling 
and facilitate processing of complex signals in neuronal networks (Südhof, 2008), as well as 
postsynaptic density (PSD) proteins including proteins of the membrane-associated guanylate 
kinase protein family (Fig. 6B-a), and scaffolding proteins (Fig. 6B-b). Moreover, these 
pathways included proteins associated with synaptic vesicles (Fig. 6B-c).  
Proteins linked with ion channel function showed a complex regulation pattern in Dravet mice. 
Thereby, the abundance of voltage-gated calcium channels (Fig. 6B-d), voltage-gated 
potassium channels (Fig. 6B-e) and two inward-rectifier potassium channels (Fig. 6B-f) was 
reduced in Dravet mice. Another inward-rectifier potassium channel (Fig. 6B: KCNJ10) was 
up-regulated in Dravet mice.      
Interestingly, several neurotransmitter receptor proteins exhibited a differential expression 
pattern in Dravet mice. The list of these proteins was dominated by glutamatergic receptor 
proteins (Fig. 6B-g), which all proved to be expressed at lower levels in Dravet mice. In 
addition, a change in expression of three GABAA receptor subunits (Fig. 6B-h) and of two 
GABAB receptor subunits (Fig. 6B-i) became evident with an induction of GABRA1 and 
GABBR1, and a down-regulation of GABRB1, GABRB3 and GABBR2. 
In the context of neurotransmitter signaling, it is of additional interest that four pathways 
involved in glutamatergic signaling, specifically AMPA and NMDA receptor activation, 
binding, and synapses were regulated in Dravet mice (Glutamatergic synapse; Unblocking of 
NMDA receptor, glutamate binding and activation; Trafficking of AMPA receptors; Glutamate 
binding, activation of AMPA receptors and synaptic plasticity with q-values 1.4e-04; 0.001; 




metabotropic glutamate receptors, glutamate transporters (Fig. 6B: EAAT1, EAAT2), and 


























































































Fig. 6. Expression analysis of proteins significantly regulated in Dravet mice before and 
following epilepsy manifestation. A Expression analysis of proteins significantly regulated in 
Dravet mice prior to epilepsy manifestation, with a minimum change of at least 15 % compared 
to expression rates in wildtype mice. R package ‘gplots’ was used for heat maps and the 
respective color key is provided next to the heat map. B Expression analysis of proteins linked 
to all significantly enriched pathways in Dravet mice following epilepsy manifestation. R 
package ‘gplots’ was used for heat maps. The heat map illustrates the fold change in protein 
level in relation to the mean of the wildtype group and the respective color key is given under 
the heat map. a PSD membrane-associated guanylate kinase protein family, b PSD scaffolding 
proteins, c proteins associated with synaptic vesicles, d voltage-gated calcium channel proteins, 
e voltage-gated potassium channel proteins, f inward-rectifier potassium channel proteins, g 
glutamatergic receptor proteins, h GABAA receptor subunits, i GABAB receptor subunits, j 
proteins functionally associated with dopaminergic (DAergic) synapse function, k calcium 
transporter proteins, l calcium/calmodulin-dependent protein kinases. (Blue cell color indicates 
an up-regulation, while red cell color stands for a down-regulation). 
 
Pathway enrichment analysis also revealed an overrepresentation of proteins functionally 
associated with dopaminergic synapse function (q=0.002, Fig. 6B-j). The changes in the 
pathway were dominated by alterations in the expression of proteins regulating dopamine 
metabolism or stabilizing D2 and D3 receptors on plasma membranes with MAOA being up-
regulated and MAOB, EPB41L1, EPB41L3 being down-regulated. In four-week-old Dravet 
mice, reduced expression levels were also evident for GNG7, the G protein responsible for A2A 
adenosine or D1 dopamine receptor-induced neuroprotective responses (Schwindinger et al., 
2012). Another protein, which plays a role in synaptic plasticity and can be modulated by both, 
dopaminergic D1 and glutamatergic NMDA receptors is the neuronal phosphoprotein 
PPP1R1B. Our data set revealed an overexpression in the hippocampus of four-week-old 
Dravet mice, which was further confirmed by immunohistochemistry. All Dravet animals 
demonstrated a marked hippocampal overexpression, particularly evident in CA1 stratum 
pyramidale neurons (Fig. 7A-B). 
In four-week-old mice, pathway enrichment analysis also demonstrated an over-representation 
of proteins functionally linked to calcium signaling (q=1.4e-04). Individual protein changes 




Calcium/calmodulin-dependent protein kinases (Fig. 6B-l) proved to be reduced in Dravet 
mice.  
The list of regulated pathways also included a pathway involved in secondary cell signaling 
(Phosphatidylinositol signaling pathway, q=0.008). Moreover, an over-representation of 
proteins linked with the nitric oxide (NO) signaling pathway (q=0.005) became evident. In this 
context, the increased level of nitric oxide synthase, the main enzyme responsible for NO 
synthesis from L-arginine (Knowles et al., 1994), seems to be of interest. 
In addition to pathway enrichment analysis, we also identified the proteins with the most 
prominent regulation pattern. The strongest up-regulation was evident for the intermediate 
filament proteins glial fibrillary acidic protein (GFAP) and vimentin. The expression of both 
proteins was elevated by at least two-fold in Dravet mice.  
The proteins with the strongest down-regulation were TRIM32 and HSD11B1. Proteomic 
profiling pointed to a reduction in HSD11B1 expression in Dravet mice, with a two times lower 
abundance than in wildtype mice. This finding was further confirmed by 
immunohistochemistry. An apparent down-regulation of the protein was evident in the 
hippocampus with the most obvious reduction in the hilus (Fig. 7C-D).  
 
Comparison with published data from models of acquired epilepsy 
Previously, we have completed a proteomic profiling study in an electrical post-status 
epilepticus (SE) rat model (Bauer et al., 2016; Keck et al., 2017; Keck et al., 2018; Walker et 
al., 2016). In that study, we analyzed the course of proteome alterations during epileptogenesis 
focusing on the early post-insult (2 days post SE), latency (10 days post SE) and chronic phase 
(8 weeks post SE).  
In order to compare molecular alterations in a model of acquired and a model of genetic 
epilepsy, we have directly compared the respective time points before and following epilepsy 




old Dravet mice and in the post-SE latency phase comprised 25 proteins, of which 19 showed 
the same direction of change (Fig. 7E). In general, these nine up- and ten down-regulated 
proteins exhibited a more pronounced regulation in the model of acquired epilepsy. This pattern 
was particularly evident for SHANK3 protein, a scaffold protein of the PSD, and CKAP4, a 
cytoskeleton-associated protein and cell proliferation promoter.  
Fig. 7. Immunohistochemical staining of representative proteins and comparison with 
electrical post SE induced rat model. A-B Representative immunohistochemical staining of 
PPP1R1B protein in the hippocampus (low magnification, A) and hippocampal CA1 region 
(high magnification, B). A pronounced protein immunostaining was particularly evident in the 
CA1 region in Dravet mice. C-D Immunohistochemical staining of HSD11B1 protein in the 
hippocampus (low magnification, C) and hippocampal hilar region (higher magnification, D). 
Protein immunoreactivity was reduced in Dravet mice, which was particularly evident in the 
hilus. Scale bars = 200 µm (A, C, D) and 50 µm (B). E Proteins significantly regulated before 
epilepsy manifestation in two-week-old Dravet mice and 10 days following SE induction in the 
kainate post-SE model. F Proteins significantly regulated during the chronic phase with 
spontaneous generalized seizures, corresponding to four-week-old Dravet mice and 8 weeks 
following the SE induction in the kainate post-SE model. GFAP and ANXA2 were the two most 




Comparison of data sets obtained following epilepsy manifestation confirmed a regulation of 
28 proteins in both epilepsy models. Twenty of these proteins showed the same direction of 
change. A general trend for a stronger regulation in one of models was not evident at this time 
point. Interestingly, two proteins showed a strong induction in both epilepsy models: GFAP, 
known as a marker of mature astrocytes, and ANXA2, a pro-angiogenic protein (Fig. 7F).   
Considering that species differences may affect the comparison between these data sets, we 
additionally compared our present data from the mouse Dravet model with published proteomic 
data from a mouse model of mesiotemporal lobe epilepsy reported by Bitsika et al. (Table 2). 
Comparison of data sets prior to epilepsy manifestation, i.e. from the early time point in the 
Dravet model and from 3 days following kainate-induced SE, revealed an overlap of four 
proteins with down-regulation in both epilepsy models. Three of these proteins are functionally 
linked with synaptic transmission. These comprise one presynaptic (PCLO) and two 
postsynaptic proteins (SHANK3, BAIAP2). The fourth protein that proved to be regulated in 
both models is SIPA1L1, involved in regulation of cell processes (Gao et al., 1999). 
Following epilepsy manifestation, an interesting overlap has been observed between four-week-
old Dravet mice and mice 30 days after the kainic acid injection. This overlap between the lists 
of differentially expressed proteins comprised 44 proteins with 23 up-regulated and 21 down-
regulated in both, genetic and acquired epilepsy. Protein regulation was more prominent in the 
acquired epilepsy model (data not shown). Among others, the list of co-regulated proteins 
included cytoskeletal proteins (ARPC1A; DBN1; MAP1A; ADD2; MYO6, PLEC; EZR; 
CTTNBP2) as well as proteins linked with angiogenesis (ANXA4; VIM; ITGAV) and synaptic 






Large-scale proteomic analysis in a novel conditional mouse model of Dravet syndrome with 
Scn1a genetic deficiency provided comprehensive information about molecular alterations 
characterizing different disease phases. Respective information about the proteomic signature 
of the Dravet syndrome suggests possible pathophysiological mechanisms that beyond the 
Scn1a haploinsufficiency may be involved in epileptogenesis and ictogenesis in Dravet mice.  
As a basis for the proteomic analysis, we initially aimed to validate the novel conditional knock-
in mouse model of Dravet syndrome with a heterozygous Scn1a-A1783V mutation. A model 
with this mutation has previously been generated on a pure C57BL/6J background (Ricobaraza 
et al., 2019) and a mixed (90:10) C57BL/6J and 129S1 background (Kuo et al., 2019) resulting 
in a more severe phenotype and higher mortality rate. Here, we characterized the model bred 
on a mixed (50:50) C57BL/6J and 129S1 background with an Hprt promoter mediated neuronal 
knock-in. We confirmed the development of spontaneous seizures and an increased 
susceptibility for hyperthermia-induced seizures, and demonstrated a mortality rate of 40 %. 
Besides the seizure phenotype, we also observed behavioral alterations dominated by 
hyperactivity, which seem to reflect hyperactivity and attention deficits as common behavioral 
symptoms in patients with Dravet syndrome (Battaglia et al., 2016; Besag, 2004; Dravet, 2011).  
When compared to other animal models of Dravet syndrome with heterozygous Scn1a 
mutation, our model showed a similar age for onset of spontaneous seizures, increased 
susceptibility to thermally provoked seizures and notable hyperactivity. The SUDEP rates were 
relatively low as compared to other models occurring within a short time frame (Table A.2). 
With the approaches used in this study, we failed to detect motor and social deficits in Dravet 
mice, which have been reported in selected mouse models (Table A.2). However, an improved 
performance on accelerated rotarod test was also found in another mouse model (Ito et al., 




alterations in motor function and coordination. In this context, it is of interest that we confirmed 
alterations in gait in a follow-up study based on a catwalk test and a detailed assessment of gait 
(Miljanovic et al., under revision).   
To our knowledge, we were the first ones to report anhedonia-associated behavior in a Dravet 
mouse model indicating that SCN1A deficiency may have an impact on the affective state and 
may predispose to depression.   
Information about body weight development has not been provided for all Dravet mouse 
models, so that it is not clear for several models whether there was no delay or whether body 
weight development was not assessed and documented. So, an impact of the genetic deficiency 
on body weight development has only been reported in selected Dravet mouse models with 
heterozygous (Ricobaraza et al., 2019) and homozygous mutation (Martin et al., 2010; Ogiwara 
et al., 2007). In line with these reports, we observed a transient delay in body weight around 
weaning with animals catching up within five (females) or 20 (males) days following weaning. 
Taken together, our comprehensive characterization demonstrated an excellent face validity of 
the Dravet model, thus providing a perfect basis for investigating molecular patterns involved 
in disease manifestation and its further development.  
 
GABAergic, glutamatergic, and dopaminergic neurotransmission 
Loss of function of sodium channel subunits encoded by the SCN1A gene in GABAergic 
interneurons is considered as the main source of hyperexcitability and ictogenesis in Dravet 
patients (Brunklaus and Zuberi, 2014; Catterall, 2018) and animals carrying a respective 
mutation (Almog et al., 2019; Kalume et al., 2015a; Mantegazza and Broccoli, 2019; Mistry et 
al., 2014; Rubinstein et al., 2015b; Salgueiro-Pereira et al., 2019; Tai et al., 2014; Tsai et al., 
2015; Yu et al., 2006). However, an impact of cellular consequences in excitatory neurons on 
seizure susceptibility has also been suggested based on experimental findings. For instance, 




granule cells in dentate gyrus (Tsai et al., 2015) in the period of chronic epilepsy, may promote 
life-threatening seizures, known to worsen mice phenotype (Dutton et al., 2017; Salgueiro-
Pereira et al., 2019). On the other hand, Ogiwara and colleagues demonstrated that Scn1a 
haploinsufficiency in hippocampal excitatory neurons, can ameliorate seizures in Dravet mice 
(Ogiwara et al., 2013). Interestingly, Almog and colleagues showed how hyperexcitability of 
CA1 pyramidal neurons during the pre-epileptic state can switch to hypoexcitability during the 
epileptic state in Dravet mice, suggesting the role of these neurons in seizure propagation 
(Almog et al., 2019).  
Altogether, these data already suggest that, both, inhibitory and excitatory neurotransmission 
may be directly and indirectly affected by NaV1.1 dysfunction. Interestingly, the proteomic data 
suggest differential expression of multiple proteins linked with inhibitory and excitatory 
neurotransmission in Scn1a+/− mice.  
With changes in the abundance of various GABAA and GABAB receptor subunits, our findings 
indicate that signaling via both GABA receptor systems can be altered as a consequence of an 
Scn1a genetic deficiency with potential consequences for phasic and tonic inhibition.  Thereby 
it needs to be considered that, both, an up- and a down-regulation was observed for the different 
receptor subunits.  
Concerning glutamatergic signaling, proteomic patterns in Dravet mice revealed a 
comprehensive down-regulation of subunits of NMDA, AMPA, and kainate glutamate 
receptors. In this context, it is of additional interest that several proteins linked with NMDA 
receptor function in the post-synaptic density showed a decreased abundance in Dravet mice. 
In addition, SYNGAP1, a post-synaptic density protein that negatively modulates trafficking 
of AMPA receptors to the membrane (Jeyabalan and Clement, 2016), also exhibited a 
dysregulation in the hippocampus as a consequence of the Scn1a deficiency.  
Concerning the expression patterns of metabotropic glutamate receptor proteins, one needs to 




limitation of excessive glutamate secretion (Dedeurwaerdere et al., 2015). Along this line, 
reduced expression of the class two metabotropic glutamate receptor proteins mGluR2 and 
mGluR3 in Dravet mice might be of functional interest.  
In addition to alterations in receptor proteins and PSD proteins, the lowered abundance of 
glutamine synthase and higher abundance of CTPS2, which contributes to deamination of 
glutamine to glutamate (Kassel et al., 2010), may imply that changes occur in glutamate 
metabolism.  
Taken together our proteomic data set suggests that complex alterations occur affecting GABA 
and glutamatergic signaling. The direction of the alterations seems to suggest that some of these 
changes may contribute to hyperexcitability, whereas others may rather reflect compensatory 
mechanisms. Further research is necessary to explore the potential functional consequences.  
Depending on the receptor subtype, dopaminergic signaling can affect seizure thresholds (Bozzi 
and Borrelli, 2013). Altered abundance of the dopamine metabolizing enzymes MAOA and 
MAOB, of a downstream effector protein of D1 receptors (Bozzi and Borrelli, 2013; O'Sullivan 
et al., 2008), and of proteins stabilizing D2 and D3 receptors, suggests that it may also be of 
interest to assess dopamine concentrations in the brain of Dravet mice.  
 
Voltage-gated ion channels 
Voltage-gated ion channels affect neuronal excitability in different subcellular localizations 
therefore serving as important target sites for different antiseizure drugs (Sills and Rogawski, 
2020).  
At the presynaptic level, P/Q- and N-type calcium channels represent important regulators of 
neurotransmitter release (Kassel et al., 2010). Thus, the extensive down-regulation of voltage-
gated calcium channel subunits may constitute a compensatory mechanism counteracting 
increased neuronal excitability characterizing the Dravet syndrome. In this context, it is of 




subtypes proved to be reduced in hippocampal tissue from Dravet mice. CaMK are important 
regulators, which translate intracellular calcium concentrations into phosphorylation patterns 
with functional consequences for the targeted proteins (Swulius and Waxham, 2008).  
Several potassium channels regulate outward potassium currents, thereby affecting membrane 
polarization and neuronal excitability (Villa and Combi, 2016). Proteomic data revealed a 
reduction of three potassium channel subunits (Kv1.2, Kv2.1 and Kv4.2), that attenuate back-
propagating action potentials and prevent highly repetitive neuronal firing as one of the 
pathophysiological hallmarks of epileptic seizures (Niday and Tzingounis, 2018).  
In summary, various changes in voltage-gated ion channel proteins occur in the Dravet mouse 
model. The reduction of calcium channel subunits and of potassium channel subunits may have 
contrasting consequences, which, however, need to be further assessed in follow-up 
investigations.  
While previous studies also suggested alterations in sodium channel subunits with an up-
regulation of NaV1.3 in hippocampal interneurons in a different Dravet mouse model (Yu et al., 
2006), our data did not detect this protein in the Scn1a-A1783V mouse model.  
 
Astrogliosis, angiogenesis and NO signaling 
Reactive astrogliosis can promote hyperexcitability, affect inflammatory signaling, and disrupt 
integrity of the blood–brain barrier (Devinsky et al., 2013). Increased GFAP abundance 
provides evidence for astrogliosis in the Scn1a-A1783V mouse model. This finding is in line 
with previous reports describing astrogliosis in other mouse models of Dravet syndrome 
(Alonso Gómez et al., 2018; Hawkins et al., 2019).  Alterations in the astrocytic functional state 
are further supported by evidence for a reduction of astroglial excitatory amino acid transporters 
(EAAT1 and EAAT2) and for an overexpression of the inward rectifying potassium channel 
Kir4.1 (KCNJ10). These findings may imply contrasting functional consequences, which, 




Following seizure onset, we observed an additional regulation of ANXA2 and vimentin, which 
both act as modulators of VEGF signaling and angiogenesis (Dave and Bayless, 2014; Liu and 
Hajjar, 2016), previously discussed as a pro-epileptogenic factor and as a potential target for 
antiepileptogenesis (Morin-Brureau et al., 2012; Rigau et al., 2007).  
Proteomic profiling also revealed a dysregulation of nitric oxide (NO) signaling in Dravet mice 
with an increased expression of neuronal nitric oxide synthase (nNOS) following onset of 
spontaneous recurrent seizures. Considering that NO can induce reactive glial proliferation and 
promote angiogenesis (Arhan et al., 2011; Morbidelli et al., 2004), it is discussed that it might 
play a role during epileptogenesis and for hyperexcitability in the epileptic brain. 
  
Proteomic alterations before epilepsy manifestation 
While rather limited alterations were evident before epilepsy manifestation, these changes may 
be of interest as they might provide information about molecular mechanisms that occur as an 
early consequence of the SCN1A genetic deficiency and that may contribute to disease onset. 
In this context, the down-regulation of RASGRF1 might be of functional relevance considering 
the fact that a contribution of RASGRF1 to epileptogenesis has been suggested based on a study 
with genetic and pharmacological targeting (Bao et al., 2018). Thus, it might be of interest to 
further explore a potential contribution of early RASGRF1 down-regulation to disease 
manifestation and seizure onset in Dravet mice.  
 
Shared and common pathophysiological mechanisms: Dravet model versus models of acquired 
epilepsy  
The molecular perspective taken in the present study revealed, both, differences to and 
commonalities with mechanisms reported for acquired epilepsies following an initial brain 
insult. Our proteomic data set provides evidence that astrogliosis, enhanced angiogenesis and 




epilepsy, but may also contribute to hyperexcitability states in Dravet syndrome. However, the 
findings rather argue against a relevant induction of pro-inflammatory signaling pathways, 
which characterizes epileptogenesis and disease manifestation of acquired epilepsies (Fabene 
et al., 2010; Klein et al., 2018; Terrone et al., 2017; Vezzani, 2014). 
The Scn1a deficiency in the Scn1a-A1783V mouse model triggers complex alterations, which 
may affect GABAergic, glutamatergic and dopaminergic signaling at multiple levels including 
synaptogenesis, synaptic vesicle trafficking, neurotransmitter release, receptor subunit 
expression and composition, and post-synaptic density modulation of receptor function. 
Synaptic plasticity and more specifically plasticity of GABAergic and glutamatergic 
mechanisms has been repeatedly described in different models of acquired epilepsy and in the 
brain of patients with temporal lobe epilepsy (Joshi and Kapur, 2012; Klein et al., 2018; 
Scharfman and Brooks-Kayal, 2014).  
 
Study limitations 
Considering the whole proteome approach applied to hippocampal samples and the 
characteristics of the mouse model, one also needs to take respective limitations into account.   
Firstly, disease manifestation occurs early on in Dravet mice resulting in a delayed postnatal 
bodyweight development, which in itself may also impact molecular alterations in the brain.  
Moreover, considering that untargeted proteomic studies are limited to screening proteins in the 
entire sample, further studies investigating the expression patterns in different hippocampal 
sub-regions and cell types along with studies addressing the functional consequences are needed 
to provide more specific information allowing conclusion about the functional relevance of the 
findings. The present findings provide a perfect basis to design respective studies applying 
targeted proteomic approaches. Finally, one needs to consider that bulk approaches imply the 




As a matter of course interpretation needs to take into account that molecular alterations can be 
a mere consequence of repeated seizure activity or disease-associated alterations without 
functional implications. Thus, as repeatedly pointed out, it is of utmost relevance to further 
assess functional implications in future studies.  
 
Conclusions 
In conclusion, the whole proteome analysis in a mouse model of Dravet syndrome demonstrated 
complex molecular alterations in the hippocampus as a consequence of the genetic deficiency.  
Some of these alterations may have an impact on excitability or may serve as a compensatory 
function, which, however, needs to be further confirmed by future investigations.  
The findings provide evidence that genetic epilepsy due to Scn1a haploinsufficiency may share 
pathophysiological mechanisms with acquired epilepsies developing following brain insults. 
Moreover, the proteomic data indicate that due to molecular consequences of the genetic 
deficiency the pathophysiological mechanisms become more complex during the course of the 
disease, and that the management of Dravet syndrome may need to consider further molecular 
and cellular alterations. Along this line, based on functional follow-up studies the data sets may 
provide valuable guidance for future development of novel therapeutic approaches.  
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Table 1. Overrepresented pathways in four-week-old mice (q<0.01, ConsensusPathDB) 
p-value q-value Pathway Source Overlap members 
0.000 0.000 Neuronal System Reactome 
SLC6A1; CACNG8; PDLIM5; GLUA2; GLUA3; 
GLUA1GLUA1; GLUA4; CACNA1E; CAMKK1; 
GLUL; KCND2; CACNA2D3; GABBR1; 
GABBR2; CACNB4; KCNA2; AP2B1; GNAI1; 
DLGAP2; DLG3; DLG2; GNAI3; PPFIA3; 
GABRA1; CACNB3; CACNA1A; CAMK4; 
NTRK3; AP2M1; ADCY9; DLGAP1; GRIK2; 
DLGAP4; SIPA1L1; MGLUR5; GLUN1; 
HOMER2; RIMS1; EPB41L1; PLCB1; EPB41L3; 
KCNJ10; NLGN2; NLGN3; NPTN; PRKCA; 
PRKCB; CAMK2A; CAMK2B; KCNAB2; 
PRKCG; AP2A2; GABRB1; GABRB3; SHANK3; 
SHANK2; SHANK1; DLG4; KCNJ3; ACTN2; 
PTPRS; RASGRF2; SYT1; KCNJ9; MYO6; 
ALDH2; SYT7; GLUN2B; GNG7; MAOA; 
GLUN2A; FLOT1; FLOT2; NEFL; PDPK1; 







GLUA2; GLUA3; GLUA1; GLUA4; ADCY9; 
GABBR1; GABBR2; GABRA1; AP2B1; GNAI1; 
CACNG8; DLG3; NPTN; DLG4; NEFL; CAMK4; 
GNAI3; AP2M1; GLUN1; EPB41L1; PLCB1; 
KCNJ10; PRKCA; PRKCB; CAMK2A; 
CAMK2B; PRKCG; AP2A2; GABRB1; 
GABRB3; KCNJ3; ACTN2; RASGRF2; KCNJ9; 






SLC6A1; GLUA2; GLUA3; GLUA1GLUA1; 
GLUA4; ADCY9; CAMKK1; GLUL; 




AP2B1; GNAI1; CACNG8; DLG3; NPTN; DLG4; 
CACNB3; CACNA1A; CACNA1E; CAMK4; 
CACNB4; AP2M1; GRIK2; GLUN1; RIMS1; 
EPB41L1; PLCB1; KCNJ10; PRKCA; PRKCB; 
CAMK2A; CAMK2B; PRKCG; GABBR2; 
AP2A2; GABRB1; GABRB3; PPFIA3; KCNJ3; 
ACTN2; RASGRF2; SYT1; KCNJ9; MYO6; 
ALDH2; GLUN2B; GNG7; MAOA; GLUN2A; 
NEFL; PDPK1; SYN3; EAAT2; EAAT1 
0.000 0.000 
Amphetamine addiction - 
Homo sapiens (human) 
KEGG 
GLUN2B; PPP1R1B; PPP1CA; PRKCA; GLUA3; 
GLUA1; CAMK4; CAMK2B; CAMK2A; 
GLUA2; MAOB; MAOA; ARC; GLUA4; 




pathway - Homo sapiens 
(human) 
KEGG 
CAMK1D; ATP2A2; NOS1; PRKCG; CACNA1E; 
PTK2B; VDAC1; ATP2A1; ATP2B2; CACNA1A; 
PDE1A; RYR2; CAMK4; ITPKA; MGLUR5; 
GLUN1; SLC8A2; PLCB1; PRKCA; PRKCB; 
CAMK2A; CHRM1; CAMK2B; ATP2B1; ITPR1; 
MCU; GNAQ; ADCY9; GLUN2A; GNA11; 
PPP3CA; PPP3CB 
0.000 0.000 
Glutamatergic synapse - 
Homo sapiens (human) 
KEGG 
GLUA2; GLUA3; GLUA1; GLUA4; GLUL; 
GNAI3; GNAI1; DLG4; CACNA1A; DLGAP1; 
MGLUR5; GLUN1; HOMER2; MGLUR2; 
MGLUR3; PLCB1; PRKCA; PRKCB; PRKCG; 
ITPR1; SHANK3; SHANK2; SHANK1; KCNJ3; 
GNAQ; GRIK2; ADCY9; GLUN2B; GNG7; 
GLUN2A; PPP3CA; PPP3CB; EAAT2; EAAT1 
0.000 0.000 
Protein-protein 
interactions at synapses 
Reactome 
GLUA3; GLUA1; GLUA4; DLG3; DLG2; 
PPFIA3; NTRK3; DLGAP2; DLGAP1; DLGAP4; 
SIPA1L1; MGLUR5; GLUN1; HOMER2; 
EPB41L1; PDLIM5; EPB41L3; NLGN2; NLGN3; 




SYT1; SYT7; GLUN2B; GLUN2A; FLOT1; 
FLOT2 
0.000 0.001 
Unblocking of NMDA 
receptor. glutamate 
binding and activation 
Reactome 
ACTN2; DLG4; GLUA2; GLUA3; GLUA1; 
CAMK2A; GLUA4; GLUN2B; GLUN2A; 
CAMK2B; NEFL; GLUN1 
0.000 0.002 
Dopaminergic synapse - 
Homo sapiens (human) 
KEGG 
GLUA2; GLUA3; GLUA1; GLUA4; AKT3; 
MAPK10; GNAI3; GNAI1; PPP1R1B; MAOB; 
CACNA1A; MAPK8; PLCB1; PRKCA; PRKCB; 
PPP2R2A; CAMK2A; CAMK2B; PRKCG; 
PPP3CA; ITPR1; KCNJ3; GNAQ; PPP1CA; 
KCNJ9; GSK3A; GLUN2B; GNG7; MAOA; 
GLUN2A; PPP2R5E; PPP3CB; PPP2R5C 
0.000 0.002 
Trafficking of AMPA 
receptors 
Reactome 
EPB41L1; CACNG8; PRKCB; DLG4; PRKCA; 
GLUA3; GLUA1; CAMK2B; CAMK2A; PRKCG; 




activation of AMPA 
receptors and synaptic 
plasticity 
Reactome 
EPB41L1; CACNG8; PRKCB; DLG4; PRKCA; 
GLUA3; GLUA1; CAMK2B; CAMK2A; PRKCG; 






DLG3; PTPRS; DLG4; GLUA3; GLUA1; 




receptor interaction - 
Homo sapiens (human) 
KEGG 
GLUA2; GLUA3; GRIK2; GLUA1; S1PR5; 
GLUN2B; GLUN2A; GLUA4; CHRM1; 
GABBR1; MGLUR5; GABRB1; GABBR2; 




sclerosis (ALS) - Homo 
sapiens (human) 
KEGG 
GPX1; TOMM40L; RAC1; NEFM; NEFL; 
GLUA1; NEFH; GLUN2B; GLUA2; NOS1; 






nitric oxide signaling 
pathway 
BioCarta 
NOS1; DLG4; PRKCA; PRKCB; CAMK2B; 






DLG3; DLG2; DLG4; DLGAP2; DLGAP1; 
DLGAP4; SIPA1L1; MGLUR5; GLUN1; 
HOMER2; EPB41L1; PDLIM5; EPB41L3; 
NLGN2; NLGN3; SHANK3; SHANK2; 
SHANK1; SYT1; SYT7; GLUN2B; GLUN2A 
0.000 0.008 
Cocaine addiction - 
Homo sapiens (human) 
KEGG 
PPP1R1B; DLG4; GLUA2; GLUN2B; MAOB; 
MAOA; GLUN2A; GLUN1; MGLUR3; GNAI3; 
MGLUR2; GNAI1 
0.000 0.008 
Fmlp induced chemokine 
gene expression in hmc-1 
cells 
BioCarta 
PLCB1; RAC1; PRKCA; PRKCB; MAP2K1; 
CAMK2B; MAP2K2; CAMKK2; CAMKK1; 
MAP2K6; PPP3CA; PPP3CB 
0.000 0.008 
Phosphatidylinositol 
signaling system - Homo 
sapiens (human) 
KEGG 
OCRL; PLCB1; PRKCB; PI4KA; INPPL1; 
PRKCA; CDS1; CDS2; DGKQ; PIK3CD; 
SACM1L; INPP4A; ITPKA; IMPA1; PRKCG; 








Table 2. An overlap in differentially expressed proteins with a kainic acid mouse 
model of mesiotemporal lobe epilepsy reported by Bitsika et al., 2016. 
Dravet      
2 weeks 
3 days   
post KA 
PCLO; BAIAP2; SIPA1L; SHANK3 




ARPC1A; CYB5R3; SNAP91; CAMKV; HRSP12; NPTX1; ADD2; 
BAIAP2; RPH3A; SYNGAP1; PRMT1; ITGAV; VIM; MYO6; MAP1A; 
CST3; EPB41L1; MYH9; PPP3CB; SUCLG1; CTTNBP2; OXR1; PRRT1; 
PRKCG; CD44; APRT; ANXA4; SNX5; GFAP; RAPGEF2; DLG4; 
PPP3CA; MLC1; EZR; ENDOD1; PLEC; P4HB; SCG2; CYB5A; DBN1; 
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Table A.1. List of abbreviations (left column) and full names (right column) of all 
regulated proteins mentioned in the manuscript and their general function.  
GABAergic signaling 
GABBR1 Gamma-aminobutyric acid type B receptor subunit 1 
GABBR2 Gamma-aminobutyric acid type B receptor subunit 2 
GABRA1  Gamma-aminobutyric acid receptor subunit alpha-1 
GABRB1 Gamma-aminobutyric acid receptor subunit beta-1 
GABRB3  Gamma-aminobutyric acid receptor subunit beta-3 
SLC6A1 Sodium- and chloride-dependent GABA transporter 3 
Glutamatergic signaling 
CTPS2 Cytidine triphosphate synthetase 2  
GluA1 Glutamate ionotropic receptor AMPA subunit 1 
GluA2 Glutamate ionotropic receptor AMPA subunit 2 
GluA3 Glutamate ionotropic receptor AMPA subunit 3 
GluA4 Glutamate ionotropic receptor AMPA subunit 4 
GluK2 Glutamate ionotropic receptor kainate type subunit 2 
GLUL Glutamine synthetase 
GluN1 Glutamate ionotropic receptor NMDA type subunit 1 
GluN2A Glutamate ionotropic receptor NMDA type subunit 2A 
GluN2B Glutamate ionotropic receptor NMDA type subunit 2B 
mGluR2 Metabotropic glutamate receptor type 2 
mGluR3 Metabotropic glutamate receptor type 3 
mGluR5 Metabotropic glutamate receptor type 5 
Synaptic transmission 
DLG2 Disks large homolog 2 
DLG3 Disks large homolog 3 
DLG4 Disks large homolog 4 
DLGAP1 Disks large-associated protein 1 
DLGAP2 Disks large-associated protein 2 
DLGAP4 Disks large-associated protein 4 
HOMER2 Homer Scaffold Protein 2 
NLGN2 Neuroligin 2 
NLGN3 Neuroligin 3 
PCLO Protein piccolo 
PPP3CA Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 
PPP3CB Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform 
PRKCG Protein kinase C gamma type 
RASGRF1 Ras-specific guanine nucleotide releasing factor 1  
RIMS1 Regulating Synaptic Membrane Exocytosis 1 
SHANK1 SH3 and multiple ankyrin repeat domains protein 1 
SHANK2 SH3 and multiple ankyrin repeat domains protein 2 
SHANK3  SH3 and multiple ankyrin repeat domains protein 3 






BAIAP2 Brain-specific angiogenesis inhibitor 1-associated protein 2 
Dopaminergic signaling 
EPB41L1 Band 4.1-like protein 1 
EPB41L3  Band 4.1-like protein 3 
GNG7 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 
MAOA  Monoamine oxidase A 
MAOB Monoamine oxidase B 
PPP1R1B Protein phosphatase 1 regulatory subunit 1B 
Calcium signaling 
CACNA1A  Calcium voltage-gated channel subunit alpha1 A 
CACNA1E Calcium voltage-gated channel subunit alpha1 E 
CACNA2D3 Calcium voltage-gated channel auxiliary subunit alpha2delta 3 
CACNB3 Calcium voltage-gated channel auxiliary subunit beta 3 
CACNB4 Calcium voltage-gated channel auxiliary subunit beta 4 
CACNG8 Calcium voltage-gated channel auxiliary subunit gamma 8 
CAMK1D Calcium/calmodulin-dependent protein kinase type 1D 
CAMK2A Calcium/calmodulin-dependent protein kinase type II subunit alpha 
CAMK2B Calcium/calmodulin-dependent protein kinase type II subunit beta 
CAMK4 Calcium/calmodulin-dependent protein kinase type IV 
CAMKK1 Calcium/calmodulin-dependent protein kinase kinase 1 
CAMKK2 Calcium/calmodulin-dependent protein kinase kinase 2 
Potassium channels 
KCNA2 Potassium voltage-gated channel subfamily A member 2 
KCNAB2 Voltage-gated potassium channel subunit beta-2 
KCND2 Potassium voltage-gated channel subfamily D member 2 
KCNJ10 ATP-sensitive inward rectifier potassium channel 10 
KCNJ3 G protein-activated inward rectifier potassium channel 1 
KCNJ9 G protein-activated inward rectifier potassium channel 3 
Reactive astrogliosis 
GFAP glial fibrillary acidic protein 
EAAT1 Excitatory amino acid transporter 1 
EAAT2 Excitatory amino acid transporter 2 
Angiogenesis 
ANXA2 Annexin A2 
ANXA4 Annexin A4 
ITGAV Integrin alpha-V 
KDR  Vascular endothelial growth factor receptor 2 
VIM Vimentin 
Nitric oxide signaling 
NOS1 Neuronal nitric oxide synthase  
Cytoskeletal proteins 
ADD2  Beta-adducin 
ARPC1A Actin-related protein 2/3 complex subunit 1A 
CKAP4 Cytoskeleton-associated protein 5 






MAP1A Microtubule-associated protein 1A 







Table A.2. A comparison between here characterized mouse model of Dravet syndrome 
(Scn1a-A1873V, first row) and other available mouse models with a heterozygous Scn1a 
mutation. The arrow indicates increased or reduced behavior characteristic. Minus (-) indicates 
no significant changes in evaluated tests. P – postnatal day, PW – postnatal week, M – months, 
n.a. - not available. A grey horizontal line was used between mouse models carrying the same 
Scn1a mutation, while a black horizontal line was used between mouse models carrying a 
different Scn1a mutation. 1(Ricobaraza et al., 2019); 2(Kuo et al., 2019); 3(Ogiwara et al., 2007); 
4(Ito et al., 2013); 5(Dutton et al., 2013); 6(Han et al., 2012; Kalume, 2013; Oakley et al., 2009); 
7(Yu et al., 2006); 8(Cheah et al., 2012); 9(Ogiwara et al., 2013); 10(Miller et al., 2014); 11(Mistry 























































































































































Scn1a-A1783V  50:50 40 P16 39.4  
(P23) 
↑ ↓ ↑ - ↑ ↓ ↓ 
1Scn1aWT/A1783V 100:0 75 PW3 38.2 
(1-6 M) 
↑ ↑ - ↓ n.a. ↓ ↓ 
2Scn1a∆E26 90:10 100 P14 41.1 
(P12-14) 
n.a n.a. n.a. n.a. n.a. n.a. - 
3 Scn1aRX/+ 
 
75:25 40 P18 n.a. n.a. n.a. n.a. n.a. n.a. - - 
4Scn1aRX/+ 
 
100:0 40 P18 n.a. ↑ ↓ ↓ ↓ n.a. - - 
5Scn1aFlox/+Cre+/- 100:0 100 P21 40.7  
(P22) 
↑ ↑ ↓ ↓ n.a. n.a. n.a. 
6Scn1a+/- 
 
99.9:0.1 40 P21 39.5  
(P20-46) 
↑ ↑ ↓ ↓ n.a. ↓ n.a. 
7Scn1a+/- 
 
0:100 10 P21 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
7Scn1a+/- 
 
100:0 80 P21 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
8Scn1afl/+  
 
100:0 70 P18 39  
(P35) 
↑ n.a. ↓ ↓ n.a. n.a. n.a. 
9Scn1ad/+  
 
97:3 25 PW3 n.a. 
 
n.a. n.a. n.a. n.a. n.a. - n.a. 
10Scn1atm1Kea  
 
75:25 54 P24 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
11Scn1atm1Kea 50:50 50 P18 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
12Scn1aE1099X/+  75:25 46 P20 40.2  
(PW3-5) 
n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
13Scn1aRH/+ 
 
100:0 5 n.a. 41.3 
(P14-15) 
↑ - ↓ ↓ n.a. ↓ - 
14Scn1aRH/+ 
 
mix 5 n.a. 43.1 
(P14-15) 





 Fig. A.1. Social interaction, thigmotaxic behavior, elevated plus maze and accelerated 
rotarod test. A Time spent in active social interaction. Dravet mice engaged more in active 
interaction than their wildtype littermates. B Time spent in passive social interaction. Dravet 
mice spent less time than wildtype animals engaged in passive interaction. A-B Data shown are 
from 10 animal pairs with a Dravet genotype vs 9 wildtype animal pairs (Two-way ANOVA, 
Bonferroni post hoc; * p < 0.05, mean ± SEM). C Time spent in wall, middle and center zone 
over 30 minutes. Dravet mice spent more time in the wall zone than wildtype mice, while no 
significant difference was observed in the time spent in the middle or center zone (Three-way 
RM ANOVA, Bonferroni post hoc; * p < 0.05, mean ± SEM). D Time spent exploring open 
arms of elevated plus maze. Dravet mice exhibited a significantly higher preference towards 
open arms of the maze as compared to wildtype group. E Frequency to dip head over the maze. 
Dravet animals made significantly more head dips than wildtype mice. F Stretching postures to 
explore open arms of EPM. Dravet animals showed significantly lower number of stretching 
positions as compared to wildtype mice (Three-way ANOVA, Bonferroni post hoc; * p < 0.05, 
mean ± SEM). G-I Time on accelerated rod on three consecutive test days. Dravet mice 
performed better on rotarod comparing to wildtype mice. Females performed better than males 
(Five-way RM ANOVA, Bonferroni post hoc; * p < 0.05, mean ± SEM). C-I Data shown are 
from 21 (D-F) or 22 (C, G-I) animals with a Dravet genotype (n = 10 or 11 males, n = 11 
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2. Manuscript II 
This chapter contains a manuscript submitted to the journal Epilepsia (doi: 10.1111/epi.16976). 
The manuscript aimed to identify metabolic consequences of Scn1a genetic deficiency in the 
hippocampus and plasma of Dravet mice. In addition, we intended to examine the impact of the 
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Objective: Alterations in metabolic homeostasis can contribute to neuronal hyperexcitability 
and seizure susceptibility. While the pivotal role of impaired bioenergetics is obvious in 
metabolic epilepsies, there is a gap-of-knowledge regarding secondary changes in metabolite 
patterns as a result of genetic Scn1a deficiency and ketogenic diet in the Dravet syndrome.  
Methods: A comprehensive untargeted metabolomics analysis along with assessment of 
spontaneous seizure activity and behavioral tests, were completed in a Dravet mouse model. 
Data sets were compared between animals on a control and a ketogenic diet and metabolic 
alterations associated with Dravet mice phenotype and ketogenic diet were identified. 
Results: Hippocampal metabolomic data revealed complex alterations in energy metabolism 
with an effect of the genotype on several glycolysis and tricarboxylic acid (TCA) cycle 
intermediates. While low glucose, lactate, malate, and citrate concentrations became evident, 
the increase of several intermediates suggested a genotype-associated activation of catabolic 
processes with enhanced glycogenolysis and glycolysis. Moreover, we observed an impact on 
the glutamate/GABA-glutamine cycle with reduced levels of all components along with a shift 
towards an increased GABA:glutamate ratio. Further alterations in metabolic patterns 
comprised a reduction in hippocampal levels of noradrenaline, corticosterone and of two bile 
acids.  
Significance: Considering that energy depletion can predominantly compromise the function 
of GABAergic interneurons, the changes in energy metabolism may contribute to seizure 
susceptibility and ictogenesis. They may also explain the therapeutic potential of the ketogenic 
diet, which aims to shift energy metabolism towards a more fat-based energy supply. 
Conversely, the increased GABA:glutamate ratio might serve as an endogenous compensatory 
mechanism, which can be further supported by GABAergic drugs, the mainstay of therapeutic 




it might be of interest to explore a possible therapeutic potential of bile-acid mediated therapies, 
which are already in discussion for neurodegenerative disorders.  
Keywords: metabolomics, epileptic encephalopathy, ketogenic diet, Scn1a, mice. 
 
 
Key points box: 
 Metabolomic analysis in a mouse model demonstrated that Dravet syndrome can be 
associated with complex alterations in the metabolome.  
 Pronounced alterations in glucose and TCA cycle metabolism may contribute to seizure 
susceptibility and ictogenesis in Dravet mice. 
 The findings may explain the potential of dietary approaches including KD aiming to 
shift metabolism towards a fat-based energy supply. 
 The increased GABA:glutamate ratio may represent an endogenous compensatory 
mechanism, which can be further supported by GABAergic drugs. 






Changes in metabolic homeostasis and dysmetabolic states have a major impact on neuronal 
excitability and seizure susceptibility (Masino and Rho, 2019; McDonald et al., 2018; Patel, 
2018). Experimental and clinical research in epileptology has so far focused on energy fueling 
of the brain and its links with hyperexcitability, epileptogenesis and ictogenesis (Kovács et al., 
2018; Oyarzabal and Marin-Valencia, 2019). The fact that permanent neuroglycopenia can 
affect seizure thresholds has been convincingly proven by the characterization of the glucose 
transporter-1 (GLUT1) deficiency syndrome (Pong et al., 2012). The identification of further 
genetic epilepsies related to variance in metabolic pathways has resulted in an integration of 
the term ‘metabolic epilepsies’ in the etiological classification suggested by the International 
League against Epilepsy (Scheffer et al., 2017).  
While the pivotal role of impaired bioenergetics is obvious in metabolic epilepsies, evidence 
exists that relevant alterations in the metabolic state also occur in other genetic epilepsies as 
well as acquired epilepsies (Patel, 2018; Reid et al., 2014; Waldbaum and Patel, 2010). The 
functional relevance of perturbed brain bioenergetics received indirect confirmation by the 
therapeutic success of the ketogenic diet (KD) and alternate dietary approaches aiming to shift 
the energy metabolism from glucose-based towards fat-based energy generation (Barañano and 
Hartman, 2008; McDonald et al., 2018; Youngson et al., 2017). While it is an established first 
line therapeutic concept for GLUT1 deficiency syndrome, the list of possible indications 
comprises different genetic epilepsy syndromes including the Dravet syndrome, which is 
characterized by a severe clinical phenotype and a poor pharmacoresponsiveness (Dravet, 
2011). For Dravet syndrome a recent meta-analysis has suggested an improvement of seizure 
control and behavioral symptoms in response to the KD (Wang et al., 2020).  This finding 
supports the recommendation of KD for Dravet patients with failure to respond to three or four 
different antiseizure drugs (Cross et al., 2019). Therapeutic success of the ketogenic diet 




with Dravet syndrome rendering it a valuable target for therapeutic intervention. Further 
evidence for changes in brain bioenergetics came from a limited number of 18F-labelled 
fluorodeoxyglucose positron emission tomography (FDG-PET) studies reporting alterations in 
glucose uptake in a Dravet mouse model and in patients with Dravet syndrome (Haginoya et 
al., 2018; Kumar et al., 2018; Ricobaraza et al., 2019).      
Despite the use of dietary approaches, there is a surprising gap in knowledge when it comes to 
the metabolic consequences of epilepsy syndromes. A gain-in-knowledge will provide a basis 
for a more rational application of dietary approaches, for the identification of potential 
biomarkers predicting responsiveness guiding individualized therapeutic decisions, and 
information for the design and development of small molecule compounds targeting metabolic 
pathways as an alternate to dietary approaches. Alternate metabolism-targeting 
pharmacological approaches are of particular interest considering that KD is characterized by a 
relatively poor tolerability and a high adverse effect potential.    
Thus, there is a particular interest to improve the knowledge about the metabolic state 
developing following SCN1A deficiency as the most frequent clinical cause of Dravet 
syndrome. Therefore, we have completed a metabolomics analysis in a genetic Dravet mouse 
model with animals exposed to a control diet or a KD. Among other findings, the data set 
revealed pronounced alterations in energy metabolism and in the glutamate/GABA-glutamine 
cycle in Dravet mice. The metabolic patterns are of particular interest in the context of 
pathophysiological mechanisms of seizure susceptibility and ictogenesis and of possible 





Material and methods 
Animals 
Parental breeding lines, B6(Cg)-Scn1atm1.1Dsf/J (#026133 (Kuo et al., 2019; Ricobaraza et al., 
2019)) and 129S1/Sv-Hprttm1(CAG-cre)Mnn/J (#004302 (Tang et al., 2002)), were purchased from 
the Jackson Laboratory (Bar Harbor, Maine, USA). Heterozygous A1783V-Scn1a Dravet 
(mutant) and wildtype (control) mice were generated by crossing female mice heterozygous for 
Cre recombinase (X-linked to Hprt gene) with male mice with floxed Scn1a. The resulting 
offspring was generated on a mixed (50:50) C57BL/6J and 129S1 genetic background and 
genotyped as previously described (Miljanovic et al., under revision). In a parallel study, we 
demonstrated that Dravet mice exhibit first spontaneous tonic-clonic seizures from P16 on, 
followed by recurrent seizure with a high seizure frequency, a transient delay in body weight 
development and a SUDEP rate of 40 % around the time of weaning. Moreover, a pronounced 
hyperactivity became evident in Dravet mice (Miljanovic et al., under revision). 
All experiments were approved by the government of Upper Bavaria (license number 55.2-1-
54-2532-168-2016) and conducted in line with the EU directive 2010/63/EU for animal 
experiments and the German Animal Welfare act. Experiments were designed and executed in 
line with ARRIVE guidelines and Basel declaration (http://www.basel.declaration.org) 
including the 3R concept. 
A pilot study designed to determine an adequate duration of ketogenic diet exposure was 
performed in five Dravet (2 males; 3 females) and five wildtype (2 males; 3 females) mice (Fig. 
S6). For the main study, 35 heterozygous Dravet and 28 wildtype mice were generated. Nine 
Dravet mice died due to probable SUDEP resulting in a mortality rate of 25.7 %. From 
remaining animals, twenty-two heterozygous (11 males; 11 females) and 20 wildtype mice (10 
males; 10 females) were selected for the experiment and split in two cohorts with 2 weeks apart, 




Please note that baseline data from video-EEG recordings in heterozygous mice have already 
previously been presented in the context of a study characterizing the line (Miljanovic et al., 
under revision; Table S1).  
 
Experiment timeline 
Twelve-week-old wildtype and Dravet mice were implanted with telemetric transmitters (HD-
X02, DSI, St. Paul, USA) and depth electrodes in the hippocampus. Recordings were initiated 
after a two-week recovery phase. Following a one-week baseline video-EEG-ECG recording, 
animals were allocated to four groups considering genotype and treatment: wildtype control 
diet (WT CD, n=10), wildtype ketogenic diet (WT KD, n=10), Dravet control diet (Dra CD, 
n=10) and Dravet ketogenic diet (Dra KD, n=11) group. When allocating Dravet mice to 
groups, the number of convulsive seizures was used as a relevant parameter for stratified 
randomization (R software). One male and two female Dravet mice with no seizures during the 
baseline recording, were excluded for the second recording session. Animals were provided 
with CD or KD for a period of 3 weeks, following which the mice had a second week of 
continuous video-EEG-ECG recordings. For the next 2 weeks animals were exposed to 
different behavioral tests comprising nest building activity, saccharin preference test, open field 
test, novel object recognition and gait assessment. Mice were fasted for 6 hours prior to 
euthanasia, and plasma and hippocampal tissue were collected for metabolomic analysis 
(metaSysX GmbH). The experimental timeline is sketched in Fig. S1A. All experimental 
procedures are described in detail in Supporting Information (Fig. S1B). 
 
Statistical analysis 
R software (version 3.6.1.) was used for statistical analysis. GraphPad Prism (Version 5.04, 
GraphPad, USA) and R software (version 3.6.1.) were used for data visualization. Spearman 




et al., 2016)) and the significance level was set at < -0.5 or > 0.5. Missing data from individual 
animals were not considered for the respective correlation analysis. 
All data were expressed as mean ± SEM except for nest complexity score and body weight, for 
which the median and mean are illustrated in respective graphs. Smoothing of body weight 
graph line in Fig. S7 is based on a Loess regression. All results were firstly checked for possible 
batch and sex effects. If present, they were considered in the statistical analysis. 
Two-tailed paired t-test was used for comparison between baseline and post diet seizure data in 
Dravet mice where indicated. Two-tailed unpaired t-test was used for a comparison between 
wildtype and Dravet mice CD fed where indicated. Two-way ANOVAs were used for testing 
the genotype and diet effect where appropriate, followed by a Bonferroni post-hoc test. In 
addition, false discovery rate (FDR) correction was applied to metabolome analysis to minimize 
multiple comparisons error. Next complexity score was analyzed with Friedman non-
parametric test, Dunn's Multiple Comparison Test. The significance level was set at p < 0.05 












Metabolomic screening detected 118 and 120 different metabolites in plasma and hippocampal 
samples, respectively. Genotype differences between Dravet and wildtype mice were identified 
for 72 metabolites in the hippocampus and for none of the metabolites in the plasma (Two-way 
ANOVA, FDR corrected).   
The KD affected metabolite levels in both, plasma (18 metabolites) and hippocampus (14 
metabolites) samples of wildtype and Dravet mice (Two-way ANOVA, FDR corrected). No 
relevant difference between sexes were observed. 
 
Genotype associated alteration in hippocampus and plasma metabolites in Dravet  
Following entry into cells, glucose is phosphorylated to glucose-6-phosphate to prevent its 
diffusion out of the cell and create a pool that draws more glucose into the cell (Mergenthaler 
et al., 2013). Interestingly, a decrease in glucose and an increase of phosphorylated glucose (D-
glucose-6-phosphate and α-D-glucose-6-phosphate) were noted in the hippocampus of Dravet 
mice when compared to wildtype mice (Fig. 1, S2A-C). Additionally, α-D-glucose-1-phosphate 
was up-regulated in the hippocampus of Dravet mice (Fig. S2D). Depending of the energetic 
state, it can act as glycogen precursor or as the main product of glycogen degradation, which 
next converts to glucose-6-phosphate and enters glycolysis (Obel et al., 2012). Furthermore, β-
hydroxybutyrate (BHB), a ketone body and alternative brain fuel, was neither regulated in 
plasma nor in the hippocampus of Dravet mice fed CD (Fig. 1, 3D-E). 
Several intermediate metabolites in glycolysis proved to be up-regulated in the hippocampus of 
Dravet mice. These included D-fructose-6-phosphate, D-fructose-1,6-biphosphate, D-fructose-
1-phosphate, dihydroxyacetone-phosphate and pyruvic acid (Fig. 1, S3). Pyruvate can enter the 
tricarboxylic acid (TCA) cycle. Some intermediates of the TCA cycle were down-regulated in 




lactate is one of the favored brain fuels produced from pyruvate (Smith et al., 2003). Recently, 
its significance in shuttle between astrocytes and neurons and microglia, revealed a pivotal role 
in neuroenergetics (Mason, 2017). Interestingly, Dravet mice displayed a reduced level of (S)-
lactate in the hippocampus in comparison with wildtype controls (Fig. 1, S4F). 
 
Fig. 1 Hippocampal glycolysis, the pentose phosphate pathway and tricarboxylic acid 
(TCA) cycle in mice with Dravet mice. This sketch illustrates metabolites (presented in 
blocks) and proteins detected in the previous study (only text; Miljanovic et al., under revision). 
Changes in metabolite or protein abundance in Dravet mice as compared to wildtype mice are 
indicated by text color (blue = up-regulation, red = down-regulation). Ketogenic diet effects on 
selected metabolites in Dravet mice are indicated with an arrow (up = up-regulation, down = 
down-regulation). HX – hexokinase, GPD - glucose-6-phosphate dehydrogenase, GPI - 
glucose-6-phosphate isomerase, PFK – phosphofructokinase, TA – transaldolase, TK – 
transketolase, FBA - fructose-bisphosphate aldolase, GAPD – glyceraldehyde 3-phosphate 
dehydrogenase, TPI - triose-phosphate isomerase, PGK - phosphoglycerate kinase, PGM - 
phosphoglycerate mutase, ENO – enolase, PK – pyruvate kinase, PDH – pyruvate 
dehydrogenase, BHB – β-hydroxybutyrate, SSADH - succinic semialdehyde dehydrogenase. 
 
Glucose-6-phosphate can be processed in the pentose phosphate pathway (Mergenthaler et al., 
2013). Some of the intermediate metabolites were up-regulated in Dravet mice (Fig. 1). These 




an intermediate which can enter glycolysis. In contrast, ribose-5-phosphate remained 
unchanged in Dravet mice (Fig. S4H). 
Fig. 2 Hippocampal levels of GABA, glutamic acid and its amino acids precoursors. A 
Hippocampal abundance of GABA. Hippocampal levels of GABA were significantly reduced 
in mice with the Dravet genotype. B Hippocampal level of glutamic acid. Dravet mice exhibited 
a reduced abundance of glutamic acid when compared to wildtype mice. C GABA:glutamic 
acid ratio in the hippocampus. This ratio was higher in Dravet mice as compared to wildtype 
mice. D Spearman correlation matrix between GABA, glutamic acid, GABA:glutamic acid 
ratio, and  behavioral parameters, selected hippocampal metabolites and plasma corticosterone. 




Dravet mice. The color scale is shown below the matrix with blue and red indicating positive 
and negative correlations, respectively.  GABA:glutamic acid ratio showed a strong positive 
correlation with levels of noradrenaline and β-alanine, and a negative correlation with levels of 
phosphorylated forms of glucose, lactate and glutamic acid precursors in the hippocampus. E-
J Hippocampal abundance of L-glutamine (E), L-aspartic acid (F), L-asparagine (G), L-lysine 
(H), L-proline (I) and L-histidine (J). E-G The level of L-glutamine, L-aspartic acid and L-
asparagine was reduced in Dravet mice regardless of the applied diet. H Hippocampal 
abundance of L-lysine was enhanced in Dravet mice. In addition, KD significantly reduced the 
metabolite level only in Dravet mice. I The level of L-proline in the hippocampus of KD fed 
mice was significantly lower in Dravet, as compared to wildtype mice. J The hippocampal level 
of L-histidine remained constant in  all four groups. Data shown are from 20 wildtype mice (10 
CD, 10 KD) and 21 Dravet mice (10 CD, 11 KD). (Two-way ANOVA, FDR correction, 
Bonferroni post-hoc test, * = p<0.05, mean±SEM). 
 
The balance between GABA and glutamate in the brain resembles one of the most important 
mechanisms contributing to hyperexcitability in epilepsies. Hippocampal levels of both, GABA 
and glutamate (glutamic acid), were reduced in Dravet mice (Fig. 1, 2A-B). Yet, the 
GABA:glutamate ratio was significantly increased in Dravet mice, implying a more 
pronounced reduction of glutamate levels (Fig. 2C). Interestingly, the ratio showed a negative 
correlation with D-glucose-6-phosphate, α-D-glucose-6-phosphate, α-D-glucose-1-phosphate, 
α-ketoglutarate, (S)-lactate, L-glutamine, L-asparagine and L-aspartic acid (R=-0.55; -0.53; -
0.53, -0.56, -0.69, -0.55, -0,64, -0.69, respectively) and a positive correlation with noradrenaline 
and β-alanine (R=0.58, 0.74, respectively) (Fig. 2D). 
Since glutamate can be synthesized from L-glutamine through the glutamate/GABA-glutamine 
cycle, it is of interest that Dravet mice showed a pronounced L-glutamine down-regulation in 
the hippocampus (Fig. 1, 2E). Other amino acids known as glutamate precursors were also 
regulated in mice with Scn1a deficiency with aspartic acid and asparagine showing a down-
regulation and lysine showing an up-regulation (Fig. 1, 2F-H). On the other hand, proline and 
histidine were not regulated in the hippocampus of mutant mice (Fig. 1, 2I-J). Lastly, no 
changes in the level of α-ketoglutarate, an TCA cycle intermediator and important glutamate 




Several neurotransmitters were detected in hippocampal tissue. Noradrenaline was reduced and 
beta-alanine, which has been suggested to act as an amino acid neurotransmitter(Tiedje et al., 
2010), was increased in the hippocampus of Dravet mice. Further neurotransmitters including 
serotonin, acetylcholine, histamine and glycine were not affected by the genotype (Fig. S5). 
Analysis of the plasma metabolome in CD fed mice, pointed towards a down-regulation of 
corticosterone, allocholic and cholic bile acid and an up-regulation of malic acid in Dravet mice 
(Fig. 3A-C; unpaired t-test, FDR corrected). Deoxycholic and hyodeoxycholic acid plasma 
levels remained unaffected (data not shown).  
 
Fig. 3 Plasma metabolites and ketosis confirmation. A Plasma level of corticosterone. The 
metabolite level was reduced in mice with the Dravet genotype, regardless of the diet. B-C 
Plasma levels of allocholic (B) and cholic acid (C). Allocholic and cholic acids were reduced 
in Dravet mice, regardless of the diet. D-E β-hydroxybutyrate (BHB) level in the hippocampus 
(D) and plasma (E). KD increased hippocampal and plasma BHB in both wildtype and Dravet 
mice. In addition, the BHB level was higher in wildtype mice consuming KD, as compared to 
Dravet mice in both the hippocampus and plasma. F Plasma level of glucose. KD decreased 
plasma glucose in both wildtype and Dravet mice. Data shown are from 20 wildtype mice (10 
CD, 10 KD) and 21 Dravet mice (10 CD, 11 KD). (Two-way ANOVA, FDR correction, 






Ketogenic diet effect on hippocampus and plasma metabolome 
An increased BHB in wildtype and Dravet animals, confirmed that KD exposure induced 
ketosis in both genotypes. However, hippocampus and plasma BHB levels in wildtype mice 
exceeded the respective levels in Dravet mice (Fig. 3D-E). As KD is poor in carbohydrates, it 
was no surprise that exposure was associated with lowered plasma glucose levels (Fig. 3F). Yet, 
hippocampal glucose levels remained unaffected (Fig. S2A). Intracellular glucose forms (D-
glucose-6-phosphate, α-D-glucose-6-phosphate) were increased only in Dravet mice fed KD, 
as compared to those fed CD (Fig. 1, S2B-C). Additionally, a mild KD effect on glucose 
metabolism was observed. An increase of two glycolysis intermediates was noted, with D-
fructose-1-phosphate increased only in wildtype and dihydroxyacetone-phosphate increased 
only in Dravet mice (Fig. 1, S3C-D). An intermediate metabolite of the phosphate pentose 
cycle, 6-phosphogluconic acid, was increased in Dravet mice fed KD, as compared to those fed 
CD (Fig. 1, S4G). Concerning the TCA cycle, levels of α-ketoglutarate and succinic acid in 
wildtype mice fed KD exceeded those in Dravet mice with KD exposure (Fig. S4A, D). 
 
Effect of KD on food intake and body weight development 
Over the period of 7 weeks, wildtype and Dravet mice fed CD consumed a higher amount of 
diet than mice fed KD. Additionally, the amount of KD consumption in Dravet mice, exceeded 
the amount consumed by wildtype mice (Fig. S7A). In this context it needs to be considered 
that the caloric value of the KD was higher than that of the CD (KD: 6.7 kcal/g; CD: 3.8 kcal/g). 
Mice fed KD had an overall higher caloric intake. Additionally, Dravet mice fed KD exhibited 
the highest overall caloric intake exceeding that in all other groups (Fig. S7B). 
As expected body weight increased in all groups during the experimental course. However, 
body weight of Dravet mice fed KD exceeded that from all other groups in both, males and 





Effect of KD on spontaneous generalized tonic-clonic seizures and behavior 
Dravet mice had two video-EEG recording sessions, and the diet effect was examined by 
analyzing a relative change of motor seizure parameters. The diet did not affect any of the motor 
seizure parameters including: total seizure duration, seizure frequency, number of days with 
seizures within a week and Racine score (Fig. 4A, Table S2). Electrographic seizure activity 
was confirmed with EEG recordings and high amplitude spiking over 500 µV (Fig. 4B).   
However, in Dravet mice fed CD seizures were prolonged and more frequent in animals with 
lower levels of D-glucose-6-phosphate and higher levels of citric acid, L-glutamine and other 
amino acids (Fig. 4C-up). Following KD exposure of Dravet mice a positive correlation 
between seizure parameters and metabolites was restricted to α-D-glucose-6-phosphate, α-D-






Fig. 4 Generalized tonic-clonic seizure parameters. A Total seizure duration, seizure 
frequency, number of days with seizures within a week and Racine score in Dravet mice. KD 
did not affect any of the assessed seizure parameters. Data shown are from 17 Dravet mice (8 
CD, 9 KD). (Unpaired t-test, * = p<0.05, mean±SEM). B A representative EEG recording of a 
spontaneous, generalized tonic-clonic seizure in a Dravet mouse. C Spearman correlation 
matrix between seizure parameters, behavioral parameters, selected hippocampal metabolites, 




selected parameters in Dravet mice fed control diet (CD, upper band) and Dravet mice fed KD 
(lower band). The color scale is shown below the matrix with blue and red indicating positive 
and negative correlations, respectively. Seizure severity (total seizure frequency and duration) 
showed a strong positive correlation with levels of citric acid, L-glutamine and other amino 
acids and a negative correlation with the level of D-glucose-6-phosphate in Dravet mice fed 
CD (upper band). In Dravet mice fed KD, a positive correlation between seizure severity and 
α-D-glucose-6-phosphate, α-D-glucose-1-phosphate, α-ketoglutarate and malic acid was 
observed (lower band).  
 
Assessment of gait revealed no differences in stride length, regardless of the genotype and diet 
(Fig. 5A). The angle between forelimb paw orientation and body direction proved to be wider 
in Dravet mice (Fig. 5B) without an influence of the diet. The forelimb base of support (BOS) 
was neither affected by genotype nor diet (Fig. 5C). However, hindlimb BOS proved to be 
shorter in Dravet mice. Interestingly, exposure to the KD in Dravet mice, reversed hindlimb 
BOS to wildtype values (Fig. 5D). Notably, an improvement of gait with an increase of 
hindlimb BOS in Dravet mice, showed a strong positive correlation with glucose, D-glucose-
6-phosphate, α-D-glucose-6-phosphate and acetylcholine, and a negative correlation with β-
alanine in the hippocampus (Fig. 5E-up). Moreover, when analyzing data from Dravet mice on 
KD, the hindlimb BOS parameter positively correlated with glucose, lactate, GABA, glutamate, 
acetylcholine, glutamine, aspartic acid, threonine, phenylalanine, lysine and histidine 
concentrations in the hippocampus. Lastly, a negative correlation with fumaric acid was noted 
(Fig. 5E-down). No differences between sexes were detected in any of the gait parameters. 
The impact of genotype and KD on open field test, novel object recognition, saccharin 




Fig. 5 Gait analysis. A Stride length. Dravet and wildype mice had a comparable length of 
stride, regardless of the consumed diet. B Angle between forelimb paw and body direction. 
Mice with the Dravet genotype had a significantly wider angle than wildtype mice. C-D Base 
of support (BOS) between forelimbs (C) and hindlimbs (D). No differences in forelimb BOS 
were noted between all four groups. Hindlimb BOS was reduced in mice with the Dravet 
genotype. Application of KD in Dravet mice, restored this parameter to the values of wildtype 
mice, thus improving the gait. Data shown are from 20 wildtype mice (10 CD, 10 KD) and 21 
Dravet mice (10 CD, 11 KD). (Two-way ANOVA, Bonferroni post hoc test, * = p<0.05, 
mean±SEM). E Spearman correlation matrix between assessed gait parameters, other 
behavioral parameters and selected hippocampal metabolites (except for corticosterone, 
measured in plasma). The heat map represents individual Spearman correlations between 
selected parameters in Dravet mice (upper band) and Dravet mice fed KD (lower band). The 
color scale is shown below the matrix with blue and red indicating positive and negative 
correlations, respectively. Hindlimb BOS showed a positive correlation with levels of glucose, 




with levels of β-alanine in the hippocampal tissue of Dravet mice (upper band). In Dravet mice 
fed KD, hindlimb BOS showed a positive correlation with levels of glucose, lactate, GABA, L-
glutamic acid, acetylcholine, L-glutamine, L-aspartic acid, L-threonine, L-phenylalanine, L-
lysine and L-histidine, and a negative correlation with the level of fumaric acid in the 






Hippocampal metabolomic analysis in a Dravet mouse model revealed complex alterations in 
energy metabolism.  Moreover, we obtained evidence for a direct and indirect impact of Scn1a 
deficiency on the glutamate/GABA-glutamine cycle, on concentrations of noradrenaline and 
two bile acids concentrations. A previous large-scale proteomic analysis gave us the 
opportunity to interpret the present findings in the context of alterations in enzymes or 
transporter molecules.  
Alterations in glucose metabolism point to a genotype-associated activation of catabolic 
processes with enhanced glycogenolysis and glycolysis. A shift in brain glucose transport and 
metabolism in Dravet syndrome with Scn1a deficiency has previously been suggested by 
experimental and clinical FDG-PET data (Haginoya et al., 2018; Ricobaraza et al., 2019). As 
intracellular FDG accumulation largely depends on glucose uptake at the blood-brain barrier 
and its metabolism to glucose-6-phosphate by hexokinase, it is of interest that we observed a 
lowered expression of glucose-1 transporter responsible for astrocytic uptake of glucose and an 
increased expression of hexokinase in the proteomic analysis (Table S1).     
While we obtained evidence for an enhanced supply of pyruvate and increased expression of 
several enzymes contributing to TCA cycle activity, reduced concentrations of lactate and of 
the TCA cycle intermediates malate and citrate indicate that there might be a failure to 
adequately fulfil increased neuronal energy demands related to enhanced synaptic activity. 
Along this line, the up-regulation of glycogenolysis and glycolysis might reflect the cellular 
attempt to compensate for energetic failure. In this context, it is of particular interest that the 
neuronal transporter, glucose transporter 3 and the lactate transporter monocarboxylate 
transporter 1, are up-regulated in Dravet mice (Table S1). Thus, the metabolic coupling between 
astrocytes and neurons, with predominant regulation of glycolysis in astrocytes, shuttling of 




Adamson, 2011), seems to be significantly altered in Dravet mice with genetic deficiency (Fig. 
6).  
Fig. 6 Hippocampal glucose metabolism in Dravet mice. This sketch illustrates detected 
metabolites (presented with text) and proteins detected in the previous study (enzymes, 
receptors and transporters; Miljanovic et al., under revision). Changes in metabolite or protein 
abundance in Dravet mice are indicated by text color (blue = up-regulation, red = down-
regulation). Glu – glutamate, Gln – glutamine, α-KG - α-ketoglutarate, G-6-P – glucose-6-
phosphate, G-1-P – glucose-1-phosphate, KB – ketone bodies, GLUT – glucose transporter, 
VGLUT - vesicular glutamate transporter, MCT1 - monocarboxylate transporter 1, EAAT – 
excitatory amino acid transporter, GS - glutamine synthetase, HX – hexokinase, LDH – lactate 
dehydrogenase, GP3 - glycogen phosphorylase 3a., PPP – pentose phosphate pathway, TCA - 
tricarboxylic acid cycle. 
 
In the epileptic brain, energy depletion occurring during seizures is considered an important 
contributor to seizure termination (Yang et al., 2013b). In the interictal phase, enhanced spiking 
activity of neurons is associated with enhanced energy consumption related to ion channel 
activity as well as synaptic neurotransmitter processing (Ivanov et al., 2015). Our present 
findings provide evidence that Dravet syndrome can also be associated with a significantly 
altered energy metabolism. This finding might at least partly be related to enhanced interictal 




into account that alterations in glucose metabolism and TCA cycle activity should not only be 
considered as a consequence of seizures and interictal activity, but can also contribute to an 
enhanced seizure susceptibility and ictogenesis. The pathophysiological relevance has been 
convincingly demonstrated by the characterization of genetic epilepsies with primary failure of 
energy supply related to a genetic deficiency of glucose transporter 1 or the sodium-dependent 
citrate transporter NaCT encoded by the SLC13A5 gene (Henke et al., 2020; Pong et al., 2012). 
In the context of SLC13A5 deficiency the interneuron energy hypothesis has been formulated 
(Bhutia et al., 2017), which is based on the fact that inhibitory interneurons are characterized 
by a higher energy consumption than excitatory principal neurons (Kann, 2016). As discussed 
previously (Henke et al., 2020), energy deficits in inhibitory interneurons may result in 
disinhibition of excitatory neurons causing hyperexcitability. Thus, cumulative neuronal energy 
depletion as a consequence of increased interictal spiking may actually pave the way for a 
continuous lowering of the seizure threshold and generation of the next seizure event. Along 
this line, changes in TCA cycle activity can reduce ATP and adenosine concentrations with an 
impact on adenosine A1 receptors subsequently affecting inwardly-rectifying potassium 
channels and neuronal excitability (Boison, 2017; Boison and Steinhäuser, 2018; Henke et al., 
2020; Masino and Rho, 2019). Our data therefore suggest that the complex alterations in energy 
metabolism may contribute to the high seizure frequency often characterizing the clinical 
phenotype of Dravet syndrome. This conclusion received further confirmation by the fact that 
we identified a correlation between seizure duration and frequency, and glucose metabolism 
and TCA cycle intermediates. 
Another key finding of the broad-scale metabolic analysis was the down-regulation of the entire 
glutamate/GABA-glutamine cycle. Considering that TCA cycle activity is linked to glutamate 
formation via its intermediate α-ketoglutarate (Wu et al., 2016; Youngson et al., 2017), lowered 
concentrations of glutamate, GABA, and glutamine might be related to decreased TCA cycle-




of the major excitatory and inhibitory neurotransmitters glutamate and GABA will likely affect 
neuronal excitability. Thereby, the increased GABA:glutamate ratio indicates a shift favoring 
GABA synthesis from glutamate. Thus, the alterations affecting the glutamate/GABA-
glutamine cycle may actually reflect a mechanism that may partially compensate the Scn1a-
deficiency related limitations in GABAergic interneuron function that seems to drive network 
hyperexcitability in Dravet syndrome according to experimental findings in different mouse 
models (Dutton et al., 2013; Oakley et al., 2011; Tran et al., 2020; Yu et al., 2006). However, 
it needs to be considered that proteomic analysis revealed a down-regulation of excitatory 
amino acid transporters and of glutamine synthetase responsible for astrocytic uptake of 
glutamate and its conversion of glutamine (Table 1). Thus, it is possible that an accumulation 
of extracellular glutamate concentrations triggering neuronal hyperexcitability might occur 
despite an overall decrease of the total glutamate concentration (Fig. 6). However, this greater 
decrease in glutamate may also be related to the age of animals, which is why it would be of 
interest to assess GABA and glutamate levels in younger mice.  
Interestingly, further neurotransmitters comprising aspartate and noradrenaline exhibited 
lowered concentrations in hippocampal samples from Dravet mice. Considering their role in 
neuronal excitability (Dingledine and McBain, 1999; Giorgi et al., 2004; O'Donnell et al., 2012; 
Patri, 2019), these changes might additionally affect seizure susceptibility. However, further 
studies would be necessary to explore a potential functional relevance.  
While it is common knowledge that highly increased levels of bile acids can exert toxic effects 
on neuronal function, we just more recently started to develop a more differentiated perspective 
about the impact of bile acids in the healthy and diseased brain (Grant and DeMorrow, 2020; 
Kiriyama and Nochi, 2019; McMillin and DeMorrow, 2016). This resulted in a discussion about 
the potential of bile-acid mediated therapies in neurodegenerative disorders(Grant and 
DeMorrow, 2020). Along this line, reduced levels of two bile acids in Dravet mice suggest that 




consequences in order to provide information about a potential pathophysiological role and 
possible basis for therapeutic intervention.   
Despite ongoing research efforts, the mechanisms of the KD diet still remain to be incompletely 
understood at this point of time. Among other mechanisms, a shift in energy supply and in 
catabolic pathway activities, with a reduction of glycolysis and an enhanced oxidation of fatty 
acids and ketone bodies, may represent one key mechanism. This shift might help to provide 
more ATP resulting in adenosine increases, and related to alternate fueling of the TCA cycle 
might provide more α-ketoglutarate as a precursor for glutamate and subsequent GABA 
synthesis (Youngson et al., 2017). Interestingly, the fact that the level of ketosis in wildtype 
mice exceeded that in Dravet mice, provides evidence that related to a different metabolic 
baseline situation, it can be more difficult to increase ketone body levels in individuals with 
Dravet syndrome.  
Despite the confirmation of ketosis, the alterations in energy metabolism were rather limited. 
While we observed an increase of different glycolysis intermediates, we failed to confirm a 
direct effect on TCA cycle activity in both genotypes. Thus, our data do not confirm the energy 
shift with a down-regulation of glycolytic activity and enhanced TCA cycle activity suggested 
by previous studies (D'Andrea Meira et al., 2019; Puchalska and Crawford, 2017; Youngson et 
al., 2017). However, in clinical practice KD is in the majority of patients applied as an 
adjunctive therapy in combination with antiseizure drugs (Cross et al., 2019). Therefore, we 
cannot exclude that additional therapy with antiseizure drugs results in an at least partial control 
of interictal neuronal activity resulting in a better metabolic initial situation, which is then easier 
to influence by a dietary approach. This assumption is further confirmed by the failure to control 
seizure activity by the exposure to KD as a monotherapy in the present study. Considering these 
findings, it would be of interest to assess the impact of different antiseizure drugs on the 
metabolomic signature of Dravet syndrome. In this context, it is of particular interest that 




metabolism based on an inhibition of lactate dehydrogenase (Sada et al., 2015). Lastly, we 
cannot exclude the possibility that it might be easier to demonstrate an effect of KD in a mouse 
model with a more severe seizure phenotype. 
The clinical manifestation of Dravet syndrome is also characterized by the development of 
ataxia, motor deficits and gait disturbance (Gataullina and Dulac, 2017). The latter is partly 
explained by the fact that Nav1.1 encoded by the SCN1A gene is also expressed in cerebellar 
Purkinje cells and in nodes of Ranvier of motor neurons (Duflocq et al., 2008; Gataullina and 
Dulac, 2017). KD exposure in Dravet mice resulted in partial normalization of one of the main 
outread parameters of gait assessment. This finding demonstrates that the metabolic 
consequences of KD were sufficient to affect the clinical phenotype and that glucose, glucose-
6-phosphate, acetylcholine and β-alanine may be relevant markers for gait improvement. 
Moreover, this result draws attention to a potential beneficial impact of dietary approaches such 
as the KD on motor dysfunction. So far, there is only very limited clinical information providing 
first evidence that KD can improve coordination and gait in patients with Dravet syndrome 
(Tian et al., 2019). Concerning the beneficial effect on gait disturbance, it is recommended to 
additionally assess the impact of KD on metabolomics in the cerebellum and in peripheral motor 
neurons.  
In conclusion, the comprehensive metabolomic analysis revealed substantial alterations in 
energy metabolism in mice with the Scn1a genetic deficiency. These complex changes might 
contribute to seizure susceptibility and ictogenesis. In response to KD exposure a beneficial 
effect on motor dysfunction became evident suggesting that metabolic changes contribute to 
ataxia and gait disturbances developing during the course of Dravet syndrome.  
Interestingly, we also demonstrated alterations in the glutamate/GABA-glutamine cycle, which 
might serve as an endogenous compensatory mechanism, which can be further supported by 
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Housing of animals 
From birth until weaning time (P19-21), each litter was housed in individually ventilated cages 
(Tecniplast, Hohenpeißenberg, Germany). Following weaning, animals were kept in groups of 
3-5 animals per standard Makrolon type III cage (Ehret, Emmendingen, Germany). Following 
surgery, mice were kept single-housed.  
Once per week, each cage was provided with fresh sawdust as a bedding material (Lignocel, 
Rosenberg, Germany), one animal house (Tecniplast, Hohenpeißenberg, Germany; Zoonlab 
GmbH, Castrop-Rauxel, Germany), and 7 g of Enviro-dri® nest material (Claus GmbH, 
Neuwied Germany). Animal housing was maintained under standard conditions (temperature 
22 ± 2 ̊ C, humidity 40-60 %, regular 12-hour light/dark cycle).  
All animals received ad libitum tap water and food (ssniff® R/M-H, Sniff, Soest, Germany). 
Between postnatal day P14 and P26 animals had additional access to a Dietgel76A as a 
supplement (Sniff, Soest, Germany).  
Following group allocation, animals were provided either with 6:1 fat:protein ketogenic diet 
(KD; #TD07797, Envigo, Italy), or a vitamin and mineral balanced control diet (CD; 
#TD150300, Envigo, Italy). CD or KD were provided to animals over a period of 41-42 days 
(depending on the day of sacrifice). The amount of consumed food was measured daily. Since 
the food had a consistency of paste, animals were provided with wooden popsicles as an 
enrichment (Pura Sticks, Labodia AG, Niederglatt, Switzerland). 
 
Ketosis confirmation 
A pilot study with five wildtype and five Dravet mice was conducted in order to determine the 




of blood was sampled from the facial vein with a lancet (Cat# GR-5MM, BioSebLab, Vitrolles, 
France), and beta-hydroxybutyrate (BHB) was measured with ß-ketone test stripes and 
Glucomen Areo 2K device (GlucoMen® Areo, Berlin, Germany. Due to the circadian nature 
of BHB concentrations, onset and end of the light phase (6 a.m. and 6 p.m.) were chosen as the 
two time points for measurement. Before the exposure to KD, mice were fed a standard chow 
and baseline blood BHB was measured. Then, mice were fed KD for 3 weeks and blood BHB 
was measured weekly. Blood BHB from three wildtype and three Dravet mice was not 
measured at 6 a.m. for the baseline and 1 week after the initiation of KD. One wildtype female 
mouse died in the context of blood sampling after one-week exposure to the KD. Once ketosis 
was confirmed, KD was replaced with standard chow and animals were euthanized with 600 
mg/kg pentobarbital.  
 
Surgery and video-EEG recordings 
Twelve-week-old wildtype and Dravet mice underwent a survival surgery for telemetric 
transmitter (HD-X02, DSI, St. Paul, USA) and electrode implantation preparing the animals for 
EEG-ECG recordings. Wildtype mice were used as controls and were therefore implanted with 
a dummy transmitter with no recording opportunity. Each cohort was implanted within 1 week, 
and the order of animals during the day was randomized (R software).  
Mice received 1 mg/kg meloxicam s.c. (Metacam®, Boehringer Ingelheim, Germany) for 
analgesia 30 minutes before the anesthesia induction and 24 hours afterwards. Isoflurane 
(Isofluran CP®, Henry Schein Vet, Hamburg, Germany) was used as a general anesthetic: 4 % 
for induction and 1.5 % for maintenance of anesthesia. Bupivacaine was applied subcutaneously 
as a local anesthetic: 0.25 % (Jenapharm®, Mibe GmbH, Brehna, Germany) to surgical areas 
affected by transmitter implant and placement of leads; and 0.5 % + 0.0005 % epinephrine 




For the subcutaneous placement of telemetric transmitter, the skin was opened in the 
dorsocaudal part of the scapula region. ECG leads were fixed intramuscularly: negative lead to 
the right pectoral muscle, and positive lead to xyphoid. Skin was closed over the ECG lead with 
absorbable sutures (Smi AG, St. Vith, Belgium) and animals were fixed in the stereotactic 
surgical frame. Three screws were fixed into the scull and the negative EEG lead was connected 
to the screw placed over the cerebellum. The positive EEG lead was connected to a bipolar 
Teflon-isolated stainless-steel electrode, before implanting it in the hippocampal CA1 region 
(ap: - 2.00; lat: + 1.3; dv: - 1.6). 
Paladur (Heraeus®, Hanau, Germany) was used for fixation of the electrode and absorbable 
sutures for closing the skin around the skull. A tissue adhesive (Surgibond®, Henry Schein Vet, 
Hamburg, Germany) was applied to close the initial cut for placing the transmitter.  
Mice were provided with oxygen (Oxyboy oxygen generator, Hugo Sacks Electronic, March-
Hugstetten, Germany) until regaining consciousness. Following a recovery time of 2 weeks, a 
one-week continuous video-EEG-ECG baseline recordings was completed using Ponemah 
software (Ponemah R, v. 5.2.0, DSI, St. Paul, USA). Spontaneous seizure activity was detected 
automatically (NeuroscoreTM v. 3.0, DSI, St. Paul, USA) and further confirmed and analyzed 
using acquired videos (Axis communications, Lund, Sweden). The amplitude threshold for 
seizure spikes was set to 500 µV. Seizure duration, frequency, severity, and number of days 
with seizures within a week were evaluated. Seizure severity was scored based on the adapted 
Racine scoring system: (Dutton et al., 2017; Racine, 1972): I (orofacial movements), II (head 
nodding), III (forelimb myoclonus), IV (forelimb clonic convulsions with rearing), V 
(generalized motor convulsions followed by rearing and falling) and score VI (generalized 





Behavior tests were completed in morning hours starting from 8 a.m. Nest-building activity and 
saccharin preference were conducted in the home cage during the first week of behavior tests. 
In the second week of behavioral testing, the open field test, the novel object recognition test 
and gait assessment were completed and video documented in a test room under standard 
conditions (temperature 22 ± 2 ̊ C, humidity 40-60 %, lighting 15-20 lx).  
 
Nest-building activity  
Following the second week of continuous video-EEG recording, nest building activity was 
assessed. For seven consecutive days, nests were photographed each morning. The images were 
used for nest complexity scoring by an investigator blinded to animals’ genotype and treatment. 
Nest complexity was scored based on a scoring system adapted from Jirkof and colleagues 
(Jirkof et al., 2013): score 0 = nesting material is intact; score 1 = nesting material is noticeably 
manipulated and possibly spread around the cage; score 2 = nest site is evident with over 50 % 
of nesting material at nest site or animals starting to build walls (one to two sides) and nest is 
hollow in bedding; score 3 = a flat nest with visible walls, can be hollow in bedding; score 4 = 
a complex, bowl-shaped nest with walls higher than mice, surrounding the nest in more than 50 
%.  
 
Saccharin Preference Test  
In parallel with the nest building assessment, the saccharin preference test was completed. The 
aim of the test is to assess anhedonia-associated behavior used for detection of depressive-like 
behavior in mice (Klein et al., 2015). The test was carried out at four consecutive days (24-hour 
periods). On each day, mice were provided with two water bottles and liquid consumption was 
measured at the end of each period. On the first day, animals were provided two bottles of water 




with 0.1 % saccharin solution to assess preference for sweet solution. On the third day, both 
bottles were filled with water. During the last period, the left bottle was filled with 0.1 % 
saccharin solution, aiming to check for possible side preference. Saccharin is an artificial 
sweetener with no effective calories, meaning it could not interfere with the composition of 
provided diet. 
 
Open Field Test 
The open field test is frequently used to examine locomotion and exploratory behavior in an 
unfamiliar surrounding (Carola et al., 2002). One hour prior to testing, mice were placed in the 
test room to habituate. The order of animals was randomized. Two white cylinders (diameter 
61 cm, height 40 cm) were used simultaneously, in order to test two mice in parallel. Mice were 
placed individually into the cylinder, facing the wall at a distance of 10 cm from the wall. Ten-
minute-long trials were recorded with Ethovision 8.5 Software (EthoVision XT, Noldus, 
Wageningen, The Netherlands). The software was used for automatic analysis of locomotion 
and time spent in different zones (wall, middle, center). Rearing behavior was scored manually 
by an observer unaware of animals’ group allocation. Following the end of the trial, mice were 
returned to their home cage. Cylinders were cleaned with 0.1 % acetic acid between trials. 
 
Novel Object Recognition 
Novel object recognition test is a common test for assessing learning and memory in mice, 
performed over three consecutive days (Lueptow, 2017). The open field test was used as the 
first test day (habituation phase). On the second and third day of testing, all conditions were 
replicated with the exception of providing two objects in the open field arena. On the second 
day (training phase), mice were introduced to two identical objects (grey, textured pyramid or 
white, smooth cylinder; diameter 4 cm, height 10 cm) placed 15 cm apart and 12 cm from the 




replaced with an unfamiliar object. The order of the animals, the object for the training phase 
(pyramid or cylinder) and the position of the novel object in the test phase were randomized. 
Over the 10-minute session, the time sniffing at and exploring the familiar (TF) and novel object 
(TN) was automatically measured with Ethovision 8.5 Software and the nose point tracking 
tool. Mice were considered to sniff an object once their nose point was up to 2 cm away from 
the object and/or mice were touching the object with the nose or forepaws. Sitting on the object 
was not counted as active object exploration. Discrimination index was calculated using 
following formula: TN/(TN+TF) x100 %. 
 
Gait analysis 
A transparent plexiglas runway (length 100 cm, width 10 cm) surrounded by white walls (height 
10 cm), was placed 1 m over the ground and used for gait assessment. An entrance to a covered 
black box (15x15 cm), a dark shelter, was placed at the end of the runway. Each animal was 
placed on the runway, 80 cm from the black-box entrance, and their gait was recorded with a 
camera (Bastler acA1300-60gm, Noldus, Wageningen, The Netherlands) positioned under the 
runway and Ethovision 12.0 Software (Ethovision XT, Noldus, Wageningen, The Netherlands). 
The lighting from the ground was adjusted to ensure sufficient lighting for camera and was 
around 20 lx on the runway surface. For each animal, five trials were completed. Only a straight 
walk without any interruptions was considered for gait analysis. Thus, the second trial was 
chosen for analysis, excluding the first and last 10 cm of the walk. Video frames (60/s) were 
extracted using VLC 2.2.4. “Weatherwax” media player (VideoLan Organization) and merged 
for analysis with GIMP 2.10.14 software. The two consecutive strides per animal were selected 
and the following parameters were measured: stride length, forelimb and hindlimb base of 






Euthanasia, plasma and hippocampus sampling 
Prior to sacrifice, all mice were fasted for 6 hours during the light cycle phase in order to 
eliminate direct effects of diet consumption. Mice were euthanized between 12 and 3:30 p.m. 
with 600 mg/kg Pentobarbital i.p. in 10 ml/kg injection volume. In order to minimize circadian 
effects on metabolites, animals were randomly divided into groups euthanized at two separate 
days.  
Following the stop of breathing, the thorax was opened and blood was collected from the heart 
into 1.3 ml K3 EDTA micro tubes (SARSTEDT AG & Co. KG, Nümbrecht, Germany). The 
tubes were gently shaken and then centrifuged on 3500 rpm (Hettich® MIKRO 200/200R, 
Andreas Hettich GmbH & Co. KG, Tuttlingen, Germany) for 10 minutes at room temperature. 
Plasma was pipetted into 1.5 ml Protein LoBind Tubes (Eppendorf, Wesseling-Berzdorf, 
Germany) and fresh frozen in liquid nitrogen (Besamungsstation München-Grub, Poing, 
Germany). Hippocampal tissue was dissected from both hemispheres, fresh frozen in liquid 
nitrogen using 1.5 ml Protein LoBind Tubes and stored at -80 °C until analysis. Tail samples 
were collected for PCR genotype confirmation. Plasma and hippocampus samples were sent to 
metaSysX GmbH for analysis. Firstly, all samples were prepared in line with metaSysX 
standard procedure. Metabolites were extracted from the whole grounded hippocampus samples 
and 100 µl of the plasma samples. Polar and semi-polar primary and secondary metabolites 
were measured with a Waters ACQUITY Reversed Phase Ultra Performance Liquid 
Chromatography (RP-UPLC; C18 column) coupled to a Thermo-Fisher Exactive mass 
spectrometer which consists of an ElectroSpray Ionization source (ESI) and an Orbitrap mass 
analyzer. Extraction of the data was accomplished with the software REFINER MS® 11.1 
(GeneData, http://www.genedata.com), after which it was annotated using the in-house 
metaSysX database of chemical compounds (database query of m/z and the retention time). 
In addition, primary metabolites were measured on an Agilent Technologies Gas 




°C/minute up to 360 °C) coupled to a Leco Pegasus High Throughput mass spectrometer, which 
consists of an electron ionization source and a time-of-flight mass analyzer. Samples were 
measured in splitless (injection of full volume) and split mode (injection of 1/5 of full volume) 
to allow the selection of the proper mode for the compounds of interest. The compound 
annotation was done by comparing the spectra and the retention index to the Fiehn Library and 
to a user created library. Lastly, the hippocampal data were normalized first to the weight of 
the samples and then to the median of intensities of each sample and plasma data were 
normalized to the median of intensities of each sample. 
 
Data availability 








A pilot study has been completed to determine the duration of KD exposure sufficient to ensure 
ketosis in the majority of animals. The blood level of BHB increased over the time of exposure 
to KD. In the evening samples one, 2 and 3 weeks following KD onset, BHB blood levels were 
significantly higher as compared to baseline (Fig. S6). In contrast, there was no significant 
change in BHB levels in the morning samples, when compared to baseline. However, at 2 and 
3 weeks following KD introduction, BHB levels in blood were higher in the morning than in 
the evening, implying a pronounced effect of nocturnal feeding. Based on the pilot data 3 weeks 
were selected as a sufficient duration for KD exposure. 
 
Genotype and diet effect on behavioral parameters 
The open field paradigm revealed a pronounced hyperlocomotion with total distance moved 
and mean velocity significantly increased in Dravet mice, regardless of the diet (Fig. S8A-B). 
Immobility time was significantly reduced in all Dravet animals (Fig. S8C). Rearing behavior 
and jumping on the walls proved to be significantly increased in all Dravet mice (Fig. S8D-E). 
An impact of the diet on rearing behavior became evident with Dravet mice fed KD exhibiting 
more rearing behavior as compared to Dravet mice fed CD. Thigmotaxis was evident in all 
Dravet mice regardless of the diet, with an increase in time spent in wall zone and decrease in 
time spent in middle and center zones as compared to wildtype mice (Fig. S8F). Sex differences 
were not observed. 
Assessment of novel object recognition test did not show any effect of genotype or diet on 
cognitive performance in mice (Fig. S8H).   
Wildtype mice consuming CD or KD, and Dravet mice consuming CD showed a preference of 




reduced in Dravet mice, when compared to wildtypes. Moreover, KD reduced the preference 
for saccharin in both genotypes (Fig. S8G). Findings proved to be comparable in males and 
females.  
Nest-building activity assessment revealed a strong genotype effect, with a significantly poorer 
performance in Dravet mice when compared to wildtype mice fed CD (Fig. S8I). Diet and sex 
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Tables and figures: 
Table S1. Abundances of selected proteins detected in the hippocampus of Dravet mice 
following the disease manifestation. The fold change is provided in relation to wildtype controls 
along with the level of significance (p). Please note that the data are from a study focused on a 
broad scale proteomic analysis presented in a manuscript by Miljanovic et al., under revision. 
 
Genes Protein names 
fold  change 
Dravet/ WT p-value 
Hk3 Hexokinase-3 1.34 0.1155 
Ldha L-lactate dehydrogenase A chain 1.00 0.8912 
Ldhb L-lactate dehydrogenase B chain 0.87 0.0008 
Pdha1 
Pyruvate dehydrogenase E1 component subunit alpha, 
somatic form, mitochondrial 1.04 0.0006 
Pdhb 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial 1.04 0.1901 
Pdhb 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial 1.04 0.1901 
Slc2a1 
Solute carrier family 2, facilitated glucose transporter 
member 1 0.93 0.0601 
Slc2a3 
Solute carrier family 2, facilitated glucose transporter 
member 3 1.13 0.0009 
Slc16a1 Monocarboxylate transporter 1 1.20 0.0150 
Gpi Glucose-6-phosphate isomerase 1.04 0.0209 
Taldo1 Transaldolase 0.98 0.4335 
Tkt Transketolase 0.99 0.4577 
Aldoa Fructose-bisphosphate aldolase A 1.05 0.0697 
Aldoc Fructose-bisphosphate aldolase C 0.92 0.0854 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 0.95 0.4178 
Tpi1 Triosephosphate isomerase 1.03 0.6351 
Pgk1 Phosphoglycerate kinase 1 1.01 0.7376 
Pgam2 Phosphoglycerate mutase 2 1.04 0.5814 
Pgam1 Phosphoglycerate mutase 1 1.03 0.1903 
Eno1 Alpha-enolase 0.97 0.3230 
Eno3 Beta-enolase 0.93 0.1477 
Eno2 Gamma-enolase 0.99 0.8365 
Pkm Pyruvate kinase PKM 1.00 0.9063 
Aldh5a1 Succinate-semialdehyde dehydrogenase, mitochondrial 0.96 0.0769 
Idh2 Isocitrate dehydrogenase [NADP], mitochondrial 1.07 0.1822 
Idh1 Isocitrate dehydrogenase [NADP] cytoplasmic 1.05 0.0571 
Idh3a 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial 1.06 0.0279 
Idh3g 
Isocitrate dehydrogenase [NAD] subunit gamma 1, 
mitochondrial 1.03 0.0773 
Cs Citrate synthase, mitochondrial 1.03 0.0899 
Acly ATP-citrate synthase 1.06 0.0099 




Aco1 Cytoplasmic aconitate hydratase 0.98 0.0842 
Sdhd 
Succinate dehydrogenase [ubiquinone] cytochrome b 
small subunit, mitochondrial 1.04 0.2673 
Sdha 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 1.04 0.0072 
Sdhc 
Succinate dehydrogenase cytochrome b560 subunit, 
mitochondrial 0.98 0.6248 
Sdhb 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, 
mitochondrial 1.03 0.0343 
Ogdh 2-oxoglutarate dehydrogenase, mitochondrial 1.05 0.0032 
Sucla2 
Succinate--CoA ligase [ADP-forming] subunit beta, 
mitochondrial 1.06 0.0046 
Suclg1 
Succinate--CoA ligase [ADP/GDP-forming] subunit 
alpha, mitochondrial 1.10 0.0037 
Suclg2 
Succinate--CoA ligase [GDP-forming] subunit beta, 
mitochondrial 1.06 0.0189 
Fh Fumarate hydratase, mitochondrial 1.01 0.4623 
Mdh1 Malate dehydrogenase, cytoplasmic 0.96 0.1202 
Mdh2 Malate dehydrogenase, mitochondrial 1.08 0.0073 
Asns Asparagine synthetase [glutamine-hydrolyzing] 0.85 0.1247 
Pc Pyruvate carboxylase, mitochondrial 1.00 0.8830 
Glud1 Glutamate dehydrogenase 1, mitochondrial 1.03 0.2844 
Glul Glutamine synthetase 0.86 0.0062 
Gad1 Glutamate decarboxylase 1 1.00 0.9607 
Gad2 Glutamate decarboxylase 2 1.15 0.0807 
Slc17a7 Vesicular glutamate transporter 1 1.06 0.0547 
EAAT1 Excitatory amino acid transporter 1 0.91 0.0100 
EAAT2 Excitatory amino acid transporter 2 0.95 0.0440 






Table S2. Parameters of generalized tonic-clonic seizures during baseline (n=19) and during 
exposure to CD (n=8) or KD (n=10) in Dravet mice. Total seizure duration, seizure frequency, 
the number of days with seizures/week and seizure severity (mean±SEM) were evaluated.  




Number of days with 
seizures/week 
Racine score 
Dra baseline 340.7 ± 43.68 6.79 ± 0.86 2.21 ± 0.22 5.69 ± 0.07 
Dra CD 289.4 ± 40.46 6.38 ± 0.94 2.75 ± 0.49 5.7 ± 0.12 






Fig. S1 A Experimental timeline. B This sketch illustrates chosen parameters for gait 
assessment in mice including stride length, angle between forelimb paw and body direction, 






Fig. S2 The abundance of glucose and its phosphorylated forms in hippocampal tissue. A 
The glucose abundance in the hippocampus. Dravet mice fed CD had a lower abundance of 
glucose as compared to wildtype mice fed CD. B-C The level of α-D-glucose-6-phosphate (B) 
and D-glucose-6-phosphate (C) in hippocampal tissue. Both metabolites were up-regulated in 
Dravet mice when compared to wildtype mice. In addition, KD further increased metabolite 
abundance only in Dravet mice. D The hippocampal abundance of α-D-glucose-1-phosphate. 
This metabolite was up-regulated in Dravet mice fed CD, when compared to wildtype mice. 
Data shown are from 20 wildtype mice (10 CD, 10 KD) and 21 Dravet mice (10 CD, 11 KD). 








Fig. S3 Intermediate metabolites of glycolysis in hippocampal tissue. The abundance of D-
fructose-6-phosphate (A) and D-fructose-1,6-biphosphate (B) in the hippocampus. Both 
metabolites were up-regulated in Dravet mice when compared to wildtype mice, regardless of 
the consumed diet. C The abundance of D-fructose-1-phosphate in the hippocampus. The 
metabolite level was increased in mice with the Dravet genotype when compared to wildtype 
mice. KD further increased metabolite levels only in wildtype mice. D The level of 
dihydroxyacetone-phosphate in the hippocampus. Dravet mice consuming KD had a 
significantly higher metabolite level than mice in the other three groups. E 
Phosphoenolpyruvate level in the hippocampus. No changes in the metabolite abundance were 
noted between the four groups. F Pyruvate abundance in the hippocampus. When consuming 
CD, Dravet mice showed an increased metabolite abundance as compared to wildtype mice. 
Data shown are from 20 wildtype mice (10 CD, 10 KD) and 21 Dravet mice (10 CD, 11 KD). 






Fig. S4 Intermediate metabolites of tricarboxylic acid cycle and the pentose phosphate 
pathway in hippocampal tissue. Hippocampal abundance of α-ketoglutarate (A), malic acid 
(B), citric acid (C), succinic acid (D), fumaric acid (E), lactate (F), 6-phosphogluconic acid (G) 
and ribose-5-phosphate (H). A, D The levels of α-ketoglutarate and succinic acid were reduced 
in Dravet mice fed KD when compared to wildtype mice fed KD. B-C Dravet mice had a 
significantly lower level of malic and citric acid in hippocampal tissue than wildtype mice. E 
No change in the hippocampal level of fumaric acid was noted. F The hippocampal lactate 
abundance was significantly lower in Dravet mice, than in wildtype mice. G Dravet mice 




to wildtype mice. In addition, KD further increased metabolite levels only in Dravet mice. H 
The level of hippocampal D-ribose-5-phosphate was comparable between all groups. Data 
shown are from 20 wildtype mice (10 CD, 10 KD) and 21 Dravet mice (10 CD, 11 KD). (Two-






Fig. S5 Neurotransmitters in the hippocampus. Hippocampal level of noradrenaline (A), β-
alanine (B), serotonin (C), acetylcholine (D), histamine (E) and glycine (F). A-B Dravet mice 
showed a reduced level of noradrenaline and an increased level of β-alanine in hippocampal 
tissue when compared to wildtypes. KD reduced neurotransmitter abundance in both wildtype 
and Dravet mice. C-E No differences in hippocampal abundance of serotonin, acetylcholine 
and histamine were noted between all four groups. F KD increased hippocampal levels of 
glycine only in mice with the wildtype genotype. Data shown are from 20 wildtype mice (10 
CD, 10 KD) and 21 Dravet mice (10 CD, 11 KD). (Two-way ANOVA, FDR correction, 






Fig. S6 Ketosis confirmation. Results of a pilot study showing the blood level of β-
hydroxybutyrate (BHB) over 3 weeks of KD consumption. Ketosis was checked twice per day. 
Over time, the number of animals reaching ketosis state increased. Evening BHB levels at one, 
2 and 3 weeks following the KD introduction were significantly increased when compared to 
the baseline (paired t-test, * p<0.05). Two and three weeks following KD onset, blood BHB 
levels were significantly higher in the morning measurement. The morning BHB level 
measured at 3 weeks post KD introduction, exceeded the BHB level measured at 2 weeks 






Fig. S7 Food intake and body weight gain. A The amount of CD or KD consumed over the 
course of the experiment. Wildtype and Dravet mice consumed more CD than KD. The amount 
of KD consumed by Dravet mice exceeded the amount consumed by wildtypes. B Calorie 
intake. Dravet mice consuming KD had an increased overall calorie intake as compared to the 
remaining three groups. (mean±SEM). C Body weight development following the onset of CD 
or KD exposure. All four groups gained body weight over the course of the experiment. 
However, weight gain in both male and female Dravet mice fed KD was significantly exceeding 
that in the remaining three groups. Data shown are from 20 wildtype mice (10 CD, 10 KD) and 




Fig. S8 Open field test, novel object recognition, saccharin preference and nest complexity 
score. A Distance moved in the open field paradigm over 10 minutes. The total distance moved 
was significantly greater in mice with the Dravet genotype as compared to wildtype mice. B 
Average velocity over 10 minutes. The average velocity of Dravet mice proved to be higher 
than that of wildtype mice. C Immobility time. Dravet mice spent significantly less time 
immobile when compared to wildtypes. D Rearing frequency. Rearing frequency in Dravet mice 
exceeded the frequency observed in wildtype mice. E Jumping on the walls of the open field 
paradigm. Dravet mice showed an increased jumping behavior when compared to wildtypes. F 
Time spent in wall, middle and center zones of the open field paradigm. Dravet mice showed 
thigmotaxic behavior by spending more time in the wall zone compared to the wildtypes and 
less time in both the middle and center zones of open field. G Total consumption of saccharin 
solution. Mice with the Dravet genotype consumed significantly less saccharin solution when 
compared to wildtypes. KD significantly reduced the preference for saccharin in wildtype and 
Dravet mice. (Data shown are from 20 wildtype mice (10 CD, 10 KD) and 21 Dravet mice (10 
CD, 11 KD)). H Discrimination index in novel object recognition test. All four groups showed 
no difference in cognitive performance. Data shown are from 19 wildtype mice (9 CD, 10 KD) 
and 19 Dravet mice (10 CD, 9 KD) (Two-way ANOVA, Bonferroni post hoc test, * = p<0.05, 
mean±SEM). I Nest complexity score over seven consecutive days. Dravet mice showed poorer 
performance in building complex nests. (Friedman test, Dunn's Multiple Comparison Test, * = 
p<0.05 compared to wildtype groups, median). Data shown are from 20 wildtype mice (10 CD, 






1. Face validity of the model 
The validity of a novel animal model should be determined to provide evidence about how 
suitable the model is for investigating the disease it attempts to recapitulate. Thus, the first aim 
of this study was to characterize the phenotype of this conditional mouse model carrying the 
Dravet syndrome mutation A1783V and compare it with symptoms observed in patients with 
Dravet syndrome. The first manuscript provided valuable data about model characteristics 
including thermally provoked seizures, spontaneous seizures, a high mortality rate and 
behavioral alterations including hyperactivity and attention deficits. In addition, the second 
manuscript confirmed the presence of motor deficits, which are common symptoms of Dravet 
syndrome. Therefore, the findings from both manuscripts provide a valuable basis for 
conclusions about face validity of the model. Further in the text, different phenotype 
characteristics are compared between mice and patients with Dravet syndrome in order to 
determine the translational significance of the model. 
1.1. Sudden unexpected death in epilepsy 
Unfortunately, SUDEP rates are high in patients with Dravet syndrome (Shmuely et al., 2016). 
The reasons for the particularly high SUDEP risk in this epileptic encephalopathy have not yet 
been completely elucidated (Kalume, 2013; Shmuely et al., 2016). However, SUDEP is often 
attributed to frequent convulsive seizures (Harden et al., 2017) and the following postictal 
immobility, linked to peri-ictal respiratory dysfunction (Kuo et al., 2016). In another Dravet 
mouse model, sudden unexpected death has shown to be related to a high frequency of Racine 
V stage seizures (Kalume, 2013), which was also observed in this animal model. Taken 
together, the cause of death in these animals can be considered as probable SUDEP (Devinsky 
et al., 2018a). In the Scn1a-A1783V mice, mortality rates were high in the affected animals. 




background. It has previously been described that C57BL/6 mice develop a severe phenotype 
upon the introduction of Dravet syndrome Scn1a mutations (Cheah et al., 2012; Kalume, 2013). 
In comparison to previously characterized Dravet mouse models with this mutation (Kuo et al., 
2019; Ricobaraza et al., 2019), the model studied here exhibits a milder phenotype and a lower 
mortality rate, rendering it more preferable for further biomedical and pharmacological 
investigation.  
The fact that an obvious peak became evident with most animals dying between P20 and 23, 
implies that the model is very well suited for studies analyzing the pathophysiological factors 
contributing to SUDEP and for studies assessing the impact of drug candidates on SUDEP rates. 
Decreasing SUDEP rates is one of the declared aims of future drug development for the 
management of Dravet syndrome (Genton et al., 2011). Thus, the commercial availability of an 
animal model for respective studies is of the utmost relevance. 
1.2. Hyperthermia-induced seizures 
Hyperthermia-induced seizures are one of the hallmarks of epilepsy manifestation in patients 
with Dravet syndrome (Dravet, 2011). Thus, we aimed to check if mice with a Dravet genotype 
are prone to exhibit a seizure with exposure to hyperthermia. Interestingly, an increased 
susceptibility to hyperthermia-induced seizures with low thresholds was evident on all three 
test days: P23, P25 and P32. In addition, mean thresholds were rather comparable between P23 
and P25 indicating that repeatedly using the animals may be possible. However, the level of 
intraindividual variation in thresholds between stimulation days must be taken into account for 
repeated drug testing.  
With the subsequent testing 1 week later (P32), a reduction in the threshold became evident in 




a progression of the disease with steadily increasing seizure susceptibility. However, a kindling 
phenomenon based on the previous induction of seizures might also have contributed.  
1.3. Spontaneous seizures 
With progression of the disease, patients with Dravet syndrome develop further seizures, which 
then also occur without any thermal trigger (Dravet, 2011). In the first study, we obtained the 
first pilot information about spontaneous seizure activity in the novel Dravet mouse model. The 
information was based on video monitoring as continuous recordings are impossible in the very 
young animals. However, further electroencephalographic recordings in adult mice (manuscript 
I and II) confirmed the presence of seizure activity. Spontaneous motor seizures started at P16 
with seizures recapitulating the convulsive generalized seizures observed in patients. Seizures 
often progressed with running and bouncing phases indicating spread of seizure activity to the 
brain stem. Considering the fact that discharges affecting the brain stem are considered a critical 
factor contributing to SUDEP (Aiba and Noebels, 2015), it will be of particular interest to 
perform electrophysiological studies in the model studying the cellular mechanisms of 
propagation to the brain stem in more detail. In addition to behavioral motor seizures, we 
repeatedly observed episodes with behavioral arrest and non-responsiveness to external stimuli. 
These episodes might reflect atypical absence seizures, which can occur in patients with Dravet 
syndrome with an onset at different ages between 4 months and 6 years (Ohki et al., 1997). 
However, further electrographic recordings will be essential to confirm seizure activity during 
these episodes.  
1.4. Behavioral alterations 
Behavioral alterations contribute to the burden in Dravet patients (Besag, 2004; Dravet, 2011; 




same animals to form a better basis for drawing conclusions about altered behaviors. In 
addition, a battery of behavioral tests can help to identify factors of bias.   
Lack of attention related to hyperactivity constitutes one of the common behavioral 
disturbances in Dravet patients (Battaglia et al., 2016; Besag, 2004; Dravet, 2011). In line with 
this clinical trait, we observed a pronounced increase in activity in the open field as well as in 
the elevated plus maze paradigm. In other Dravet mouse models including a knock-in model 
with a nonsense R1407X mutation and other knockout models, hyperactivity has become 
evident (Dutton et al., 2013; Han et al., 2012; Ito et al., 2013; Rubinstein et al., 2015a). While 
anxiety has not been reported in Dravet patients (Sinoo et al., 2019), our data showed a lower 
level of anxiety in Dravet mice observed in the elevated plus maze paradigm. However, when 
assessing anxiety-like behavior in these mice, the impact of evident hyperactivity on the test 
should also be considered as it may impact the time spent in different zones.  
Development of motor abnormalities with features of cerebellar symptoms typically occur with 
disease progression in Dravet patients (Genton et al., 2011). While the rotarod test failed to 
demonstrate any motor disturbances in Dravet mice, the analysis of their gait proved to be a 
more sensitive approach and revealed alterations in body posture and motor coordination. 
Dravet mice had a different body posture in comparison to wildtype mice as a result of a 
significantly smaller distance between the hindlimbs. External torsion of the forelimbs may 
represent an attempt to regain stability. Considering great differences between the quadruped 
and biped gait, it is hard to say whether these changes mimic symptoms in humans. 
Nevertheless, these data certainly provide valuable information about how Scn1a deficiency in 
this mouse model results not only in seizure and behavioral alterations, but also in motor 
disturbances due to its expression in cerebellar Purkinje cells and in the nodes of Ranvier of 




Autistic features have been reported in subgroups of Dravet patients (Berkvens et al., 2015; 
Besag, 2004; Genton et al., 2011). With an increased level of active social interaction, Dravet 
mice did not show autistic-like behavior when compared to wildtype littermates. However, we 
must take into account that here we examined the social interaction between affected animals, 
and that respective data for an interaction between patients with Dravet syndrome have not been 
reported yet. In addition, it might be of interest to further study the development of social 
interaction at different ages and to perform another test where a novel stimulus animal is 
introduced.  
Analyzing saccharine preference revealed prominent alterations as a consequence of the genetic 
deficiency. This finding might point to a slight increase in anhedonia-associated behavioral 
patterns. At the moment, there is a lack of clinical reports about anhedonia and depression in 
Dravet patients, perhaps attributable to the fact that depression is difficult to assess in patients 
with mental retardation and prominent behavioral disturbances. 
Nest-building represents a behavioral pattern that is considered non-essential under laboratory 
conditions (Jirkof, 2014). Dravet mice, especially the females, proved to be less motivated to 
engage in nest-building activity as compared to their wildtype littermates. We obtained no 
evidence that nest complexity was compromised by spontaneous seizure activity in the home 
cage, thus, the data indicate that Dravet mice might not enjoy in this type of “luxury” behavior. 
The poor performance in nest-building might also reflect a failure to focus on a specific task 
thereby reflecting a hyperactivity-attention deficit syndrome, which is characteristic of Dravet 
patients (Berkvens et al., 2015). For instance, it has been described that children are restless 
and do not show an interest in playing with toys or in the other usual activities for their age 




Considering that the analyses were performed sequentially in the same animals, we cannot 
exclude an influence of the sequence of the testing. However, the additional information gained 
from individual animals allows better characterization of the animal model, with a possibility 
to find correlations between data from individual animals. For instance, the correlation between 
total distance moved as the main locomotion parameter and social interaction, elevated plus 
maze parameters and nest complexity score, indicates that hyperactivity may contribute to some 





2. Comparison to other mouse models of Dravet syndrome 
The comprehensive characterization of this mouse model provided valuable information about 
the model´s similarity to the clinical symptoms of Dravet syndrome and its value for further 
scientific research. The model is also the first animal model of Dravet syndrome commercially 
available to a broad scientific audience. In addition, it is a conditional knock-in mouse model 
that avoids the breeding of affected animals. Besides these advantages, it is of particular 
relevance to compare this model to other available models (Table T1) to conclude about its 
value for the scientific community.  
Interestingly, the time of spontaneous seizure onset in our model was on the identical day of 
postnatal brain development as another model with heterozygous conditional deletion of exon 
7 (Ogiwara et al., 2013). In other Scn1a knockout models, later seizure onsets were reported 
including P18 (Cheah et al., 2012; Ogiwara et al., 2007), P20 (Miller et al., 2014; Tsai et al., 
2015), P21(Dutton et al., 2013; Yu et al., 2006) and the third postnatal week (Ricobaraza et al., 
2019). 
As in most other models, we confirmed an increased susceptibility to hyperthermia. 
Furthermore, we confirmed a reduced seizure threshold following weaning but at a later time 
point. Moreover, we demonstrated a decrease in seizure threshold over time. Similar findings 
were reported only in one other mouse model, with no seizures occurring up to 42°C at P21, 
but apparent seizures in 50% of mice at P35 (Rubinstein et al., 2015a). 
Besides the seizure phenotype, behavioral alterations are highly relevant for studies focusing 
on the pathophysiology and pharmacology of Dravet syndrome. While we failed to detect any 
social and cognitive deficits as in other models, we observed impaired motor coordination in 
Dravet mice so far reported only in a few mouse models (Ogiwara et al., 2007; Ricobaraza et 
al., 2019; Yu et al., 2006). Interestingly, cognitive decline was reported in a mouse model with 




may reveal the mutation´s impact on cognition. Furthermore, we also demonstrated poor nest 
building performance which, together with hyperactivity in these mice, may mimic attention 
deficits in humans. Interestingly, increased activity was reported in most of the other animal 
models. In contrast, the impact of hyperactivity on other behavioral tests was usually not 
assessed (Table T1). Here, we showed that hyperactivity in Dravet mice directly correlated with 
anxiety-like behavior, nest complexity score and social interaction. This suggests that 
hyperactivity impacts these other phenotypic features in Dravet mice.  
Lastly, we also described an anhedonia-associated behavior in Dravet mice, a core symptom of 
depression in patients. It is possible that depression in patients with Dravet syndrome has been 
overlooked due to the often severe language and intellectual disabilities.  
Besides excellent face validity for the investigation of Dravet syndrome, the Scn1a-A1873V 
mouse model showed several advantages over the other currently available models. Among 
these, the relatively low mortality rate and low threshold for hyperthermia-induced seizures are 
the model’s main advantages when compared to other mouse models. These render it more 





Table T1. A comparison between the Scn1a-A1783V mouse model of Dravet syndrome, other 
available mouse models with a heterozygous Scn1a mutation and a clinical manifestation of 
Dravet syndrome (the first row). The arrow indicates an increased or a reduced phenotype 
characteristic. Minus (-) indicates no significant change in the evaluated parameter. P – 
postnatal day, PW – postnatal week, M – months, n.a. - not available, HIS – hyperthermia-
induced seizure. 1(Ricobaraza et al., 2019); 2(Kuo et al., 2019); 3(Ogiwara et al., 2007); 4(Ito et 
al., 2013); 5(Dutton et al., 2013); 6(Han et al., 2012; Kalume, 2013; Oakley et al., 2009); 7(Yu 
et al., 2006); 8(Cheah et al., 2012); 9(Ogiwara et al., 2013); 10(Miller et al., 2014); 11(Mistry et 
al., 2014); 12(Tsai et al., 2015); 13(Dutton et al., 2017; Sawyer et al., 2016); 14(Martin et al., 






















































































































































Clinical picture of 
Dravet syndrome 
n.a. 1615 5-8 
M 
/ ↑ - ↓ ↓ n.a. ↓ n.a. 
Scn1a-A1783V  50:50 40 P16 39.4  
(P23) 
↑ ↓ ↑ - ↑ ↓ ↓ 
1Scn1aWT/A1783V 100:0 75 PW3 38.2 
(1-6 M) 
↑ ↑ - ↓ n.a. ↓ ↓ 
2Scn1a∆E26 90:10 100 P14 41.1 
(P12-14) 
n.a n.a. n.a. n.a. n.a. n.a. - 
3 Scn1aRX/+ 
 
75:25 40 P18 n.a. n.a. n.a. n.a. n.a. n.a. - - 
4Scn1aRX/+ 
 
100:0 40 P18 n.a. ↑ ↓ ↓ ↓ n.a. - - 
5Scn1aFlox/+Cre+/- 100:0 100 P21 40.7  
(P22) 





40 P21 39.5  
(P20-46) 
↑ ↑ ↓ ↓ n.a. ↓ n.a. 
7Scn1a+/- 
 
0:100 10 P21 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
7Scn1a+/- 
 
100:0 80 P21 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
8Scn1afl/+  
 
100:0 70 P18 39  
(P35) 
↑ n.a. ↓ ↓ n.a. n.a. n.a. 
9Scn1ad/+  
 
97:3 25 PW3 n.a. 
 
n.a. n.a. n.a. n.a. n.a. - n.a. 
10Scn1atm1Kea  
 
75:25 54 P24 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
11Scn1atm1Kea 50:50 50 P18 n.a. 
 
n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
12Scn1aE1099X/+  75:25 46 P20 40.2  
(PW3-5) 
n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
13Scn1aRH/+ 
 
100:0 5 n.a. 41.3 
(P14-15) 
↑ - ↓ ↓ n.a. ↓ - 
14Scn1aRH/+ 
 
mix 5 n.a. 43.1 
(P14-15) 




3. Molecular and metabolic consequences of Scn1a genetic 
deficiency 
In the first manuscript, we provided relevant information about alterations in the hippocampal 
proteome of Dravet mice prior to and following epilepsy manifestation. The focus of research 
in the second manuscript was the investigation of the metabolome in the plasma and 
hippocampal tissue of Dravet mice. This approach might identify potential candidate 
mechanisms contributing to the course of Dravet Syndrome.  
Dravet syndrome is closely related to SCN1A deficiency and the loss of function of sodium 
channels on GABAergic interneurons, leading to overall hyperexcitability and ictogenesis 
(Catterall, 2018). In 2006, this was demonstrated for the first time in an animal model of Dravet 
syndrome (Yu et al., 2006). Further electrophysiological studies confirmed this finding but also 
pointed towards other processes contributing to disease development such as excitability of 
hippocampal excitatory neurons (Almog et al., 2019; Mistry et al., 2014; Ogiwara et al., 2013; 
Tsai et al., 2015). In line with that, data from proteomic and metabolomic studies demonstrated 
significant alterations in inhibitory and excitatory signaling in the hippocampus of Dravet mice 
following the onset of spontaneous seizures.   
Significant changes in the expression of several GABAA and GABAB receptor proteins, as well 
as a lower level of GABA in the hippocampus of Dravet mice, indicated disrupted GABAergic 
signaling which may contribute to ictogenesis in Dravet mice.  
Interestingly, both studies also pointed towards a strong regulation of glutamatergic signaling 
in the hippocampus of Dravet mice. These changes might reflect compensatory mechanisms 
occurring as a consequence of hyperexcitability in Dravet mice. Whilst some of these aspects 
have already been discussed in the second manuscript, due to space limitations and the focus of 




In the second manuscript, we showed that glutamate, the main excitatory neurotransmitter in 
the brain, was down-regulated in the hippocampus of Dravet mice. Even though glutamate 
levels were reduced in the hippocampus, its distribution within synapses may be changed, as 
indicated by our proteomics data. Dravet mice showed a trend for the up-regulation of the 
vesicular glutamate transporter 1 (VGLUT1), leading to increased presynaptic vesicle filling 
and presynaptic glutamate release (Du et al., 2020). Once released into the synaptic cleft, the 
majority of glutamate is taken up by astrocytes via the excitatory amino acid transporters 1 and 
2 (EAAT1, EAAT2) and converted into glutamine via glutamine synthetase. In manuscript I 
we reported a down-regulation of respective proteins, which, combined with a strong up-
regulation of GFAP (glial fibrillary acidic protein), may imply reactive astrogliosis in Dravet 
mice. Altogether, this can result in glutamate accumulation in the synaptic cleft and astrocytes, 
thus contributing to neuronal hyperexcitability. Moreover, once taken up by astrocytes, 
glutamate conversion to glutamine in Dravet mice is reduced, possibly leading to glutamate 
accumulation in astrocytes and further increasing plasma membrane thresholds for its uptake 
by excitatory amino acid transporters (Mahmoud et al., 2019). This could explain why even 
with reduced hippocampal glutamate levels, its distribution within synapses could still lead to 
excitotoxicity and promote seizures in these animals.  
Interestingly, both GABA and glutamate were down-regulated in Dravet mice hippocampus. 
Yet, GABA levels were reduced to a lesser extent, resulting in an increased GABA:glutamate 
ratio in Dravet mice. This could be a compensatory mechanism to the overall lack of glutamate, 
which is known to convert to both GABA and α-ketoglutarate in cells. As already mentioned 
in the second manuscript, lower glutamate levels and alterations in the glutamate/GABA-
glutamine cycle, may also be a consequence of a decreased TCA cycle-mediated supply of the 
glutamate precursor α-ketoglutarate. However, the enzyme directing conversion of glutamate 




On the contrary, glutamic acid decarboxylase 2 is one of the two key enzymes for GABA 
formation from glutamate (Erlander et al., 1991) that showed a trend towards an up-regulation 
in four-week-old Dravet mice. This may suggest altered glutamate fueling of GABA, which 
can further contribute to the disrupted balance between GABA and glutamate observed in these 
animals. However, further studies exploring the alterations in the glutamate/GABA-glutamine 
cycle in different disease phases of Dravet syndrome are needed to confirm this concept.  
Ionotropic glutamatergic receptors, NMDA or AMPA, are frequently linked to epilepsy in 
patients and animals, as are mutations in NMDA receptor genes (Xu and Luo, 2018). Agonists 
of these receptors can provoke seizures in animals or humans while their antagonists can inhibit 
seizures in animal models, listing them as potential anti-seizure medications (Hanada, 2020). 
However, to date, perampanel is the only glutamatergic receptor antagonist that has proved 
efficacious in the treatment of focal and generalized tonic-clonic seizures (French et al., 2012; 
French et al., 2013; French et al., 2015; Krauss et al., 2012; Nishida et al., 2018). 
Aside from low glutamate levels in the hippocampus, we also noted a strong down-regulation 
of both ionotropic and metabotropic glutamatergic receptors, predominantly expressed on the 
postsynaptic neuronal and glial membranes (Hanada, 2020). These changes may be a result of 
glutamate excitotoxicity and consequential receptor internalization or apoptosis (Scott et al., 
2004).  
In addition to changes in GABAergic and glutamatergic signaling, alterations in other 
neurotransmitters systems and signaling molecules became evident in the hippocampus of 
Dravet mice. For instance, the abundance of several proteins involved in dopaminergic 
signaling was altered in Dravet mice. In addition, an interesting finding was an overall down-
regulation of calcium and potassium channel subunits with possibly contrasting consequences. 
However, the actual consequences of these changes, such as dopaminergic signaling and the 




Next, the nitric oxide signaling pathway, dominated by the up-regulation of neuronal nitric 
oxide synthetase (nNOS), was significantly regulated in Dravet mice. As a result of NMDA 
overstimulation, calcium entry through cation channels triggers nNOS, which induces the 
synthesis of nitric oxide (Lipton et al., 1993; Mahmoud et al., 2019; Yamauchi et al., 1998). 
Nitric oxide is known to further mediate oxidative stress, reactive glial cell proliferation and 
promote angiogenesis, all of which have been discussed as potential contributors to 
epileptogenesis and overall hyperexcitability in the epileptic brain (Arhan et al., 2011; 
Mahmoud et al., 2019; Morbidelli et al., 2004). In line with this, we have reported reactive 
astrogliosis and increased angiogenesis in the hippocampus of Dravet mice. However, follow 
up studies addressing the functional consequences of these alterations would be essential to 
confirm our findings. 
In addition, recent findings also proposed a link between excessive central nitric oxide 
production and hypothalamic-pituitary-adrenocortical (HPA) axis dysregulation (Bruenig et al., 
2017; Chen et al., 2015a). Interestingly, investigation of the Dravet mice metabolome revealed 
plasma depletion of corticosterone, the main glucocorticoid in rodents. Corticosterone is 
released by the adrenal glands as a result of HPA axis activation in response to stress or other 
triggers (Herman et al., 2016). While the activation of the HPA axis serves as an important 
adaptive function preparing the body for increased demands, long-term activation by chronic 
stressors can be associated with detrimental effects and, in particular, with epileptic activity 
(Castro et al., 2012; Herman et al., 2016). The lower corticosterone levels in Dravet mice are 
rather unexpected, considering its direct role in promoting seizures (Joëls, 2009). However, a 
down-regulation of HPA axis activity and reduced plasma corticosterone may represent a 
compensatory mechanism to the long-term overstimulation. Therefore, it would be of interest 
to check corticosterone levels in younger animals following the highest incidence of seizures 




One of the main findings in this study were pronounced alterations in bioenergetics in the 
hippocampus of Dravet mice, specifically in glucose metabolism and TCA cycle activity. These 
metabolic changes may be associated with increased interictal activity and a failure to fulfill 
higher energy demands. Furthermore, these alterations may not only represent a consequence 
of seizure activity, but can also contribute to an increased susceptibility to seizures and 
ictogenesis. This has also been observed in metabolic epilepsies, which in many cases also have 
a genetic cause (Scheffer et al., 2016).  
As mentioned above, the interneuron energy hypothesis may further explain the particularly 
high seizure incidence, one of the clinical manifestations of Dravet syndrome. The hypothesis 
is based on evidence that inhibitory interneurons require a higher amount of energy (Kann, 
2016). This may in turn result in excitatory neuron disinhibition and hyperexcitability, as 
previously discussed (Henke et al., 2020). This could explain how energy depletion in neurons 
caused by an increased interictal spiking may further contribute to lowering of seizure threshold 
and ictogenesis. In line with this hypothesis, intermediates of glucose metabolism and the TCA 
cycle significantly correlated with the severity of spontaneous motor seizures in Dravet mice.  
Lastly, we have also observed some possible compensatory changes to energy deficits, 
including increased glycolysis and glycogenogenesis. Particularly interesting were alterations 
pointing towards a dysregulation in the metabolic coupling between neurons and astrocytes in 
Dravet mice. These changes could affect glycolysis in astrocytes, lactate shuttle to neurons and 








4. The impact of the ketogenic diet on the phenotype and 
metabolome of Dravet mice 
A ketogenic diet has been recommended as a second-line therapy in Dravet syndrome (Cross 
et al., 2019). The diet is known to shift energy metabolism towards a more fat-based energy 
supply, thus providing indirect evidence for metabolic and bioenergetic alterations in patients 
with Dravet syndrome. In the second manuscript, we aimed to identify metabolic changes in 
the hippocampus and plasma samples of Dravet mice. In addition, we aimed to investigate the 
impact of a ketogenic diet on these alterations and its therapeutic potential in the mouse model 
of Dravet syndrome here evaluated.  
The ketogenic diet failed to improve the seizure and behavioral phenotype in Dravet mice. 
However, the diet succeeded to partially improve their impaired gait. This might be related to 
an increase in intracellular forms of glucose in the hippocampus. In line with this assumption, 
this improvement in gait positively correlated with hippocampal levels of glucose and glucose-
6-phosphate. Therefore, replacing glucose utilization by ketone bodies, may be sufficient to 
improve the gait in Dravet animals. Importantly, the level of ketosis did not show a significant 
correlation with this improvement. Altogether, these findings trigger an interest to further 
investigate the therapeutic potential of the ketogenic diet in the treatment of gait abnormalities 
in patients with Dravet syndrome, so far shown in only one clinical study (Tian et al., 2019).  
Due to word count limitations and the focus of the manuscript, some interesting aspects 
regarding the application of the ketogenic diet and its metabolic consequences in Dravet mice 
were not discussed in the manuscript. Therefore, they are discussed here. A lower intake of 
ketogenic diet than the control diet was expected, considering that its caloric value is almost 
twice as high as the control diet. However, an interesting finding was that mutant mice 
consumed significantly higher amounts of the ketogenic diet than wildtype mice, which resulted 
in a much steeper body weight curve as compared to the remaining three groups. This 




diet. In patients with epilepsy, an increase of appetite and body weight is frequently observed 
especially when taking antiseizure drugs (Ben-Menachem, 2007). Seizures are high-energy 
events for the brain (Yang et al., 2013a), which could promote appetite in Dravet animals, the 
results of which would be much more pronounced on a high-energy diet, such as the ketogenic 
diet. However, this behavior has not been observed in Dravet patients. Conversely, in some 
patients with Dravet syndrome, loss of appetite has been described, particularly when taking 
stiripentol, topiramate and zonisamide as antiseizure drugs (Knupp and Wirrell, 2018). Since 
we did not detect any differences between Dravet and wildtype mice on the control diet, the 
change in appetite may also be triggered by the lower glucose intake and an attempt to 
compensate for the already depleted glucose levels.  
Even though mutant mice consumed a higher amount of ketogenic diet, they still exhibited a 
lower level of ketosis in the hippocampus and plasma, when compared to wildtype controls. 
This may explain a failure to refill reduced TCA cycle intermediates from ketone bodies, 
compensate energy deficiency and reduce seizures in these mice. Consistent with this, we have 
observed a negative correlation between intracellular phosphorylated glucose forms, lactate, 
glutamate precursors (α-ketoglutarate, L-glutamine, L-asparagine and L-aspartic acid) and the 
GABA:glutamate ratio, the main representation of inhibitory/excitatory balance in the brain 
postulated as one mechanism of epileptogenesis and seizure generation (Fritschy, 2008). Except 
for an increased abundance of phosphorylated glucose in Dravet mice, all other metabolites 
directly or indirectly fueling the TCA cycle, were down-regulated in Dravet mice and the 
ketogenic diet failed to restore wildtype levels, thus confirming our hypothesis. On the other 
hand, reduced free glucose import, glucose concentration in cells and up-regulated glucose-6-
phosphate in the hippocampus of Dravet mice might point towards a mechanism compensating 
for energy deficiency and an attempt of cells to shift glucose metabolism towards glycolysis. 
Furthermore, an increased level of glucose-1-phosphate may indicate a higher degradation or 




seemed to further increase glucose-6-phosphate forms in the hippocampus. This could be 
explained by the dominant use of ketone bodies for energetic needs and saving glucose for other 
relevant processes such as the pentose phosphate pathway, a non-oxidative metabolic pathway 
for the synthesis of nucleotides (Soty et al., 2017). An observed increase of 6-phosphogluconic 





5. Study limitations 
As mentioned above, “Omics” studies are a useful approach for the broad screening of data and 
obtaining the first information about disease-associated molecular alterations. Similarly, here 
we managed to demonstrate overall information about neuronal signaling in the brain of Dravet 
mice. However, we must not overlook some of the inevitable study limitations.  
Firstly, proteomic data can only provide information about protein abundance but not about the 
functional relevance of this molecular change. Therefore, future studies will be essential to 
provide further information, thus confirming or opposing our hypotheses.  
Secondly, proteomic and metabolic screening of hippocampal tissue cannot provide 
information about protein or metabolite distribution within hippocampal cell structures, 
neuronal or glial cells or the intra- or extracellular space. Respective data may provide crucial 
information about the functional relevance of proteome and metabolome alterations and help 
the interpretation of our results. Immunohistochemical studies could provide information about 
the localization and distribution of selected proteins in the hippocampus and are thus of 
particular interest for the future. 
Moreover, we should also consider the difference in age of mice sampled in these two studies. 
Four-week-old mice in manuscript I are considered early adolescent mice, while mice in 
manuscript II are fully adult (Brust et al., 2015). Considering that the adolescent brain still 
undergoes intense developmental changes, this may result in differences in the expression of 
certain proteins which were compared to metabolites of adult mice in the second study. 
However, we must state that the different sampling time in the two studies was due to the 
different study aims. The proteomics study focused on molecular alterations at the early 
developmental age in order to capture all changes before and shorty following epilepsy 
manifestation. The later time point was chosen in order to pass the period with the highest 




other hand, the metabolomics study aimed to assess which metabolic changes are linked to 
Dravet syndrome and the use of the ketogenic diet. In order to capture the impact of these 
alterations on both seizures and the behavioral phenotype of Dravet mice, we needed to conduct 
experiments in adult animals. In addition, the minimum duration of ketogenic diet application 
to induce ketosis is 3 weeks, which also influenced the time point of sampling. 
Lastly, four-week-old Dravet mice still exhibited lowered body weight as compared to wildtype 
littermates, an observation that disappeared by adulthood. Therefore, certain proteome changes 
may also result from poor brain and body weight development, which by themselves are known 
to deteriorate disease pathology in both animal models and humans (Crepin et al., 2009). Still, 
body weight loss is part of the phenotype of Dravet mice and should therefore be considered 












Taken together, our findings revealed excellent face validity of the conditional, heterozygous 
Scn1a-A1783V Dravet mouse model bred on a mixed (50:50) C57BL/6J and 129S1 background 
with Hprt promotor-mediated neuronal knock-in. The model accurately replicates the clinical 
syndrome in patients with Dravet syndrome with an increased susceptibility to hyperthermia-
induced seizures, development of spontaneous seizures, a relatively high incidence of SUDEP, 
hyperactivity and motor deficits. The model is therefore highly valuable for the evaluation of 
pharmacological strategies in Dravet syndrome and emerging novel “personalized” treatment 
options. In addition, the rate of mortality within a narrow time frame makes this model highly 
suitable for studies investigating mechanisms of SUDEP and approaches for its prevention.    
The untargeted proteomic profiling in Dravet mice revealed significant proteome differences 
and molecular alterations in hippocampal tissue both before and following disease 
manifestation. Several proteins involved in synaptic plasticity were affected before epilepsy 
manifestation. Thus, it would be of relevance for future studies to investigate if these molecular 
alterations represent early consequences of Scn1a genetic deficiency or can contribute to 
disease onset. Following epilepsy manifestation, molecular alterations beyond GABAergic 
interneuron dysfunction became evident. More complex pathophysiological mechanisms 
underlying the disease’s pathology should be considered in the future development of treatment 
strategies. Among those, glutamatergic synaptic transmission stood out as the most affected 
molecular mechanism in the hippocampus, later confirmed by the metabolome analysis in 
Dravet mice. The findings also indicated further alterations of components of the 
glutamate/GABA-glutamine cycle. These may serve as an endogenous compensatory 
mechanism, which can be supported by GABAergic drugs, already recommended as first line 





The extensive metabolomic screening revealed prominent alterations in energy metabolism in 
the hippocampus of Dravet mice. Interestingly, some of these metabolites directly correlated 
with the severity of motor seizures observed in Dravet mice, including the hippocampal level 
of glucose-6-phosphate, TCA cycle intermediates and several amino acids. Their potential as 
target candidates for the treatment of Dravet syndrome should be explored in future studies. 
The ketogenic diet improved the motor deficits observed in Dravet mice, thus pointing to a 
potential role of metabolic alterations in ataxia and gait disturbances in Dravet syndrome. The 
development of therapeutic modulating concentrations of glucose and glucose-6-phosphate 
may be considered in the future for the treatment of Dravet syndrome and associated gait 
disturbances. Lastly, the ketosis state in Dravet and wildtype mice differed. This might explain 
why the diet failed to improve seizure susceptibility. In line with this, the diet is frequently 
prescribed in combination with other antiseizure drugs for therapeutic management of Dravet 
syndrome.  
Altogether, our findings revealed several molecular alterations beyond SCN1A deficiency that 
might contribute to the pathophysiology of Dravet syndrome. Their role as possible candidates 
for novel pharmacological treatments should be explored in future studies. However, further 
research addressing the functional consequences of these molecular alterations in different 
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